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ABSTRACTS  
 
MSA WITH COGNITIVE IMPAIRMENT 
Introduction: Multiple system atrophy (MSA) is a progressive neurodegenerative 
disease characterized by parkinsonism, cerebellar ataxia and autonomic 
dysfunction. According to the second consensus on MSA, a clinical diagnosis of 
MSA is excluded in the presence of cognitive impairment (CI). However, this 
view has been challenged by neuropsychological studies documenting CI in MSA 
patients and by some case studies of pathologically confirmed MSA patients 
reported to have CI. This study investigates the pathological substrates of CI in 
MSA by comparing the neuropathological profiles of MSA cases with 
documented CI (MSA-CI) and those with normal cognition (MSA-CN).  Methods: 
Nine MSA-CI and nine MSA-CN cases were selected from the archive of the 
Queen Square Brain Bank (QSBB) for Neurological Disorders. 
Immunohistochemistry and routine histological techniques were employed to 
determine neuronal and glial α-synuclein pathology, A deposition, tau 
pathology, gliosis, TDP-43 pathology and neuronal loss. These pathological 
changes were assessed using quantitative and semi-quantitative approaches.   
Results: No differences in the severity of neuronal or α-synuclein pathologies in 
any region were identified between the two MSA groups. A deposits were more 
frequent in the CN group, while Alzheimer-type tau pathology was no greater the 
Braak and Braak stage II in either group. Other secondary pathologies (Lewy 
body, cerebral amyloid angiopathy, TDP-43 and small vessel disease) were 
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uncommon in this cohort.  Conclusions: Brain regions important for cognition did 
not show more severe neuronal loss, α-synuclein pathology, Alzheimer or other 
secondary pathologies in MSA-CI as compared with MSA-CN. These findings 
indicate that CI is an inherent feature of MSA and is not due to concomitant 
pathologies or the load or distribution of α-synuclein pathology.  Furthermore, 
the synergism displayed between α-synuclein, tau and Aβ in Parkinson’s disease is 
not apparent in MSA. Further explorations into other substrates such as synaptic 
pathology, neurotransmitter abnormalities and subcortical deafferentation may 
have an impact on CI in MSA. 
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LONG DURATION AND MINIMAL CHANGE MSA 
Introduction: Multiple system atrophy (MSA) is a progressive neurodegenerative 
disease characterized by parkinsonism, cerebellar ataxia and autonomic 
dysfunction. Widespread -synuclein positive glial cytoplasmic inclusions (GCIs) 
found in oligodendrocytes and neuronal loss are two pathological features of 
MSA. The mean disease duration of MSA is 6-9 years, however, there are some 
patients that experience a longer disease course. Long duration (LD) and minimal 
change (MC) MSA are two unusual subtypes of the disease. LD-MSA exhibits a 
disease duration 15 years or longer, while in MC-MSA neuronal loss is largely 
restricted to the substantia nigra and locus coeruleus. The clinico-pathological 
profiles of these subgroups are explored in this study. Methods: 
Immunohistochemical and routine histological staining were performed on tissue 
from LD-MSA (n=4), MC-MSA (n=6) and control (n=8) MSA cases. Neuronal 
loss, GCIs, neuronal cytoplasmic inclusions (NCIs) and gliosis were semi-
quantitatively assessed in addition to investigation of concomitant pathologies. A 
review of the clinical records was also performed.   Results: GCI and NCI burden 
in LD-MSA was greater in the caudate compared to control MSA cases 
(p0.002). No statistical difference in GCI load was found between MC-MSA 
and control  MSA in any region despite increased numbers of NCIs in the 
caudate and substantia nigra (p0.002). Regional neuronal loss was not 
statistically different between LD-MSA and control MSA cases and was not 
evident in the cortical and limbic regions of any of the three groups. Conclusions: 
All cases showed typical neuropathological changes of MSA with widespread 
pathology in cortical, limbic, striatonigral and olivopontocerebellar regions. LD-
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MSA may represent a benign disease variant with slower accumulation of GCIs 
and no increase in neuronal loss compared to control MSA. In contrast, MC-
MSA may be a more aggressive form of the disease with a similar GCI load to 
control MSA despite the shorter disease duration. Delayed onset of autonomic 
dysfunction appears to be associated with the favourable clinical outcome in 
these cases.  Further investigation of pathology in nuclei and connections 
associated with the autonomic system is warranted to determine their significance 
on clinical outcome.  
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GCIS IN THE OLIGODENDROGLIAL LINEAGE 
Introduction: Glial cytoplasmic inclusion (GCI) in oligodendrocytes is the 
pathological hallmark of MSA. GCIs are composed of many proteins but with α-
synuclein as the main constituent. GCIs are widespread in multiple brain regions 
and are hypothesized to play a primary role in the pathogenesis of MSA. 
Although GCIs have been determined to accumulate in oligodendrocytes, 
detailed characterization of their accumulation in different cells of the 
oligodendrocyte lineage has not been established. This study investigates the 
occurrence of GCIs in oligodendrocyte precursor cells (NG2+ cells), 
premyelinating (CNPase¯/MBP+) and mature myelinating (CNPase+/MBP+) 
oligodendrocytes in MSA.  Methods: Double and triple immunofluorescence using 
anti-α-synuclein, NG2, CNPase and MBP antibodies were carried out on 8µm 
thick frozen sections  from the posterior frontal cortex and cerebellum of 3 MSA 
cases. Qualitative analysis was conducted by systematically scanning the entire 
section for evidence of co-localisation using widefield and confocal fluorescence 
microscopy. Results: α-Synuclein accumulates in CNPase+/MBP+ cells but not in 
NG2+ cells. CNPase¯/MBP+ cells were unidentifiable in this cohort. Conclusions: 
GCIs occur within mature myelinating oligodendrocytes while oligodendrocyte 
precursor cells or immature oligodendrocytes are unaffected by α-synuclein 
pathology. These findings raise the possibility of interaction of α-synuclein with 
myelin and microtubules, rendering mature oligodendrocytes more susceptible to 
GCI formation than NG2+ cells.  
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REGIONAL AND CELLULAR EXPRESSION OF SNCA IN MSA 
Introduction: The pathological hallmark of MSA is the glial cytoplasmic inclusion 
(GCI) found in oligodendrocytes and composed of many proteins, but with α-
synuclein as the main constituent. The mechanisms by which α-synuclein 
accumulates in oligodendrocytes as GCIs have not been established, but are 
crucial to understanding the molecular pathology of the disease. The aim of this 
study is to investigate alterations in regional and cellular SNCA mRNA 
expression in MSA as a possible substrate for GCI formation. Methods: 
Quantitative reverse transcription polymerase chain reaction (qPCR) was 
performed on post-mortem brain samples from 15 MSA, 5 PD and 5 control 
cases to investigate regional expression in the frontal region, occipital regions, 
dorsal putamen, pontine base and cerebellar white matter. For cellular expression 
analysis, neurons from the putamen and oligodendrocytes from the cerebellum 
were isolated by laser capture microdissection from 5 MSA and 5 control cases.  
Results: SNCA mRNA expression was not significantly different between the 
MSA, PD and control cases in all regions (multilevel statistical model, p=0.14). 
After adjusting for group effect, the highest expression was found in the occipital 
grey matter while the lowest was in the putamen (multilevel statistical model, 
p<0.0001). At the cellular level, both oligodendrocytes and neurons expressed 
SNCA mRNA. MSA oligodendrocytes expressed more SNCA than control 
oligodendrocytes and expression in MSA neurons was slightly lower than that in 
controls, however, these results did not reach statistical significance. Conclusions: 
There are regional variations in SNCA expression as it is higher in cortical than 
subcortical regions. Furthermore, SNCA mRNA expression was detected in 
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oligodendrocytes of  control and MSA cases, with greater expression in MSA. 
This suggests that SNCA mRNA overexpression may be a possible mechanism 
for GCI formation. 
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THE ROLE OF EXTRACELLULAR ALPHA-SYNUCLEIN IN GCI FORMATION 
Introduction: The pathological hallmark of MSA is the glial cytoplasmic inclusion 
(GCI) found in oligodendrocytes and composed of many proteins, but with α-
synuclein as the main constituent. The mechanisms by which α-synuclein 
accumulates in oligodendrocytes as GCIs have not been established, but are 
crucial to understanding the molecular pathology of the disease. The aim of this 
study is to investigate internalization of extracellular α-synuclein by 
oligodendrocytes as a possible mechanism for GCI formation. Methods: 
C57BL/6JOlaHsd mice (Harlan, Bicester, UK) between 2-4 months of age were 
anesthetized using isoflurane. The mice were placed on the stereotaxic frame and 
injected in one hemisphere with MSA, PD, or control human brain lysates (5µg 
total protein). One set was sacrificed after 4 days post inoculation (dpi) and 
another after 30 dpi and the brains removed, fixed and processed. A total of six 
mice were injected for each lysate and time point.  After serially sectioning the 
brain blocks (8µm), α-synuclein immunohistochemistry was performed. Results: 
The entire mouse brain was sectioned (120 sections) and a battery of α-
synuclein antibodies was tested on tissue sections at 40µm intervals. α-Synuclein 
positive staining was undetectable in neurons or glial cells in all sections and 
levels of the mouse brain inoculated with MSA, PD or control lysate.  Conclusions: 
The in vivo model of this study was unsuccessful in determining internalization of 
extracellular α-synuclein by oligodendrocytes. The study needs to be taken 
forward by inoculating wild-type mice that express α-synuclein and transgenic 
mice with human MSA brain homogenate to look for evidence of α-synuclein 
uptake by oligodendrocytes. Also, other pathological changes such as myelin loss, 
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axonal damage, neuronal loss and gliosis may also be examined to determine if 
any correlations exist with α-synuclein pathology load and progression with time.  
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1    
 INTRODUCTION 
 
1.1.  MULTIPLE SYSTEM ATROPHY 
1.1.1. Historical perspective 
The term multiple system atrophy (MSA) was first introduced in 1969 by 
Graham and Oppenheimer to combine three disease entities with overlapping 
clinical and pathological pictures (Graham and Oppenheimer, 1969). The three 
neurodegenerative diseases considered were striatonigral degeneration (SND), 
olivopontocerebellar atrophy (OPCA) and Shy-Drager syndrome (SDS). Twenty 
years later, the discovery of glial cytoplasmic inclusions (GCIs) as a distinct 
pathological finding in all three conditions by Papp and colleagues gave further 
credence to the unified classification of MSA (Papp et al., 1989). 
1.1.2. Clinical presentation 
The clinical presentation of MSA includes parkinsonism, cerebellar ataxia, and 
autonomic dysfunction (Stefanova et al., 2009). Where parkinsonian features 
dominate, the condition is denoted as MSA-P, whereas MSA-C represents a 
clinical picture dominated by cerebellar features. The second consensus 
statement on MSA retains the categories of MSA-P and MSA-C in addition to 
definite, probable, and possible groups in the diagnosis of MSA (Gilman et al., 
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2008). For a definite MSA diagnosis to be made, both clinical and 
neuropathological changes must be established. Probable MSA is defined as a 
sporadic, progressive adult onset disorder of autonomic failure and poorly 
levodopa responsive parkinsonism or cerebellar ataxia. A diagnosis of possible 
MSA is made where a sporadic, progressive adult onset disorder presents with 
parkinsonism or cerebellar ataxia in addition to at least one feature of autonomic 
dysfunction and another of clinical or neuroimaging abnormality. Table 1 
outlines the consensus criteria for the categories of definite, probable, and 
possible MSA. The discovery of widespread GCIs with restricted neuronal loss in 
five autopsy cases without clinically documented neurological disorder (with the 
exception the one case of sporadic Creutzfeldt-Jakob disease but no clinical signs 
of MSA) suggests that MSA may exist in a preclinical or non-progressive form 
(Parkkinen et al., 2007; Fujishiro et al., 2008; Rodriguez-Diehl et al., 2012; Kon et 
al., 2013). 
1.1.3. Pathological features 
Macroscopic changes are evident in striatonigral (StrN) and/or 
olivopontocerebellar (OPC) regions of MSA cases. The striatonigral structures 
include the striatum and midbrain, where there is atrophy and dark discoloration 
of the putamen, most marked posteriorly, and pallor of the substantia nigra. The 
olivopontocerebellar regions include the medulla, pons and cerebellum.  In the 
medulla, there may be blurring of the ribbon of the inferior olivary nucleus, while 
in the pons, there is pallor of the locus coeruleus. Furthermore, there is reduction 
in the size of the pontine base and middle and inferior cerebellar peduncles. In 
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the cerebellum, pathological changes affect both the grey and white matter. 
These changes present as cortical atrophy, narrowing of the folia, atrophy and 
dark discoloration of the white matter as is seen in Figure ‎1.1. (Quinn, 1989; 
Fearnley and Lees, 1990; Burn and Jaros, 2001; Greenfield, 2008)  
Microscopically, the pathological hallmark of MSA is the GCI found in the 
cytoplasm of oligodendrocytes (Papp et al., 1989) (Figure ‎1.2). In addition to 
GCIs, neuronal cytoplasmic inclusions (NCIs), neuronal nuclear inclusions 
(NNIs), glial nuclear inclusions (GNIs) and threads are also observed in MSA 
cases (Wakabayashi and Takahashi, 2006).  These inclusions are visualized by 
different staining techniques such as Gallays silver impregnation and ubiquitin 
and α-synuclein (αsyn) immunohistochemistry. Pathological changes are seen in 
both the grey and white matter in cortical and subcortical regions. In a study of 
cortical and subcortical regions (striatum, pons, medulla, and cerebellum), 
vacuolation and the presence of GCIs were observed in white matter tracts 
(Armstrong et al., 2007). GCIs are randomly distributed or occur in large clusters, 
with no apparent spatial correlation to abnormal neurons or neuronal inclusions 
(Armstrong et al., 2006). Neuronal inclusions, on the other hand, are found in 
regular clusters and are spatially correlated with abnormal neurons (Armstrong et 
al., 2006).  Abnormal neurons were characterized as having enlarged cell bodies 
with displaced nuclei or distorted cell bodies due to shrunken, atrophic 
perikaryon (Armstrong et al., 2004, 2006). The  random distribution of GCIs was 
interpreted as indicting that oligodendrocytes, rather than topographically 
 ‎1.1   Multiple system atrophy      32 
 
organized neurons, represent the cell population primarily affected in MSA 
(Armstrong et al., 2006). 
In a review of 203 pathologically proven MSA cases, neuronal loss was most 
severe in the substantia nigra, locus coeruleus, putamen, inferior olives, pontine 
nuclei, Purkinje cells, and intermediolateral columns in the spinal cord (Wenning 
et al., 1997). The cerebral cortex, thalamus, subthalamic nucleus, caudate nucleus, 
globus pallidus, dentate nucleus, nucleus ambiguus, vestibular nuclei, anterior 
horn cells, and pyramidal tracts, on the other hand, are less affected (Wenning et 
al., 1997). Moreover, there is a positive correlation between GCI burden and 
neuronal loss and disease duration in both striatonigral and olivopontocerebellar 
regions (Inoue et al., 1997; Ozawa et al., 2004).  
MSA pathological grading scales have been proposed to reflect the burden of 
pathology in StrN and OPC regions (Wenning et al., 2002; Ozawa et al., 2004; 
Jellinger et al., 2005). Based on semi-quantitative assessment of neuronal loss, 
astrogliosis and GCI burden in StrN and OPC regions, Jellinger and colleagues 
graded lesions on a four-point scale (SND 0-III and OPCA 0-III) thereby 
classifying cases as predominantly SND, OPCA or mixed (Jellinger et al., 2005). 
Ozawa and colleagues  pathologically sub-typed MSA cases as SND, OPCA or 
mixed by only assessing neuronal loss on a four-point scale (0-3+) in the caudate, 
putamen, substantia nigra, pontine base, olive and cerebellum (Ozawa et al., 
2004). SND subtype reflects predominant neuronal loss in StrN structures, 
OPCA reflects predominant neuronal loss in OPC structures while mixed 
reflects an equal neuronal loss score in both regions. Another MSA sub-type that 
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is classified according to pathological criteria is the ‘minimal change’ MSA group. 
The prominent defining feature of minimal change MSA in published literature is 
restricted neuronal loss to the substantia nigra and/or locus coeruleus (Wenning 
et al., 2002; Wakabayashi et al., 2005; Wenning et al., 1994 a; Huang et al., 2005).  
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Figure 1.1. Macroscopic features in MSA 
Normal control (A) & MSA (B) brain. Note pontine (arrows) atrophy in MSA 
brain. Normal control (C) MSA (D) cerebellum. Note narrowing of folia 
white matter (arrows) and discoloration of white matter in MSA.  
Normal control (E) & MSA (F) pallor of the substantia nigra & pontine 
atrophy (arrow head).  
A B 
C D 
E 
F 
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Figure 1.2. Typical neuropathological changes in MSA   
Typical neuropathological changes in MSA include αsyn-positive inclusions, 
neuronal loss, myelin damage and gliosis. The pathological hallmark of MSA 
are αsyn-positive GCIs (A).  αSyn-positive NCIs are also present as shown here 
in a severely affected dentate gyrus (B). Neuronal loss in the cerebellum (C) and 
substantia nigra (D) with few Purkinje cells and pigmented neurons remaining 
(arrows) as seen by H&E staining. LFB staining shows myelin damage in the 
cerebellum (E). Gliosis is demonstrated by GFAP immunohistochemistry (F).  
H&E: Haematoxylin & Eosin. LFB: luxol-fast blue. GFAP: glial fibrillary acidic 
protein; αsyn α-synuclein; GCIs: glial cytoplasmic inclusions; NCIs: Neuronal cytoplasmic 
inclusions.  
Scale bar: A, B: 20µm; C,D: 50µm; E: 500µm; F: 20µm.    
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1.1.4. Pathogenesis 
The pathogenesis of MSA is not well understood and the mechanisms leading to 
αsyn aggregation in neurons and oligodendrocytes and neuronal degeneration are 
yet to be established.  MSA is largely regarded as a sporadic disease as to date 
there are only three reports suggesting inheritance of MSA in German  and 
Japanese families (Wullner et al., 2004; Soma et al., 2006; Hara et al., 2007). Also, 
only a few groups identified single nucleotide polymorphism (SNP) in SNCA 
gene; rs11931074, rs3822086 and rs3775444, to be associated with increased risk 
for developing MSA, while others have failed to do so (Ozawa et al., 1999; 
Lincoln et al., 2007; Al-Chalabi et al., 2009; Scholz et al., 2009; Ross et al., 2010). 
Recent findings of the Multiple System Atrophy Research Collaboration have 
implicated mutations in COQ2 to increased risk of MSA (Multiple-System 
Atrophy Research Collaboration, 2013). The levels of coenzyme Q10 (COQ10), 
an energy carrier and antioxidant in the mitochondria, were found to be 
decreased in MSA patients with mutations in COQ2. The implication therefore is 
that mutations in the enzyme encoded by COQ2 hinder COQ10 biosynthesis 
leading to impairment of the mitochondrial respiratory chain and increased 
susceptibility to oxidative stress. Mitochondrial dysfunction is implicated in the 
pathogenesis of PD and may prove to play a significant role in MSA (Stefanova 
et al., 2005 a; Exner et al., 2012).  
MSA is increasingly being regarded as a primary oligodendrogliopathy with 
secondary neurodegeneration due to myelin dysfunction, accumulation of αsyn, 
and axonal damage (Wenning et al., 2008; Jellinger and Lantos, 2010; Fellner et 
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al., 2011 b).  An alternative hypothesis is that primary and secondary  
neurodegenerative processes occur synergistically in MSA, where primary 
neurodegeneration is due to accumulation of αsyn in neurons and secondary 
neurodegeneration results from the disruption of the oligodendroglial-myelin-
axon-neuron axis due to αsyn accumulation in oligodendrocytes (Nishie et al., 
2004; Yoshida, 2007).   Subcellular mechanisms implicated in MSA pathogenesis 
include the unfolded protein response (UPR) which is part of the ER stress 
response system, the ubiquitin-proteasome system (UPS), autophagy and 
macroautophagy systems as protein components of each of these systems have 
been found to be present in GCIs (Makioka et al., 2010; Schwarz et al., 2012; 
Tanikawa et al., 2012; Tanji et al., 2013). This may imply that impairment in these 
systems has a role in GCI formation and MSA pathology. The vital issue in 
understanding the pathogenesis of MSA is determining the mechanisms by which 
αsyn accumulate in oligodendrocytes.  
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Table ‎1.1. Criteria for diagnosing MSA (adapted from (Gilman et al., 2008)) 
Definite MSA 
Features of probable or possible MSA in addition to neuropathological 
demonstration of CNS α-synuclein–positive glial cytoplasmic inclusions with 
neurodegenerative changes in striatonigral or olivopontocerebellar structures. 
 
Probable MSA 
A sporadic, progressive, adult (>30 y)–onset disease characterized by 
 Autonomic failure involving urinary incontinence (inability to control the 
release of urine from the bladder, with erectile dysfunction in males) or an 
orthostatic decrease of blood pressure within 3 min of standing by at least 30 
mm Hg systolic or 15 mm Hg diastolic and 
 Poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, 
or postural instability) or 
 A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or 
cerebellar oculomotor dysfunction) 
 
Possible MSA 
A sporadic, progressive, adult (>30 y)–onset disease characterized by 
 Parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or 
 A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or 
cerebellar oculomotor dysfunction) and 
 At least one feature suggesting autonomic dysfunction (otherwise unexplained 
urinary urgency, frequency or incomplete bladder emptying, erectile 
dysfunction in males, or significant orthostatic blood pressure decline that 
does not meet the level required in probable MSA) and 
 At least one of the additional features: 
Possible MSA-P or MSA-C 
 Babinski sign with hyperreflexia 
 Stridor 
 
Possible MSA-P 
 Rapidly progressive parkinsonism 
 Poor response to levodopa 
 Postural instability within 3 y of motor onset 
 Gait ataxia, cerebellar dysarthria, limb ataxia, or cerebellar oculomotor 
dysfunction 
 Dysphagia within 5 y of motor onset 
 Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or 
cerebellum 
 Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum 
 
Possible MSA-C 
 Parkinsonism (bradykinesia and rigidity) 
 Atrophy on MRI of putamen, middle cerebellar peduncle, or pons 
 Hypometabolism on FDG-PET in putamen 
 Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET 
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1.2. OLIGODENDROCYTES AND GLIAL CYTOPLASMIC INCLUSIONS 
1.2.1. Oligodendrocytes 
Glial cells of the central nervous system include oligodendrocytes, astrocytes, 
radial glia, ependymal cells and microglia. The importance of oligodendrocytes 
resides in their ability to extend processes and  form layers of myelin sheath 
around axons, thereby facilitating propagation of action potentials through 
saltatory conduction (Baumann and Pham-Dinh, 2001). In addition, 
oligodendrocytes produce neurotrophic factors that are essential in maintaining 
the integrity of axons (Ransom and Sontheimer, 1992; Nave, 2010). There are 
different subgroups of oligodendrocytes present in the central nervous system 
(CNS) as they undergo maturational changes. These subpopulations have been 
characterized both morphologically and antigenically (Baumann and Pham-Dinh, 
2001).   
Mature oligodendrocytes are known as myelinating (intrafasicular) or satellite 
(perineuronal) oligodendrocytes. Myelinating oligodendrocytes myelinate axons 
while satellite oligodendrocytes are found around neurons and are not in direct 
contact with the myelin sheath. Myelinating oligodendrocytes have been further 
divided according to their size and to the size and thickness of their myelin 
sheath from small to large. Furthermore, biochemical markers characterize 
oligodendrocytes at different maturational stages. A few markers may be present 
at one or more of the maturational stages, therefore, more than one marker is 
needed to better identify the maturational point of the cell.  With that in mind, 
some of the markers used to identify oligodendrocyte precursor cells include 
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NG2, platelet-derived growth factor receptor α (PDGFRα), and  A2B5;  
galactocerebroside (GC) and 2’,3’-Cyclic nucleotide-3’-phosphohydrolase (CNP) 
for premyelinating oligodendrocytes; GC , CNP and myelin basic protein (MBP),  
for mature oligodendrocytes with the addition of myelin/oligodendrocyte 
glycoprotein (MOG) for myelinating oligodendrocytes. (Baumann and Pham-
Dinh, 2001; Nishiyama et al., 2009). Oligodendrocytes may also be identified by 
their expression of the basic helix-loop-helix transcription factors olig1 and olig2. 
Characterization of the olig genes has shown their importance in the 
development of oligodendrocytes. Olig2, in turn, is used as a marker for 
oligodendrocytes. (Rowitch et al., 2002)   
1.2.2. GCI discovery 
In 1989, Papp and colleagues identified cells containing GCIs as the pathological 
hallmark of MSA (Papp et al., 1989).  GCIs are present in oligodendroglia, 
however, a full profile of the subpopulations of oligodendroglia that contain 
GCIs has yet to be established (Wenning et al., 2008). Identifying these 
subpopulations may give further insight into the pathogenic mechanisms of 
MSA.  
1.2.3. GCI antigenic characteristics 
Extensive research has been conducted on profiling the content of GCIs. GCIs 
were found to be within oligodendrocytes and not neurons, astrocytes or 
microglia, as the cells containing GCIs were negative for the markers 
neurofilaments (neurons), glial fibrillary acidic protein (GFAP) (astrocytic) and 
Mac 387 (macrophage) (Papp et al., 1989).  Furthermore, they  were found to be 
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composed of multilayers of filaments, with α-synuclein at the core (Gai et al., 
2003). Alpha-synuclein is a key component of GCIs and is the most sensitive 
marker for these inclusions (Gai et al., 1998; Tu et al., 1998; Wakabayashi et al., 
1998; Wang et al., 2002).  Other components of GCIs include ubiquitin, non-
phosphorylated tau, α- and β-tubulin, 14-3-3 protein, aggresomal proteins,  
metallothionein (MT)-III, Rab5 and rababptin-5 (Papp et al., 1989; Gai et al., 
1999; Nakamura et al., 2000; Kawamoto et al., 2002, 2007; Wakabayashi and 
Takahashi, 2006; Pountney et al., 2011; Chiba et al., 2012).  
1.2.4. GCI morphology and distribution 
GCIs portray various morphologies such as sickle-shaped, flame-shaped, ovoid, 
triangular and conical (Figure ‎1.3).  Staining techniques that demonstrate GCIs 
include Gallyas silver impregnation and α-synuclein and ubiquitin 
immunohistochemistry (Castellani, 1998; Wakabayashi and Takahashi, 2006; 
Jellinger and Lantos, 2010).  
GCIs are distributed throughout the CNS with varying frequencies according to 
brain region, disease severity and MSA pathological subtype. GCI density 
increases with disease severity, however, in very severe cases where there is great 
tissue damage, they are very few or absent. Areas mostly affected in MSA, and 
therefore where GCIs are present but not restricted to, include striatonigral and 
olivopontocerebellar structures. (Papp and Lantos, 1994; Inoue et al., 1997; 
Ozawa et al., 2004; Wakabayashi and Takahashi, 2006). 
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Figure ‎1.3. GCI and GNI morphology 
GCIs occur in various shapes such as sickle-shaped, flame-shaped, ovoid, 
triangular and conical as shown by αsyn immunohistochemistry (A-G). 
GNIs are less common than GCIs and present as a filamentous line 
across the nucleus (H-I). Scale bar: 10µm 
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1.2.5. GCI significance 
As mentioned previously, GCIs are the pathological hallmark of MSA. As an 
accumulation of misfolded proteins in oligodendrocytes, GCIs are believed to 
play a central role in the pathogenesis of MSA through dysfunction of 
oligodendrocytes, leading to impaired myelin formation and consequently 
neurodegeneration (Wenning et al., 2008). A correlation has been shown between 
GCI burden and neuronal loss and these pathological changes and disease 
duration in a large cohort of MSA cases (Ozawa et al., 2004). Furthermore, there 
seems to be a relationship between GCI distribution and clinical symptoms 
observed as cases with greater GCI burden in StrN regions presented with a 
predominant parkinsonian phenotype during life and those with greater GCI 
burden in OPC regions predominantly displayed cerebellar features (Ozawa et al., 
2004; Jellinger et al., 2005). The contribution of GCI distribution to clinical 
phenotype is not straightforward as in a proportion of cases in one cohort, 
minimal pathology in StrN regions resulted in presence of parkinsonism (Ozawa 
et al., 2004) while in another parkinsonism was overshadowed by cerebellar signs 
(Jellinger et al., 2005). 
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1.3. ALPHA-SYNUCLEIN 
1.3.1. Gene and protein 
The synuclein family of proteins are natively unfolded and include α-, β- and γ-
synuclein (Iwai et al., 1995; Weinreb et al., 1996; Eliezer et al., 2001; Uversky, 
2007). αSyn  is encoded by SNCA which has been mapped to chromosome 4q21 
and consists of six exons five of which are transcribed (Spillantini et al., 1995). 
Alternative splicing of αsyn  mRNA results in the production of four  protein 
isoforms:  αsyn  140, 126, 112, and 98; however, only isoforms 140 and 112 have 
been confirmed by consensus coding sequence (CCDS) project criteria (Pruitt et 
al., 2009; Harte et al., 2012).  αSyn  140 is the transcript of the whole gene and is 
the most abundant isoform (Campion et al., 1995; Beyer et al., 2008 b).  Isoforms 
126 , 112, and 98  result from the in-frame deletion of exon 3, exon 5, and both 
exons 3 and 5,  respectively (Uéda et al., 1994; Campion et al., 1995; Beyer, 2006; 
Beyer et al., 2008 b). As a result, the missing amino acid (AA) residues in αsyn 
126 are AA 41-54 at the N-terminus and that in αsyn 112 are AA 103 – 130 at 
the C-terminus.  
The full transcript results in a 140 amino acid protein (~14 kDa) with an 
amphipathic region at the N-terminus, a hydrophobic central region containing 
the non-amyloid-  (NAC) domain, and an acidic region at the C-terminal as 
shown in Figure ‎1.4 (Jo et al., 2000; Pettersen et al., 2004; Beyer, 2006). There are 
six imperfect repeats with a KTKEGV consensus sequence from amino acid 
residues 7 -87 spanning the amphipathic and central regions. As a natively 
unfolded protein, αsyn does not assume a specific secondary structure. In fact, 
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studies have shown that αsyn can adopt various conformational states as dictated 
by different environmental factors (Uversky, 2007; Silva et al., 2013), such  as an 
α-helical membrane-bound structure or in a disordered free cytosolic state 
(Eliezer et al., 2001; Bussell et al., 2005).The N-terminal region is associated with 
lipid binding properties and assumes an α-helical conformation upon interaction 
with membranes (Eliezer et al., 2001; Jao et al., 2004). Point mutations found in 
familial Parkinson’s disease (PD) are located in this region (Beyer, 2006). The 
hydrophobic core of  αsyn  plays a role in protein-protein interactions and 
filament assembly (Giasson et al., 2001; Miake et al., 2002; Beyer, 2006). The 
carboxyl end of the protein is rich with acidic and proline residues and interacts 
with metal and cationic compounds (Nielsen et al., 2001; Uversky et al., 2001; 
Beyer, 2006). The interaction of metals and cationic compounds induces α-
synuclein oligomerisation (Nielsen et al., 2001; Uversky et al., 2001; Lowe et al., 
2004). The consensus on the conformation of the C-terminal  is that it is 
unfolded and unstructured even as other domains of the αsyn  protein undergo 
changes (Eliezer et al., 2001; Beyer, 2006; Uversky, 2007). However, a study 
using limited proteolysis method demonstrated that the acidic C-terminal tail of 
αsyn  is rigid and structured when micelle bound (de Laureto et al., 2006). More 
recent findings of the structure of αsyn suggest that it may exists physiologically 
as a helically folded  tetramer, suggesting that αsyn aggregate formation is 
preceded by destabilization of this stable tetramer state. (Bartels et al., 2011; 
Wang et al., 2011; Silva et al., 2013).  
 ‎1.3  Alpha-synuclein      46 
 
1.3.2. Function 
αSyn  is a predominantly CNS protein, however, it is also found in peripheral 
tissue (Ltic et al., 2004). In the brain, its expression is evident in neurons and 
vascular endothelial cells, however, its expression in glial cells is still a matter of 
debate (Stefanova et al., 2001; Tamo et al., 2002; Cookson, 2009; Fellner et al., 
2011 a). Expression of αsyn in oligodendrocytes has been demonstrated in rat 
and mouse oligodendrocytes (Richter-Landsberg et al., 2000; Culvenor et al., 
2002; Nielsen et al., 2006) and in human tissue (Mori et al., 2002, 2003; 
Papadopoulos et al., 2006) despite the long standing notion that oligodendrocytes 
lack αsyn  (Solano et al., 2000; Miller et al., 2005; Jin et al., 2008) 
The exact function of αsyn is yet to be determined, however, possible roles have 
been deduced based on the protein’s structure and localization in healthy and 
disease states. αSyn is located at the presynaptic terminal indicating a role in 
neuronal plasticity, vesicular transport, and membrane interaction (Iwai et al., 
1995; Kahle et al., 2000; Reynolds et al., 2011).  Findings of a  single- and double-
knockout study of αsyn and/or βsyn suggest that αsyn contributes to the long 
term regulation and/or maintenance of presynaptic function and its absence is 
not detrimental to brain function and survival (Chandra et al., 2004). The absence 
of αsyn is not lethal, however, its presence  proved important in rescuing cysteine 
string protein α (CSPα), a synaptic vesicle protein and chaperone,  null mice from 
lethality (Chandra et al., 2005). αSyn chaperone activity also extends to soluble 
N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) 
proteins, which are central to the neurotransmitter release process, as αsyn 
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ensures continuous SNARE-complex assembly (Burré et al., 2010). The 
interaction of αsyn with the CSPα and SNARE proteins highlights the 
significance of αsyn as a chaperone and in the maintenance of the nerve terminal 
(Chandra et al., 2005; Burré et al., 2010). αSyn is also implicated in the 
nigrostriatal system as the levels of catecholamines, metabolites and tyrosine 
hydroxylase decreased in the absence of αsyn (Prasad et al., 2011). αSyn’s 
interaction with the lipid bilayer may contribute to pathogenic mechanisms of 
disease as it results in disruption of the membrane and induction of αsyn helical 
conformation leading to the production of fibrils and aggregates (Zhu et al., 
2003). In addition to presynaptic localization, αsyn has been shown to localize in 
the nucleus and  interact with histones suggesting a role of αsyn in gene 
expression regulation (Goers et al., 2003) 
1.3.3. Disease 
αSyn is implicated in different neurological disorders such as neurodegenerative 
diseases, inflammatory demyelinating disease and psychiatric disorders  (Krüger 
et al., 2000; Goedert, 2001; Papadopoulos et al., 2006; Kao et al., 2009). 
Neurodegenerative diseases where αsyn is thought to be the major protein 
contributing to the disease are known as α-synucleinopathies (Krüger et al., 2000; 
Goedert, 2001). PD, MSA, and dementia with Lewy bodies (DLB) are the most 
common α-synucleinopathies. αSyn positive inclusions accumulate mostly in 
neurons in PD and DLB in the form of Lewy bodies, while in MSA they are 
primarily found as cytoplasmic inclusions in oligodendrocytes. In all cases of 
MSA however, NCIs, NNIs, and threads are also present. The role which αsyn 
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plays in the pathogenesis of these diseases is the topic of extensive research and 
potential pathogenic mechanisms include synaptic damage, impairment of the 
vesicular transport system and proteasomal system, demyelination, axonal 
damage and neuronal death (Goedert, 2001; Wenning et al., 2008; Bate et al., 
2010; Steiner et al., 2011). Furthermore, the biochemistry of αSyn is modified in 
neurodegenerative diseases. In PD, it is found to become increasingly 
phosphorylated and insoluble with the course of the disease (Zhou et al., 2011). 
In both PD and MSA, αsyn becomes increasingly insoluble, however, it is less 
protease-resistant in MSA than in PD and DLB (Campbell et al., 2001; Tong et 
al., 2010).  
Mutations and multiplications in the SNCA gene have pathological 
consequences. A53T, A30P, and E46K  are examples of mutations with 
confirmed association with PD (Polymeropoulos et al., 1996; Krüger et al., 1998; 
Athanassiadou et al., 1999; Zarranz et al., 2004; Michell et al., 2005).  In MSA, 
however, the results are conflicting as some groups failed to detect  mutations or 
multiplications in SNCA while other identified the SNPs rs11931074, rs3822086 
and rs3775444 to be associated with increased risk for developing MSA (Ozawa 
et al., 1999; Lincoln et al., 2007; Al-Chalabi et al., 2009; Scholz et al., 2009; Ross 
et al., 2010). Mutations in SNCA gene may also lead to a pathological spectrum 
encompassing that seen in PD and MSA as seen in the case of G51D mutation 
which includes neuronal and oligodendroglial αsyn-positive inclusions (Kiely et 
al., 2013). Moreover, duplication and triplication of the SNCA gene leads to 
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variable parkinsonian phenotype, affecting age of onset and rate of deterioration 
(Fuchs et al., 2007; Ross et al., 2008). 
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Figure ‎1.4. Alpha-synuclein protein structure 
(A) Predicted lipid-bound αSyn structure. The N-terminal domain (aa 1-60; blue) is the amphipathic region with -helical conformation and lipid –binding 
properties. The central domain spans aa 61-95 (yellow) and consists if the hydrophobic NAC domain believed to be aggregation-prone. The 
imperfect KTKEGV repeats are found across the N-terminal and central domains. The C-terminal domain (red) is rich in acidic, proline, and 
conserved tyrosine residues and is made up of aa 96-140. (B) Alpha-synuclein amino acid sequence alignment of Homo sapiens, Rattus norvegicus, Mus musculus 
and Macaca mulatta showing a highly conserved protein sequence across species.  Red indicates highly conserved columns, blue indicates less conserved columns 
and grey a gap region.  
 
Protein structure image produced using UCSF Chimera package and sequence alignment produced using the basic local alignment search tool (BLAST, http://blast.ncbi.nlm.nih.gov). 
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1   MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQK  80 
1   MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVTTVAEKTKEQVTNVGGAVVTGVTAVAQK  80 
1   MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVTTVAEKTKEQVTNVGGAVVTGVTAVAQK  80 
1   MRLRDPLFPGKREDAPWSFETYVLNVF----------VFVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQK  70 
 
81  TVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA  140 
81  TVEGAGNIAAATGFVKKDQMGKGEEGYPQEGILEDMPVDPSSEAYEMPSEEGYQDYEPEA  140 
81  TVEGAGNIAAATGFVKKDQMGKGEEGYPQEGILEDMPVDPGSEAYEMPSEEGYQDYEPEA  140 
71  TVEGAGSIAAATGFIKKDQLGKNEEGAPQEGILQDMPVDPDNEAYEMPSEEGYQDYEPEA  130 
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1.4. HYPOTHESIS 
a. MSA patients with clinical evidence of cognitive impairment have more 
severe pathology in brain regions that are important for cognitive 
function. 
b. The distribution and severity of pathology in patients with long disease 
duration and the minimal change group differ from the ‘classic’ MSA 
group.  
c. αSyn accumulation as GCIs in oligodendrocytes occurs at different stages 
of oligodendrocyte maturation. 
d. Accumulation of αsyn in oligodendrocytes in MSA is due to 
overexpression of αsyn mRNA in oligodendrocytes. 
e. Accumulation of αsyn in oligodendrocytes in MSA is due to uptake of 
αsyn by oligodendrocytes from neurons and/or the surrounding 
environment. 
 
1.5. AIMS OF RESEARCH PROJECTS 
a. To determine if there is a difference in the distribution and burden of   
pathological changes in MSA patients with cognitive impairment 
compared with patients with normal cognition.  
b. To determine the distribution and burden of   pathological changes in 
long disease duration and minimal change MSA as compared to control 
MSA cases and to explore possible clinic-pathological correlations.  
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c. To investigate the involvement of NG2+ cells, immature oligodendrocytes 
and mature oligodendrocytes by αsyn pathology in MSA.   
d. To determine the regional and cellular expression profile of αsyn in MSA. 
e. To assess whether exogenous αsyn can be internalized by 
oligodendrocytes and examine the pathological cascade of myelin and 
axonal damage due to accumulation of αsyn in oligodendrocytes using an 
in vivo model. 
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2                                                                                               
MATERIALS AND METHODS 
 
2.1. CASE SELECTION 
2.1.1. MSA with cognitive impairment 
Nine MSA cases with documented cognitive impairment and nine with normal 
cognition were selected in a retrospective analysis of clinical data recorded during 
life. Cognitive impairment had been assessed by Mini-mental states examination 
(MMSE) by neurologists, and in some cases (n=5), formal neuropsychometry 
testing had been performed by a clinical psychologist. Neuropsychometry tests 
assess the following parameters: verbal memory, visual memory, working 
memory, visuospatial/constructive impairment, executive function, and language 
function (e.g. verbal fluency, comprehension, etc.). An MMSE score of 24-28 
(out of 30) is suggestive of mild cognitive impairment (MCI) and 23 of 
dementia. Medical records were reviewed by a neurologist (Helen Ling). Patients 
with the pathological diagnosis of MSA were categorized as having cognitive 
impairment (MSA-CI) if their MMSE scores were consistently  28 and cognitive 
impairment was documented by a clinician on at least one occasion. The final 
MMSE score prior to death, presence of depression, hallucinations and the use 
of additional cognitive tests including formal neuropsychometry to confirm the 
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impairment of cognition were recorded.  The control MSA group was matched 
for age (≤ 5 years difference), sex, disease duration (≤ 1 year difference), and had 
no documented cognitive impairment (MSA-CN) by clinician or care giver.   
2.1.2. Long duration and minimal change MSA 
Four cases in the long duration (one of which was provided by Toronto Western 
Hospital), six in the minimal change and eight control MSA cases were selected 
from the archives of QSBB. Cases were included into the long duration group if 
they had a disease duration 15 years. The minimal change group is a 
pathological characterization where cases have neuronal loss restricted to the 
substantia nigra and/or locus coeruleus. Patients in the control MSA group are 
those that have a more ‘classical’ presentation i.e. a disease duration of 5-10 years 
and neuronal loss not restricted to either the substantia nigra or locus coeruleus. 
The cases in the long duration and minimal change MSA were age (≤ 5 years 
difference) and sex – matched with the controls.  
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Table ‎2.1. Clinico-pathological studies cohort 
 
CI: cognitive impairment; CN: cognitively normal; LDMC: Long duration minimal change; LD: Long 
duration; MC: Minimal change; C: control; MSA: multiple system atrophy. 
No.  Study Case  Diagnosis Age Sex Disease duration 
       
1 CI 
LDMC 
CI-1 
LD-MSA 1 
MSA 77 F 16 
2 CI CI-2 MSA 75 M 9 
3 CI CI-3 MSA 82 F 9 
4 CI CI-4 MSA 54 M 7 
5 CI CI-5 MSA 74 F 8 
6 CI CI-6 MSA 60 M 6 
7 CI CI-7 MSA 57.8 M 12 
8 CI CI-8 MSA 56 M 7 
9 CI 
LDMC 
CI-9 
LD-MSA 3 
MSA 66.8 F 19 
10 CI 
LDMC 
CN-10 
C-MSA 1 
MSA 76 F 8 
11 CI 
LDMC 
CN-11 
C-MSA 4 
MSA 63.1 M 12 
12 CI CN-12 MSA 54 M 7 
13 CI CN-13 MSA 57 M 8 
14 CI CN-14 MSA 72 F 8 
15 CI CN-15 MSA 76 F 12 
16 CI CN-16 MSA 72 F 15 
17 CI CN-17 MSA 73 M 9 
18 CI CN-18 MSA 65 M 7 
20 LDMC LD-MSA 2 MSA 66 F 17 
22 LDMC LD-MSA 4 MSA 62 F 18 
23 LDMC MC-MSA 1 MSA 65 M 7.5 
24 LDMC MC-MSA 2 MSA 39 F 5.5 
25 LDMC MC-MSA 3 MSA 46 M 6.5 
26 LDMC MC-MSA 4 MSA 57 F 4 
27 LDMC MC-MSA 5 MSA 45 M 4 
28 LDMC MC-MSA 6 MSA 65 M 2.5 
31 LDMC C-MSA 2 MSA 56 F 10 
32 LDMC C-MSA 3 MSA 67 F 9 
33 LDMC C-MSA 5 MSA 82 F 5 
34 LDMC C-MSA 6 MSA 72 M 8 
35 LDMC C-MSA 7 MSA 58 F 5 
36 LDMC C-MSA 8 MSA 60 F 9 
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2.1.3. Regional and cellular expression of SNCA in MSA 
MSA cases were pathologically typed according to published criteria (Ozawa et 
al., 2004) and grouped into mixed, SND and OPCA types as described in 
Chapter 2: Materials and methods section 2.4. Frozen tissue from 5 MSA-SND, 5 
MSA-OPCA, 5 MSA-mixed types were selected and sex and age –matched to 5 
PD and 4 normal control cases to study regional SNCA mRNA expression. The 
regions studied were the posterior frontal cortex (grey matter and white matter), 
occipital cortex (grey matter and white matter), dorsal putamen, pontine base and 
cerebellar white matter. For the cellular expression study, the pons of 5 MSA-
mixed type and 6 normal controls was used to isolate neurons and 
oligodendrocytes. Cases that did not have frozen tissue available were excluded.  
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Table ‎2.2. SNCA mRNA expression study cohort 
  
Study Case  Diagnosis MSA type Age Sex 
Regional 
expression 
1 MSA Mixed 56 F 
2 MSA Mixed 62 M 
3 MSA Mixed 64 F 
4 MSA Mixed 66 M 
5 MSA Mixed 70 F 
6 MSA SND 50 F 
7 MSA SND 54 F 
8 MSA SND 58 F 
9 MSA SND 63 M 
10 MSA SND 72 M 
11 MSA OPCA 56 M 
12 MSA OPCA 60 F 
13 MSA OPCA 61 M 
14 MSA OPCA 64 M 
15 MSA OPCA 66 F 
16 PD  NA 61 F 
17 PD NA 63 M 
18 PD NA 65 M 
19 PD NA 67 F 
20 PD NA 70 M 
21 Control NA 57 M 
22 Control NA 69 M 
23 Control NA 71 M 
24 Control NA 73 F 
Cellular 
expression 
1 MSA Mixed 50 M 
2 MSA Mixed 70 F 
3 MSA Mixed 56 M 
4 MSA Mixed 64 F 
5 MSA Mixed 64 M 
6 Control NA 69 M 
7 Control NA 82 F 
8 Control NA 73 F 
9 Control NA 85 M 
10 Control NA 80 F 
11 Control NA 83 M 
MSA: multiple system atrophy; PD: Parkinson’s disease; SND: striatonigral degeneration; 
OPCA: Olivopontocerebellar atrophy; NA: not applicable. 
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2.2. TISSUE PROCESSING 
Samples were collected from brains donated to the Queen Square Brain Bank 
(QSBB) for Neurological Disorders, UCL Institute of Neurology, London.   The 
donations were made according to ethically approved protocols and tissue is 
stored under a license issued by the Human Tissue Authority (No. 12198). One 
half of the brain is sliced in the coronal plane, flash frozen and stored at -80C 
upon arrival to the QSBB, while the other half is fixed in 10% buffered formalin. 
Blocks are then sampled from the formalin fixed half brain, processed and 
embedded in paraffin wax using routine protocols.  
2.3. IMMUNOHISTOCHEMISTRY ON FFPE 
Eight-micrometre-thick section were cut, deparaffinised and placed in 
methanol/H2O2 (100:1) solution for 10 min to eliminate endogenous peroxidase 
activity. Following washes in PBS, pre-treatment was carried out with formic acid 
(98%) for 30 min for -synuclein and A immunohistochemistry and proteinase 
K for GFAP immunohistochemistry and then pressure cooking (10 min) in 
citrate buffer (0.1M) at pH 6.0 (except for GFAP immunohistochemistry).  
Sections were then placed in 10% non-fat milk for 30 min at room temperature 
(RT) to reduce non-specific binding, followed by incubation in the primary 
antibody for 1 hour at RT. After washes in PBS, the sections are incubated with 
biotinylated goat anti-rabbit IgG  or biotinylated goat anti-mouse IgG (Vector 
Laboratories, Burlingame, CA) at a dilution of 1:200 for 30 min at RT. The 
secondary antibody was washed off then the sections were incubated in the 
avidin-biotin complex solution for 30 min at RT. After washes in PBS, they were 
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treated in the 3,3’-diaminobenzidine (DAB) solution for 3 min. The DAB 
solution was washed off and the tissues were counterstained in Mayer’s 
haematoxylin for 10 sec. The tissue sections were then dehydrated in graded 
alcohol (70%, 90%, and absolute alcohol), cleared in three changes of xylene, and 
then mounted with DPX mounting medium. 
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 Host Dilution Source (cat. no.) 
Primary antibody    
α-synuclein Mouse 1:50 Vector Laboratories, Burlingame, CA (VP A106) 
α-synuclein Mouse 1:1000 BD Transduction (610787) 
GFAP Rabbit 1:1000 DakoCytomation, Denmark (Z0334) 
-Amyloid (A) Mouse 1:100 DakoCytomation, Denmark (M0872) 
Tau (AT8) Mouse 1:600 Source Bioscience, UK  (90206) 
TDP – 43 Rabbit 1:2000 ProteinTech, Chicago, IL (12892-1-AP) 
Secondary antibody 
Biotinylated rabbit anti-mouse IgG Mouse 1:200 DakoCytomation , Denmark (E0354) 
Biotinylated swine anti-rabbit IgG Rabbit 1:200 DakoCytomation , Denmark (E0353) 
Table ‎2.3. Primary and secondary antibodies  
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2.4. EVALUATION OF IMMUNOHISTOCHEMISTRY 
2.4.1.  MSA cognitive impairment group 
GCI burden was assessed in the anterior frontal (Brodmann area 6), posterior 
frontal (Brodmann area 4), parietal (Brodmann areas 5&7), temporal (Brodmann 
area 19), occipital (Brodmann area 17), and cingulate (Brodmann areas 24,32 
&33) cortices, hippocampus, amygdala, caudate, putamen, substantia nigra, pons, 
medulla and cerebellum in a quantitative manner using the image analysis 
software, ImagePro Plus 7.0. A systematic uniform random distribution was used 
to generate 20 counting frames. Using the systematic uniform random 
distribution, allows for coverage of the entire region of interest and generation of 
random counting frames without any overlap (Fig. 2.1). GCI and NCI inclusions 
were visually identified and counted at 400x magnification and the counting 
frame was set at 125µm x 125µm. The density of inclusions was then calculated 
by dividing the total number of inclusions or cells counted by the total number 
of counting frames (cells/125µm2).  The counting criteria are presented in Table 
2.2. 
   
Table ‎2.4. GCI counting criteria 
Inclusion criteria Exclusion criteria 
 Flame-shaped, sickle-shaped, 
ovoid 
 α –synuclein positive  
 presence of nucleus not essential 
as long as morphology is 
characteristic 
 If the inclusion is of thin or 
reduced bulk that it could be 
confused for threads.  
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Figure ‎2.1. ImagePro Plus 7.0 analysis  
Schematic representation (A) and representative image (B) of ImagePro Plus 7.0 
analysis. Analysis was carried out using systematic uniform random distribution to 
generate counting frames set at 125µm x 125µm Using the systematic uniform random 
distribution, allows for coverage of the entire region of interest and generation of 
random counting frames without any overlap. Only GCIs or NCIs that fell within or on 
the green border of the counting frame were manually counted (C). Scale bar: 20µm. 
Region of interest 
Point frame 
Count frame 
A 
B 
C 
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Neuronal loss, gliosis and concomitant pathologies (A, CAA, tau, TDP-43, 
Lewy bodies, and SVD) were assessed in a semi-quantitative manner according to 
published criteria (Mirra et al., 1991; Braak et al., 2003, 2006; Ozawa et al., 2004; 
Williams et al., 2007; Lashley et al., 2008; Mackenzie et al., 2010, 2011). A score 
scale of 0 - +3 was used to indicate increasing pathology as seen in Table 2.3.  
Furthermore, A semi-quantitative scores for diffuse and mature A plaques 
were each summated in the regions analysed to give a sub-total score (range 0 to 
13) and a total score (diffuse + mature; range 0 to 21) in cortical regions. 
 
2.4.2. MSA long duration/ minimal change group 
Neuronal loss, GCIs, neuronal cytoplasmic inclusions, and gliosis were assessed 
in a semi-quantitative manner and MSA pathological type was determined based 
on a published method (Ozawa et al., 2004). Concomitant pathologies (A, 
CAA, tau, TDP-43, Lewy bodies, and SVD) were also assessed according to 
published criteria (Mirra et al., 1991; Braak et al., 2003, 2006; Williams et al., 
2007; Lashley et al., 2008) and summarized in Table 2.3. Diffuse and mature A 
plaque semi-quantitative scores were each summed up to give a subtotal score 
(range 0 to 13) and then calculated together to give a total score (range 0 to 21) in 
cortical regions analysed as above. 
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Table ‎2.5. Semi-quantitative scale  
Parameter Scale Objective 
magnification 
GCI & NCI 
burden 
0 No GCIs present x20 objective of  
mean of five 
random fields 
+1 1-5 inclusions   
+2 6 - 19 inclusions   
+3  20 inclusions   
Neuronal loss 
 
0 No neuronal loss x10 – x40 
 
+1 Slight neuronal loss 
+2 Moderate neuronal loss 
+3 Severe neuronal loss    
Gliosis 
 
0 Gliosis absent x10 – x20 
 
+1 Astrocytes around blood vessels and sub-pial    
+2 Astrocytes around blood vessels, sub-pial and 
extending into intervening parenchyma 
+3 Greater burden than +2 
CAA 
 
0 No amyloid  
x10 – x40 
 
+1 Scattered vessels in leptomeninges or cortex 
with patchy deposition 
+2 As +1 with occasional vessels having 
circumferential  deposition 
+3 Widespread circumferential deposition 
+4 Severe deposition of amyloid accompanied 
by projection of amyloid into the adjacent 
parenchyma 
SVD 
 
0 Vessels normal x10 – x40 
 
+1 Occasional vessels affected 
+2 A significant proportion of small vessels 
affected with few or no sequelae noted 
+3 A significant proportion of the small vessels 
affected with obvious sequelae 
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Figure ‎2.2. GCI semi-quantitative scale. 
GCI grading scale in grey (A-C) and white (D-F) matter as assessed using αSyn immunohistochemistry.  A score of ‘+1’ was 
denoted to fields that contained 1-5 inclusions (A, D), ‘+2’  6 - 19 inclusions  (B, E) and ‘+3’ where there were  20 inclusions 
(C, F).  Scale bar: 50µm 
A 
D 
B C 
E F 
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Figure ‎2.3. Neuronal loss grading scheme  
Neuronal loss semi-quantitative grading scale where ‘+1’ denotes mild, ‘+2’ moderate 
and ‘+3’ severe neuronal loss in the cerebellum, substantia nigra, olivary nucleus, 
pontine base, putamen and caudate.  
CBM: cerebellum; SbN: substantia nigra; ION: inferior olivary nucleus; PB: pontine base; 
PUT: putamen; CAU: caudate. Scale bar: 50µm (SbN, ION, PB, PUT & CAU at same 
magnification).  
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A 
D 
B C 
E F 
Figure ‎2.4. Gliosis semi-quantitative scale. 
Astrogliosis grading scale in grey (A-C) and white (D-F) matter as assessed using GFAP immunohistochemistry.  A score of ‘+1’ 
was denoted to fields where astrocytes were found around blood vessels and sub-pial (A, D), ‘+2’  where astrocytes were around 
blood vessels, sub-pial and extended into intervening parenchyma (B, E) and ‘+3’ to fields where there was greater burden than +2 
fields (C, F).  Scale bar: 50µm 
A 
D 
B C 
E F 
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Figure ‎2.5. Cerebral arterioangiopathy 
(CAA) grading scheme 
CAA graded on a 5-point scale where ‘0’ 
indicates the absence of amyloid deposits, 
‘+1’ scattered vessels in leptomeninges or 
cortex with patchy deposition (A), ‘+2’ as 
+1 with occasional vessels having 
circumferential deposition (B), ‘+3’ 
widespread circumferential deposition (C) 
and ‘+4’ severe deposition of amyloid 
accompanied by projection of amyloid into 
adjacent parenchyma (D) or vessel wall 
degeneration with ‘double barrel’ 
appearance (E) as shown by Aβ-
immunohistochemistry. Scale bar: 100µm (A, 
B, E same magnification) 
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Figure ‎2.6. Small vessel disease (SVD) 
grading scheme 
Arteriolosclerosis affects small vessels which 
show hyaline mural thickening (A,B). The 
sequelae include lacunes due to increased 
perivascular spaces (C), small infarcts (D), 
perivascular rarefaction (E), diffuse white matter 
attenuation (F) and fibrinoid necrosis of vessels 
(G). SVD graded on a 4 point scale where ‘0’ 
denotes vessels are unaffected, ‘+1’ occasional 
vessels affected, ‘+2’ a significant proportion of 
vessels are affected with few or no sequelae 
noted and ‘+3’ where a significant proportion of 
vessels are affected with obvious sequelae. Scale 
bar: 200µm (A, B, D, E same magnification); 50µm 
(F,G same magnification); 200µm (C).  
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2.5. PATHOLOGICAL SUB-TYPING ANALYSIS 
MSA cases were assigned a pathological sub-type of SND, OPCA or mixed 
according to a modification of the published scheme by Ozawa et al. (14) by only 
assessing the caudate (Cau 3 & 4), putamen (Put 3 & 4), substantia nigra (SbN 
4,5,6), pontine base (Pons 2), olive (Olive 1) and cerebellum (CBH) (Fig. 2.2). 
Neuronal loss is assessed in the above mentioned regions and given a grade of 0 
to +3 depending on the severity of cell loss. Neuronal cell loss scores are 
recorded for each structure and an overall score is given to denote the grade of 
pathology in StrN and OPC regions (Table 2.4). The combination of StrN and 
OPC pathology grades is used to assign the case as SND, OPCA or mixed sub-
type (Table 2.5). The MSA case is sub-typed as SND if neuronal loss is 
predominant in the StrN regions, OPCA if neuronal loss is predominant in the 
OPC regions, and mixed if the neuronal loss score is equal in both regions.  
 
 
 Figure 2.7. Regions for MSA pathological typing analysis 
(adapted from Ozawa et al 2004) 
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Table ‎2.6. StrN and OPC grading  
StrN Grade 
StrN 1 SbN + or ++ with 0 OR + in caudate, GP or Putamen 
StrN 2 SbN and Putamen ++ OR +++ with + OR ++ in caudate and GP 
StrN 3 SbN and putamen +++ 
OPC Grade 
OPC 1 Olive, pons or cerebellum 0 or + OR only one structure with ++ 
and others 0 
OPC 2 Olive, pons or cerebellum ++ OR one area +++ with <++ in 
remaining 2 areas 
OPC 3 Olive, pons or cerebellum +++ in more than 2 regions OR +++ in 
one region and ++ in 1 or 2 other regions 
 
Table ‎2.7. Assignment of MSA pathological type  
Pathological 
phenotype 
Grade of StrN 
pathology 
Grade of OPC 
pathology 
Name of 
combination 
SND type 3 2 SND 3–OPC 2 
3 1 SND 3–OPC 1 
2 1 SND 2–OPC 1 
OPCA type 2 3 SND 2-OPC 3 
1 3 SND 1–OPC 3 
1 2 SND 1–OPC 2 
Mixed type 3 3 SND 3–OPC 3 
2 2 SND 2–OPC 2 
1 1 SND 1–OPC 1 
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2.6. DOUBLE/TRIPLE IMMUNOFLUORESCENCE  
Double and triple immunofluorescence labelling was carried out using sequential 
labelling protocol. The antibodies used are presented in  
Table ‎2.8.  
αSyn and NG2  
Frozen tissue sections were acclimatised to RT before incubating in normal goat 
serum at a dilution of 1:100 in PBS (Vector Laboratories, Burlingame, CA) for 20 
min at RT. They were incubated in the first primary antibody, NG2 (R&D 
Systems, Minneapolis, MN), at a dilution of 1:200 for 1 hour at RT. After washes 
in PBS, the tissue sections were incubated with biotinylated goat anti-mouse IgG 
(Vector Laboratories, Burlingame, CA) at a dilution of 1:200 for 30 min at RT. 
The sections were incubated in the avidin/biotin (ABC) solution (Vector 
Laboratories, Burlingame, CA) for 30 min at RT. After washing off the ABC 
solution, the sections were incubated in fluorophore tyramide amplification 
reagent working solution of the TSA Plus Fluorescence Systems kit 
(PerkinElmer, Massachusetts, USA) for 15 min. After washes in PBS, the second 
primary antibody, αSyn (1:800; Abcam, Cambridge, UK), was then added and 
incubated for 1 hour at RT. Washing off the primary antibody was followed by 
incubation in  Alexa Fluor® 568 goat anti-rabbit IgG secondary antibody 
(1:1000; Invitrogen,  Paisley, UK) for 1 hour at RT. The secondary antibody was 
then washed off and the slides were mounted with VECTASHIELD Mounting 
Medium with DAPI (Vector Laboratories, Burlingame, CA). Autofluorescence 
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was not dramatically reduced after treatment with Sudan Black, therefore, this 
step was not further pursued. 
αSyn, MBP and CNPase 
Frozen tissue sections were acclimatised to RT before incubating in normal goat 
serum (NGS) for 20 min at RT. The first primary antibody, CNPase (1:100; R&D 
Systems, Minneapolis, MN), was added for 1 hour RT. After washes in PBS, 
sections were incubated in Alexa Fluor® 488 goat anti-chicken IgG secondary 
antibody (1:1000; Invitrogen, Paisley, UK) for 1 hour at RT. The second primary 
antibody, MBP (1:500; Convance, Cambridge, UK), was then added for 1 hour at 
RT after washing off the secondary antibody. This was followed by 1 hour 
incubation at RT in Alexa Fluor® 680 goat anti-mouse IgG secondary antibody 
(1:1000; Invitrogen, Paisley, UK). After washes in PBS, sections were incubated in 
the third primary antibody, αSyn (1:800; Abcam, Cambridge, UK). The final 
secondary antibody, Alexa Fluor® 568 goat anti-rabbit IgG secondary antibody 
(1:1000; Invitrogen, Paisley, UK), was then added to the sections for 1 hour at 
RT. After washing in PBS, the sections were mounted with VECTASHIELD 
Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). 
Qualitative analysis was conducted by systematically scanning the entire section 
for evidence of co-localisation using widefield and confocal fluorescence 
microscopy (Leica DM550 and Leica SPE, Leica Microsystems, Milton Keynes, 
UK).   
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Table ‎2.8. Antibodies used in double/triple immunofluorescence 
 Host Dilution Source (cat. no.) 
Primary antibody    
α-synuclein Rabbit 1:800 Abcam, Cambridge, UK (ab15530) 
NG2 Mouse 1:200 R&D Systems, Minneapolis, MN (MAB2585) 
CNPase Chicken 1:100 Abcam, Cambridge, UK (ab50739) 
MBP Mouse 1:500 Convance,  Cambridge, UK  (SMI-94) 
Secondary antibody    
Alexa Fluor® 568 goat anti-rabbit IgG Rabbit 1:1000 Invitrogen,  Paisley, UK (A11011) 
Alexa Fluor® 488 goat anti-chicken IgG Chicken 1:1000 Invitrogen,  Paisley, UK (A11039) 
Alexa Fluor® 647 goat anti-mouse IgG Mouse 1:1000 Invitrogen,  Paisley, UK  (A21235) 
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2.7. FROZEN TISSUE SAMPLING FOR REGIONAL EXPRESSION 
STUDIES 
Frozen tissue sample (100mg) were collected from the posterior frontal region 
(PF; Brodmann area 4), occipital region (OC; Brodmann area 17), dorsal 
putamen, pontine base and cerebellar white matter of MSA, PD, and control 
cases. Grey and white matter were separately sampled from the PF and OC. The 
following landmarks were used to ensure consistency of sampling between the 
different cases: PF at the level of the pulvinar, OC at the calcarine fissure, 
putamen at the level of the thalamus, pons at the level of the locus coeruleus and 
cerebellum at the level of the dentate. The sample were collected in sterile 
microcentrifuge tubes and stored at -80C until use.  
2.8. STAINING PROTOCOL FOR USE IN LASER CAPTURE 
MICRODISSECTION 
2.8.1. Rapid immunohistochemistry 
Frozen sections from the cerebellum (at the level of the dentate nucleus) were 
cut at 7 µm, collected on uncharged, sterile glass slides and warmed to RT for 30 
seconds. They sections were then fixed in ice-cold acetone for 3 min and 
immunostained using  oligodendrocyte-specific protein (OSP) primary antibody 
(Abcam, UK, ab7474) and VECTASTAIN Elite ABC kit (Vector labs, 
Burlingame, CA, PK-6101). Sections were blocked with normal goat serum (2%) 
for 3 min then incubated in OSP (1:10) for 3 min at RT. After a brief rinse with 
tris-buffered saline (TBS), sections were incubated in 5% biotinylated secondary 
antibody for 3 min at RT, then rinsed again with TBS. The avidin-biotin complex 
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solution was then added to the section for 3 min at RT then rinsed off. DAB 
peroxidase substrate kit (Vector labs, Burlingame, CA, SK-4100) was used to 
visualise the reaction by incubating section for 3 min at RT. The sections were 
rinsed with TBS, dehydrated in graded alcohol (70%, 95%, 100%, 100% for 1 
min each), cleared in two changes of xylene and allowed to air dry in an air-flow 
hood for an hour prior to LCM. This rapid IHC protocol was carried out under 
sterile conditions and using DEPC-treated water.  
2.8.2. Toluidine blue nuclear staining 
Frozen sections from the pons (at the level of the locus coeruleus) were cut at 7 
µm, collected on uncharged, sterile glass slides and warmed to RT for 30 
seconds. They sections were then fixed in ice-cold acetone for 3 min and placed 
in Toluidine blue stain for 1 min at RT. After careful washes in DEPC-water, the 
sections were dehydrated in graded alcohol (70%, 95%, 100%, 100% for 1 min 
each), cleared in two changes of xylene and allowed to air dry in an air-flow hood 
for an hour prior to LCM. 
2.9. LASER CAPTURE MICRODISSECTION  
PixCell II laser capture microdissection system (Arcturus Engineering, Mountain 
View, CA, USA) and Arcturus CapSure Macro caps (Applied Biosystems, UK, 
LCM0211) were used to perform LCM. The following parameters were used to 
isolate neurons: 7.5 µm spot size, 30 mW power and 20x objective and 
oligodendrocytes: 7.5 µm spot size, 20 mW power and 20x objective. A CapSure 
Macro cap was placed on the air-dried, stained section then the infrared laser was 
fired causing the thermoplastic film of the cap to melt and adhere to the cells of 
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interest. After microdissection, the film was separated from the cap using sterile 
tweezers and transferred to a sterile 0.5 mL Eppendorf tube for RNA extraction.  
2.10. RNA EXTRACTION OF REGIONAL BRAIN SAMPLES 
RNA extraction was carried out using RNeasy Mini Kit (Qiagen). 700 L of 
QIAzol to the sample, which was then disrupted and homogenized using 
TissueRuptor (Qiagen). The homogenized sample was left at RT for 5 min.  To 
the homogenized sample, 140 L of chloroform was added and the sample 
vortexed for 30 sec and incubated at RT for 2-3 min. The sample was then 
centrifuged at 12000 xg at 4C for 15 min. After centrifugation, the aqueous 
phase (upper layer) was transferred to a sterile 2 mL RNase free tube to which 
100% ethanol (1.5x the volume of the aqueous phase) was added and mixed with 
the pipette to precipitate the RNA. Up to 700 L of the sample was added into 
the spin column (including any precipitate) and  centrifuged at 10000 rpm at RT 
for 1 min. Discard flow-through and wash the samples of salt traces and 
impurities by adding 700L of the RWT solution and spin the column at 10000 
rpm at RT for 1 min. Discard flow-through then add 500L RPE solution and 
spin the column at 10000 rpm at RT for 1 min. Discard flow-through and repeat 
the washing step. Discard flow-through then add 500L RPE solution and spin 
the column at 10000 rpm at RT for 2 min. Transfer the column to a new 1.5 mL 
RNase free tube. Add 25 L RNase-free water to the column. Let stand for 5 
min at RT, then spin at 10000 rpm at RT for 1 min. The elute contains the 
extracted RNA. RNA quality and concentration was then assessed using the 
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Nanodrop and Agilent Bioanalyser 2100. The RNA sample may be stored at -
80C. 
2.11. RNA EXTRACTION OF LCM SAMPLES 
RNA extraction of LCM samples was carried out using the Arcturus PicoPure 
RNA isolation kit (Applied Biosystems, UK, KIT0204). 50 µL Extraction buffer 
was added to the sterile tube containing the film with microdissected cells and 
incubated for 30 min at 42C. After centrifugation at 800xg for 2 min at RT, the 
film was discarded and the cell extract saved. The RNA Purification Column had 
to be pre-conditioned by adding 250 µL Conditioning buffer to it, incubating for 
5 min at RT then centrifuging at 16000xg for 1 min at RT. RNA was precipitated 
by adding 70% Ethanol to the cell extract and mixed by pipetting. The cell 
extract/ethanol solution was then transferred to the pre-conditioned column and 
centrifuged at 100 xg for 2 min then 16000 xg for 1 min at RT. The column was 
then subjected to a series of washing steps as follows: 100 µL wash buffer (W1) 
and centrifuge at 8000 xg for 1 min, 100 µL was buffer (W2) and centrifuge at 
8000 xg for 1 min then 100 µL wash buffer (W2) and centrifuge at 16000xg for 2 
min at RT. The column was then transferred to a new sterile 1.5 mL Eppendorf 
tube and 13 µL Elution buffer was added to the column. After a 1 min 
incubation at RT, the column was centrifuged at 1000 xg for 1 min then at 
16000xg for 1 min at RT. The elute contains the extracted RNA. RNA quality 
and concentration was then assessed using the Nanodrop and Agilent 
Bioanalyser 2100. The RNA sample may be stored at -80C. 
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2.12. REVERSE TRANSCRIPTION  
RNA is reverse transcribed to form cDNA using SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen, UK). According to manufacturer’s instructions, the 
following components are mixed in a tube for a single reaction. For multiple 
reactions, prepare a master mix without RNA. 
 
 
 
 
 
After gently mixing tube contents, incubate at 25C for 10 min. After that, 
incubate at 42C for 60 min and terminate with a 5 min incubation at 85C. Store 
at -20C until use. cDNA may be used diluted or undiluted for PCR reaction. 
 
2.13. AGAROSE GEL ELECTROPHORESIS  
A 2% agarose gel was prepared by adding 2g of agarose to 100mL 1X TAE 
buffer in a flask and mixed by swirling the flask. This was then heated in the 
microwave for about 1 min to dissolve the agarose. The flask was then removed 
from the microwave and allowed to cool down for about a minute at RT after 
which 5 L SafeView (NBS-SV1, NBS Biologicals) into gel to help visualize the 
bands.  The gel was then poured into the gel frame and place at 4C for about 30 
min so that it may set. 
                         Contents Volume (L) 
5X VILO Reaction Mix 4 
10X SuperScript Enzyme Mix 2 
RNA (up to 2.5g) x 
DEPC-treated water to 20 
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Once the gel has set, it was placed in the electrophoresis tank containing 1X 
TAE buffer. Into the first well 4 L of HyperLadder IV or V (Bioline, UK) was 
added. Samples were mixed with 5x Orange G and 15L were loaded into the 
other wells. The gel was run at 100V for 30 - 45 min. An image of the gel was 
taken using the Gel capture software.  
2.14. QUANTITATIVE PCR (QPCR) 
2.14.1.  Primers 
Primers for the genes of interest (SNCA and SNCA112) were designed in house 
(Table ‎2.9). Where the isoform had an exon spliced out, the primer was designed 
across an exon-exon boundary, reducing contamination through amplification of 
genomic DNA. Reference genes (TBP, UBC, GAPDH) were designed using 
RTprimerDB (Table 2.8). 
 
2.14.2. Real-time PCR 
Real-time PCR was performed on Stratagene MX3000p (Agilent technologies, 
CA) using Power SYBR Green Master Mix (Applied Biosystems). According to 
manufacturer’s instructions, a master mix for each gene was prepared by mixing 
the following components in sterile tubes. The volumes presented are for a single 
reaction. 
 
 
 
 
                         Contents Volume (L) 
Power SYBR Green PCR Master Mix 10 
Forward primer (500nM) 1 
Reverse primer (500nM) 1 
Molecular biology grade water 3 
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Table ‎2.9. Alpha-synuclein primer information 
  
Gene SNCA 
Gene name synuclein, alpha (non A4 component of amyloid precursor) 
RefSeq no. NM_001146055.1 
Primer 
sequence 
F: CAACAGTGGCTGAGAAGACCA 
R: GCTCCTTCTTCATTCTTGCCCA   
Alignment F: base 228 to 249 
R: base 369 to 390 
Amplicon 
sequence 
CAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAA
TGTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGT
AGCCCAGAAGACAGTGGAGGGAGCAGGGAGCATTGC
AGCAGCCACTGGCTTTGTCAAAAAGGACCAGTTGGGC
AAGAATGAAGAAGGAGC 
Exon 3-5 
Amplicon 
length (bp) 
163 
Splice variant Full transcript 
Organism Homo sapiens 
Source In house design 
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Table ‎2.10. Reference genes primer information 
Gene TBP UBC GAPDH 
Gene name TATA box binding protein Ubiquitin C Glyceraldehyde-3-phosphate dehydrogenase 
RefSeq no. NM_003194 NM_021009 NM_002046 
Primer 
sequence 
F: TGCACAGGAGCCAAGAGTGAA 
R: CACATCACAGCTCCCCACCA 
F: ATTTGGGTCGCGGTTCTTG 
R: TGCCTTGACATTCTCGATGGT 
F: GAAATCCCATCACCATCTTCCAGG 
R: GAGCCCCAGCCTTCTCCATG 
Alignment 
F: base 892 to 913 
R: base 1004 to 1024 
F: base 399 to 418 
R: base 511 to 532 
F: base 313 to 337 
R: base 413 to 433 
Amplicon 
sequence 
TGCACAGGAGCCAAGAGTGAAGAACAGTC
CAGACTGGCAGCAAGAAAATATGCTAGAG
TTGTACAGAAGTTGGGTTTTCCAGCTAAGT
TCTTGGACTTCAAGATTCAGAATATGGTGG
GGAGCTGTGATGTG 
ATTTGGGTCGCAGTTCTTGTTTGTGGATCG
CTGTGATCGTCACTTGACAATGCAGATCTT
CGTGAAGACTCTGACTGGTAAGACCATCAC
CCTCGAGGTTGAGCCCAGTGACACCATCGA
GAATGTCAAGCA 
 
GAAATCCCATCACCATCTTCCAGGAG
CGAGATCCCTCCAAAATCAAGTGGG
GCGATGCTGGCGCTGAGTACGTCGT
GGAGTCCACTGGCGTCTTCACCACC
ATGGAGAAGGCTGGGGCTC 
 
Amplicon 
length (bp) 
132 133 120 
Organism Homo sapiens Homo sapiens Homo sapiens 
Source 
RTPrimerDB 
(ID: 2630) 
RTPrimerDB 
(ID: 8) 
RTPrimerDB 
(ID: 1108) 
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To 96-well PCR plates, 15µL of the master mix was added to each well. Add 5 
L of diluted sample (1:10) or standards to the wells. The plates were covered 
using cover strips, placed into the Stratagene and run at the following profile: 
 
Hot start 1 cycle 95C 10 min 
2-step PCR 40 cycles 95C 15 sec 
 60C 1 min 
 
2.14.3. Reference genes 
The number and choice of reference genes was determined using the Stratagene 
(Agilent Technologies, California) and qBase (Biogazelle, Belgium) softwares. 
Initial quality control check of the reference genes primers was assessed by melt 
curve analysis and agarose gel electrophoresis. Only primers that produced a 
single peak on the melt curve graph and a band at the predicted size on the 
agarose gel were included in the qBase analysis.  A qPCR experiment was set up 
on the Stratagene using standards and unknown samples for each reference gene. 
The standard curve produced provides information on the efficiency and 
dynamic range of the primers.  The expression data is then entered into the 
qBase software. The output of qBase provides gNormM and gNormV values. 
The gNormM value is indicative of the average expression stability of the gene, 
while the gNormV value reflects the optimal number of reference genes that 
need to be used for the experiment. The candidate reference genes tested were 
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TBP, UBC, GAPDH, RPLP0, YWHAZ, B2M and SDHA and were chosen 
based on published literature (Vandesompele et al., 2002; Coulson et al., 2008; 
Trabzuni et al., 2011).  
2.14.4. Standards preparation 
Pooled cDNA samples from the posterior frontal cortex, pons, and cerebellar 
white matter of control cases were used to prepare the standards. After running a 
PCR for each gene, part of the PCR product was run on an agarose gel to check 
that the predicted product size was obtained. The rest of the PCR product was 
then cleaned up using the MicroClean kit (Microzone ltd, UK) according to 
manufacturer’s instructions to remove buffers, enzymes, primers, primer dimers 
and dNTPs. Briefly, an equal volume of microClean solution is added to the PCR 
product, mixed by pipetting and incubated at RT for 5 min. The mixture is then 
centrifuged at maximum speed (10 – 13000 rpm) at RT for 7 min.  After 
centrifugation, the supernatant is carefully removed. Another brief spin is 
required to remove any remaining liquid. The pellet is resuspended in 15L of 
TE (10/1 Tris-EDTA) buffer and incubated at RT for 5 min to rehydrate the 
PCR product. The concentration of the cleaned up PCR product is obtained 
using the Nanodrop. The number of copies/L is then calculated using the 
concentration, molecular weight and product size for each gene. This usually 
results in an original stock concentration of 1010 or 1011 copies/L.  From this 
original stock, the first working dilution (108) is prepared in tRNA water 
(5g/mL), then serially diluted 10-fold to a final dilution of 101. Standards are 
stored at -20C until use. 
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2.14.5. Expression calculation 
Real-time qPCR data is analysed using absolute or relative quantification method. 
The absolute quantification method was adopted for this thesis, where copy 
number of unknown samples was derived from standard curves for each gene of 
interest (GOI) and reference genes. The standard curves were produced from a 
starting material with known copy number as described in section ‎2.14.4. The 
GOI was then normalized to the geometric mean of the reference genes as 
recommended by Vandesompele et al (2002). The mean normalized copy 
number was then calculated for each region within each disease and control 
group. Statistical analysis was performed on the mean normalized copy number 
to extrapolate expression differences.  
2.14.6. Statistical analysis 
A multilevel statistical model was used for regional expression analysis using 
STATA 12 software. Data were first controlled for regions to determine 
expression differences in the different groups and then controlled for groups to 
determine expression pattern in the different regions and in both cases the 
significance levels set at 0.05.  The Mann-Whitney U test was used to analyse 
cellular expression data and the significance levels set at 0.05.   
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2.15. IN-VIVO STEREOTAXIC EXPERIMENTS 
2.15.1. Lysate preparation 
Inoculation material for mice stereotaxic experiments from MSA, PD and 
control cases were prepared according to a previously published protocol (Luk et 
al., 2012 a). About 100 mg of brain tissue from the pontine base of MSA and 
control cases and cingulate cortex from PD cases were homogenised in 1mL 
sterile PBS. The homogenate was centrifuged at 3000g for 5 min at 4C. The 
supernatant is then collected and protein assay run to determine total protein 
concentration of the sample. The sample is stored at -80C until use for surgery. 
The protocol of Masuda-Suzukake and colleagues (Masuda-Suzukake et al., 2013) 
was also used to prepare sarkosyl-insoluble lysate only from MSA pontine base 
for inoculation.  Firstly, 1g of tissue is homogenized in 5mL of Buffer A (10mM 
Tris-HCL pH 7.4, 0.8M NaCl, 1mM EGTA & 10% sucrose). After adding 
sarkosyl at a concentration of 2% to the homogenate, incubate for 30 min at 
37C. Sonicate then centrifuge the sample at 9100g for 10 min at 25C. Transfer 
the supernatant to another tube and further centrifuge at 113000g for 20 min at 
25C. this fraction is designated as the sarkosyl-soluble fraction. Wash the pellet 
with Buffer A then resuspend in saline. After centrifugation at 800g for 5 min, 
transfer the supernatant to a new tube and designate as sarkosyl-insoluble 
fraction. A protein assay is run on this fraction to determine the concentration of 
total protein and then the sample is stored at -80C until use for surgery. 
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Figure ‎2.5. Intracerebral inoculation material 
Lysates for intracerebral inoculation were prepared from MSA (A), PD (B), and normal 
control (C) human brain tissue. αSyn-positive GCIs from MSA pontine base and LB from 
PD cingulate cortex are evident while the normal control brain does not show any αsyn 
pathology. 
αsyn: α-synuclein; GCIs: glial cytoplasmic inclusions; LB: Lewy bodies; MSA: multiple system atrophy; 
PD: Parkinson’s disease. Scale bar: 50µm 
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2.15.2. Protein assay 
Pierce BCA Kit (Thermo Scientific) was used to determine total protein 
concentration. Firstly, standard dilutions were prepared according to 
manufacturer’s instructions as follows, using RIPA buffer as the diluent: 
Vial Volume of Diluent 
(L) 
Volume & Source of BSA 
(L) 
Final BSA Concentration 
(g/mL) 
A 0 300 of Stock 2000 
B 125 375 of Stock 1500 
C 325 325 of Stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0=Blank 
 
The working reagent was prepared by mixing reagents A and B at a ratio of 50:1. 
The required volume of working reagent was calculated using the following 
formula: (# standards + # unknowns) x (# replicates) x (volume of working reagent per 
sample; 200L). To a flat-bottomed 96 well plate, 200L working reagent and 
25L sample are added. After incubation for 30 min at 37C in the dark, the 
plate is measured at 562nm (540-590nm acceptable range). 
2.15.3. Stereotaxic surgery  
C57BL/6JOlaHsd mice (Harlan, Bicester, UK) between 2-4 months of age were 
anesthetized using isoflurane. The mice were placed on the stereotaxic frame and 
injected in one hemisphere with either MSA, PD, or control human brain lysates 
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(5µg total protein). Using a single needle insertion at +0.2mm relative to Bregma 
and +2.0 from midline, 2.0µL of the inoculum was introduced into the 
dorsolateral striatum (2.6 beneath the dura) and somatosensory cortex (0.8 
beneath the dura) at a rate of 0.15µL/min. The mice were monitored carefully 
during surgery and after recovery and were then sacrificed at the pre-determined 
time points of 4 and 30 dpi with a dose of Lethobarb 20% w/v Solution (Ayrton 
Saunders Limited, UK). After transcardial perfusion with PBS, the brains were 
removed, fixed in formalin for at least 24 hours, then processed and embedded 
in paraffin.    
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3       
         CLINICO-PATHOLOGICAL STUDIES IN MSA 
 
3.1. COGNITIVE IMPAIRMENT 
3.1.1. Introduction 
Cognitive impairment (CI) is considered as a non-supporting feature in the 
diagnosis of MSA according to the second consensus statement on MSA 
(Gilman et al., 2008). Recent clinical studies, however, have revealed that a 
proportion of MSA patients do suffer from some degree of cognitive 
dysfunction (Robbins et al., 1992; Testa et al., 1993; Meco et al., 1996; Wenning 
et al., 2000; Berent et al., 2002; Bak et al., 2005; Kawai et al., 2008; O’Sullivan et 
al., 2008; Kao et al., 2009; Kitayama et al., 2009; Brown et al., 2010; Colosimo et 
al., 2010; Siri et al., 2013). A large prospective study on cognitive function in 
MSA and PSP estimates that 11-32% of MSA patients are affected by some form 
of cognitive impairment (Brown et al., 2010). Testa and colleagues found that 
MSA-P patients performed poorly in visuospatial organization tests and the 
constructive and visuomotor ability tests in a study comparing the 
neuropsychological profiles of MSA-P and PD patients (Testa et al., 1993).  In a 
study by Meco and colleagues, MSA-P cases displayed more severe attentional 
deficits as compared to both PD and normal controls, while long term memory 
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and verbal fluency were intact (Meco et al., 1996). Comparing cognitive 
dysfunction across PD, MSA, and DLB disease groups, the greatest impairment 
was found in the DLB group and the least in the PD group, while the MSA 
group displayed a range of impairment between those two (Kao et al., 2009). The 
deficits found in differing degrees across those disease groups include executive 
and visuospatial functions and memory, but not language. Attention and memory 
deficits were found in 67.7% of MSA patients in a study of non-motor symptoms 
in atypical and secondary parkinsonism (Colosimo et al., 2010).  Poor 
performance in spatial short term memory, spatial working memory, planning, 
and attention set shifting tasks by MSA, PD, and Steele-Richardson-PSP (PSP-
RS) patients demonstrates that these three disease groups exhibit frontal lobe 
dysfunction (Robbins et al., 1994).  
In addition to the comparison of cognitive profiles of MSA patients with other 
disease groups, comparisons between the different MSA subtypes have also been 
made.  Chang and colleagues used voxel-based morphometry of magnetic 
resonance imaging (VBM-MRI) and neuro-psychological tests to evaluate the 
relationship between cognitive impairment and brain atrophy in MSA cases 
(Chang et al., 2009). Both MSA-P and MSA-C patients exhibited diminished 
cognitive abilities as compared to controls and this correlated with frontal 
atrophy and disease duration. Also, of the two subtypes, the executive function 
deficits and dementia were worse in the MSA-C subtype. Similarly, in a cohort of 
58 MSA patients, cerebral atrophy and white matter lesions detected by MRI 
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scans were found in those that showed signs of frontal executive dysfunction and 
dementia (Kitayama et al., 2009). Ten patients of the 58 showed CI with the 
impairment developing after the onset of ataxia in seven and before ataxia onset 
in the other three and all ten patients with CI were of the MSA-C subtype. It 
must be noted that there were only nine MSA-P patients included in this study, 
therefore, the predominance of cognitive impairment in the MSA-C subtype does 
not necessarily suggest that this subtype is more vulnerable to cognitive deficits, 
rather it may be attributed to a better representation of the MSA-C group as it is 
the dominant subtype in Asian population. The susceptibility of either MSA 
subtype to CI is further supported by another study where a greater degree of 
cognitive dysfunction was evident in MSA-P patients compared to MSA-C 
(Kawai et al., 2008). MSA-P patients exhibited deficits in visuospatial and 
constructional function, verbal fluency and executive function while the factors 
affected in MSA-C were visuospatial and constructional function. The authors 
suggest that the MMSE is not the most sensitive scale to differentiate MSA cases 
from others, as MSA patients had similar scores to those of normal controls.  
Furthermore, there was significant hypoperfusion in the dorsolateral prefrontal 
cortex, frontal and parietal lobe in MSA cases suggesting a role of these 
structures in the CI seen in MSA. (Kawai et al., 2008)  
These neuropsychometry and neuroradiological studies on MSA indicate that 
MSA patients exhibit signs cognitive impairment and that it should no longer be 
considered an exclusion criterion for diagnosis. Neuropathological examination 
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of MSA patients with signs of cognitive impairment will prove valuable in further 
understanding the pathogenic mechanisms leading to such deficits. To date there 
are only three published case reports from Japan detailing the macroscopic and 
microscopic features of MSA patients with documented cognitive impairment 
(Wakabayashi et al., 1998; Konagaya et al., 1999; Shibuya et al., 2000). This 
chapter addresses the issue of limited published clinic-pathological reports on 
MSA patients with cognitive impairment by assessing the clinical and 
pathological profile of MSA patients with cognitive impairment as compared to 
MSA patients with normal cognition.   
3.1.2. Hypothesis 
MSA patients with clinical evidence of cognitive impairment have more severe 
pathology in brain regions that are important for cognitive function. 
3.1.3. Aim 
The aim of this study is to determine if there is a difference in the distribution 
and burden of   pathological changes in MSA patients with cognitive impairment 
compared with MSA patients with normal cognition. The contribution of 
concomitant pathologies to cognitive impairment in MSA will also be assessed.   
3.1.4. Case selection 
Nine MSA cases with documented cognitive impairment and nine with normal 
cognition were selected in a retrospective analysis of clinical data recorded during 
life. Cognitive impairment had been assessed by Mini-mental states examination 
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(MMSE) by neurologists, and in some cases (n=5), formal neuropsychometry 
testing had been performed by a clinical psychologist. Neuropsychometry tests 
assess the following parameters: verbal memory, visual memory, working 
memory, visuospatial/constructive impairment, executive function, and language 
function (e.g. verbal fluency, comprehension, etc.). An MMSE score of 24-28 
(out of 30) is suggestive of mild cognitive impairment (MCI) and 23 of 
dementia. Medical records were reviewed by a neurologist (Helen Ling). Patients 
with the pathological diagnosis of MSA were categorized as having cognitive 
impairment (MSA-CI) if their MMSE scores were consistently  28 and cognitive 
impairment was documented by a clinician on at least one occasion. The final 
MMSE score prior to death, presence of depression, hallucinations and the use 
of additional cognitive tests including formal neuropsychometry to confirm the 
impairment of cognition were recorded.  The control MSA group was matched 
for age (≤ 5 years difference), sex, disease duration (≤ 1 year difference), and had 
no documented cognitive impairment (MSA-CN) by clinician or care giver.  
Patient demographics are displayed in Table ‎3.1. 
3.1.5. Methods 
Formalin-fixed paraffin-embedded blocks from the following 14 brain regions 
were used: anterior frontal, posterior frontal, parietal, temporal, occipital, and 
cingulate cortices, hippocampus, amygdala, striatum, substantia nigra, pons, 
medulla and cerebellar hemisphere. Immunohistochemical and routine 
histological staining techniques were used to assess neuronal loss, GCIs, NCIs 
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and concomitant pathologies (A, CAA, tau, TDP-43, Lewy bodies, and SVD) as 
described in Chapter ‎2: Materials and methods, sections ‎2.3. 
GCI and NCI burden was quantitatively assessed using ImagePro Plus 7.0 
software. The systematic uniform random sampling was used to generate 20 
counting frames in the regions of interest. Using the systematic uniform random 
sampling, allows for coverage of the entire region of interest and generation of 
random counting frames without any overlap. Counting was carried out at x400 
magnification and the counting frame was set at 125µm x 125µm. The total 
number of inclusions counted was divided by the total number of counting 
frames to give the density measure in 125 µm2. ‘Total cortical load’ is the sum of 
GCI or NCI counts in the neocortical regions (anterior frontal, posterior frontal, 
parietal, temporal, and occipital cortices) and the ‘total limbic load’ is the sum of 
counts of the cingulate cortex, amygdala and hippocampus.   
Neuronal loss and concomitant pathologies were assessed in a semi-quantitative 
manner. The regional severity of neuronal loss was graded on a 0 to +3 scale 
(Ozawa et al., 2004). A deposition in the form of diffuse and mature plaques 
was semi-quantitatively assessed in the frontal, temporal, parietal, occipital and 
entorhinal cortices according to the principles of ‘The Consortium to Establish a 
Registry for Alzheimer's disease’ (CERAD) (Mirra et al., 1991; Lashley et al., 
2008). Diffuse and mature A plaque semi-quantitative scores in all cortical 
region were each summed to give a subtotal score (score range 0 to 15) and then 
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the total diffuse and mature plaque scores were added together to give a total 
score (score range 0 to 30). Other concomitant pathologies including cerebral 
amyloid angiopathy (CAA), tau, TDP-43, Lewy bodies, and small vessel disease 
(SVD) were assessed according to published criteria (Mirra et al., 1991; Braak et 
al., 2003, 2006; Williams et al., 2007; Lashley et al., 2008; Mackenzie et al., 2010, 
2011). Neuropathological assessments were conducted blind to cognitive status 
by J.L.H and Y.T.A.  
Statistical analysis 
Statistical analysis was performed using SPSS PASW Statistics 18 software. The 
Mann-Whitney U test was used to compare GCI and Aβ plaque burden between 
groups. The significance level for GCI burden was set at p < 0.004 after 
Bonferroni correction for multiple comparisons (0.05/14) and p < 0.01 for Aβ 
plaque burden (0.05/5). The Wilcoxon Mann-Whitney U test or the Student’s t 
test was used to compare semi-quantitative grading or clinical data using p value 
of 0.05. Intra-rater reliability was assessed by repeating GCI burden 
quantification in 10% of the cases resulting in an intraclass correlation coefficient 
(ICC) of 0.989 (p<0.001) indicating high reproducibility the analysis.   
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3.1.6. Results 
 
Demographic and clinical data  
There were 12 cases with MSA-P and 6 cases with MSA-C; 5 MSA-P and 4 
MSA-C in the CI group and 7 MSA-P and 2 MSA-C in the CN group. The mean 
age at death was 67 years in the MSA-CI and 67.6 years in the MSA-CN 
subgroups (Student’s t test, p=0.90). The disease duration was 10.2 years in the 
MSA-CI and 9.6 years in the MSA-CN subgroups (Student’s t test, p=0.70). 
Among the 9 MSA-CI cases, 2 cases had at least one episode of hallucination, 
which was unrelated to infection or medications. The median score of the final 
MMSE was 25.8 out of 30 in the MSA CI group, and these scores were tested on 
average 2.7 years prior to death (Table ‎3.1). 
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*
 No. of years before death at which last MMSE score was taken.                        CI: cognitively impaired; CN: cognitively normal; ND: none documented                    
 
No.  CI/CN MSA 
type 
Age Sex Disease 
duration 
Cognitive assessment  Depression Hallucinations 
      MMSE 
(score) 
MMSE* 
(years) 
Neuropsychometry 
test 
   
1 CI MSA-P 77 F 16 26 0.9 ND No No 
2 CI MSA-P 75 M 9 19 0.3 ND Yes Yes 
3 CI MSA-P 82 F 9 26 2.2 ND No No 
4 CI MSA-C 54 M 7 25 2 Yes No No 
5 CI MSA-P 74 F 8 28 0.5 Yes Yes No 
6 CI MSA-C 60 M 6 28 3.9 Yes No No 
7 CI MSA-C 57.8 M 12 28 4 Yes Yes No 
8 CI MSA-C 56 M 7 26 6.1 ND No No 
9 CI MSA-P 66.8 F 19 27 4 Yes Yes Yes 
10 CN MSA-P 76 F 8 ND ND ND ND No 
11 CN MSA-P 63.1 M 12 ND ND ND ND No 
12 CN MSA-P 54 M 7 ND ND ND ND No 
13 CN MSA-C 57 M 8 ND ND ND ND No 
14 CN MSA-P 72 F 8 29 1.7 ND ND No 
15 CN MSA-P 76 F 12 ND ND ND ND No 
16 CN MSA-C 72 F 15 ND ND ND ND No 
17 CN MSA-P 73 M 9 ND ND ND ND No 
18 CN MSA-P 65 M 7 ND ND ND ND No 
Table ‎3.1. Demographic data of the MSA-cognitively impaired (CI) and the MSA-cognitively normal (CN) groups 
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Comparison of pathologies between MSA-P and MSA-C 
GCI, NCI, neuronal loss and Aβ- pathologies were compared between MSA-P 
and MSA-C group to determine if any differences exist irrespective of CI status. 
A statistically significant difference was not established between the two groups 
in the tested pathologies (Table ‎3.2). Accordingly, the cases were stratified by 
presence of CI so that the CI and CN groups were each comprised of both 
MSA-P and MSA-C cases.  
 
Table ‎3.2. Comparison of pathologies between MSA-P and MSA-C 
Pathology MSA-P vs. MSA-C 
(p-value)  
GCI 0.17 
NCI 0.43 
Neuronal loss 0.94 
Aβ plaques  
Diffuse 0.01 
Mature 0.11 
Total 0.03 
GCI, NCI and neuronal loss: Mann-Whitney U test Bonferroni correction for multiple 
comparisons at significance level p<0.004. Aβ plaques: Mann-Whitney U test Bonferroni 
correction for multiple comparisons at significance level p<0.01. 
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Glial cytoplasmic inclusions and neuronal cytoplasmic inclusions  
GCI burden was quantitatively assessed in all 14 regions (Figure ‎3.1). Although 
minor differences were found in the regional GCI load between the MSA-CI and 
MSA-CN groups these did not reach statistical significance in any region (Mann-
Whitney U test after Bonferroni correction, p>0.004). Similarly, when the total 
GCI load in neocortical and limbic regions was calculated in the two groups the 
small increase in load in the CN group was not found to be statistically 
significant (Mann-Whitney U test after Bonferroni correction, p>0.004). GCIs 
were abundant in StrN (caudate, putamen, substantia nigra) and OPC (inferior 
olivary nucleus, pontine nuclei, cerebellar white matter) regions but there was no 
difference in the total GCI burden in these regions between the CN and CI 
patients (Mann-Whitney U test after Bonferroni correction, p>0.004). NCI 
burden was quantitatively assessed in the same manner as GCIs, however, none 
were detected in either MSA-CI or MSA-CN cases.  
 
Neuronal loss 
Neuronal loss in the neocortical and limbic regions in the MSA-CI and MSA-CN 
groups was not detected using semi-quantitative analysis. Both groups 
demonstrated neuronal loss in the StrN and OPC regions, however, a statistically 
significant difference was only observed in the cerebellar Purkinje cells where 
there was greater neuronal loss in MSA-CI (Mann-Whitney U test after 
Bonferroni correction, p=0.001) (Figure ‎3.2). 
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Concomitant pathologies 
Assessment of A-pathology revealed that, although both diffuse and mature A 
deposits were more abundant in the MSA-CN group than the MSA-CI group, 
these did not individually, or in combination, reveal a statistical difference 
between the two groups (Figure ‎3.3). Tau-positive neurofibrillary tangles and 
neuropil threads were observed in cases from both groups (Figure ‎3.4). Using 
Braak and Braak staging for Alzheimer disease-associated neurofibrillary 
pathology (Braak et al., 2006), the degree of pathology in both groups reached a 
maximum of Braak & Braak stage II. The severity of Braak stages did not differ 
between the MSA-CI and MSA-CN groups (Wilcoxon rank-sum test, p=0.78) 
(Table ‎3.3). There was no difference between the proportion of cases with SVD 
(Wilcoxon rank-sum test, p=1.00) between the two groups. CAA was not present 
in the CI group, while there were two cases with mild and two cases with 
moderate CAA in the CN group (Mann-Whitney U test, p=0.03).  Sparse Lewy 
body pathology was present in only two MSA-CI cases, in the substantia nigra of 
one case and in the substantia nigra and locus coeruleus of the other. TDP-43 
inclusions were not detected in either MSA-CI or MSA-CN cases.   
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Figure 3.1 A  
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Figure 3.1. B
Figure ‎3.1. GCI burden in MSA patients with CI and normal cognition 
GCI load in all regions (A) and total cortical and limbic region counts (B). There was greater GCI load in the MSA-CN than MSA-CI groups however 
these results did not reach statistical significance (Mann-Whitney U test, p>0.004). The plots show median values as the line within the box, the box 
reflects the interquartile range and the whiskers the range of the values. Mann-Whitney U test with Bonferroni correction for multiple comparisons was 
used and significance level set at p <0.004.  CI: cognitively impaired; CN: cognitively normal; 

outliers; extreme outliers. 
 
 
p = 0.0452 
p = 0.535 
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Figure ‎3.2. Neuronal loss in MSA patients with CI and normal cognition 
Neuronal loss was most evident in the striatonigral  and olivopontocerebellar  regions, however, a statistically significant difference was 
only observed in the cerebellum where there was greater neuronal loss in MSA-CI. The plots show median values as the line within the box, the box 
reflects the interquartile range and the whiskers the range of the values. Mann-Whitney U test with Bonferroni correction for multiple comparisons was used and significance level 
set at p <0.004.  CI: cognitively impaired; CN: cognitively normal; 

outliers; ▲extreme outliers 
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Figure ‎3.3. Aβ plaque burden in MSA patients with CI and normal cognition 
Regional and total amyloid- diffuse (A), mature (B), and diffuse + mature (C) plaque scores in MSA patients with CI (n=9) and normal cognition (n=9). 
The burden of A pathology is greater in MSA patients with normal cognition than those with CI, however, these findings did not reach statistical 
significance (Mann-Whitney U test with Bonferroni correction for multiple comparisons at significance level p <0.01). The plots show median values as 
the line within the box, the box reflects the interquartile range and the whiskers the range of the values.  CI: cognitively impaired; 

outliers; extreme outliers 
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  Braak & Braak  AD tau stage CAA grade SVD grade 
 0 I II III IV V 0 1 2 3 0 1 2 3 
CI 
(n=9) 
3 
(33.3%) 
3 
(33.3%) 
3 
(33.3%) 
0 0 0 
9 
(100%) 
0 0 0 
7 
(77.8%) 
1 
(11.1%) 
0 
1 
(11.1%) 
CN 
(n=9) 
2 
(22.2%) 
4 
(44.4%) 
3 
(33.3%) 
0 0 0 
5 
(55.6%) 
2 
(22.2%) 
2 
(22.2%) 
0 
7 
(77.8%) 
1 
(11.1%) 
0 
1 
(11.1%) 
p-value 0.78 0.03 1.00 
 
Table ‎3.3. Concomitant pathology in MSA patients with cognitive impairment and normal cognition 
Braak & Braak‎Alzheimer’s‎disease‎(AD)‎tau‎staging,‎cerebral‎amyloid‎angiopathy‎(CAA)‎and‎small‎vessel‎disease‎
(SVD) were analysed in each case. No statistically significant difference was observed in the Braak and Braak stage 
or grade of small vessel disease between the MSA groups (Wilcoxon rank-sum test, p=0.78 and  p=1.00). CAA was 
only observed in four MSA-CN cases which had mild to moderate CAA pathology (Wilcoxon rank-sum test, p=0.03). 
CI: cognitively impaired; CN: cognitively normal; AD: Alzheimer’s disease; CAA: cerebral amyloid angiopathy; SVD: small vessel disease.  
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Figure ‎3.4. Concomitant pathologies 
Concomitant pathologies screened for include tau, parenchymal A deposition, cerebral amyloid angiopathy (CAA), TDP-43, Lewy bodies, and small vessel 
disease (SVD). Tau pathology is demonstrated by NFT and threads using AT8 immunohistochemistry (A; case 5, hippocampus). Mature and diffuse Aβ 
plaques are markers of Aβ pathology (B; case 14, frontal cortex), while Aβ deposition around blood vessels is indicative of CAA (C; case 12, occipital cortex). 
Lewy body as demonstrated by αSyn immunohistochemistry (D; case 2, locus coeruleus). TDP-43 normal and pathological (arrows) staining demonstrated with 
TDP-43 immunohistochemistry, however, TDP-43 pathology was not present in the cohort of this thesis. (E).  Thickened walls of blood vessels is a sign of 
SVD (F; case 5, striatum).  Scale bar: A, F: 20m;  B-E: 20m 
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3.1.7. Discussion 
The second consensus on MSA states that signs of impaired cognition are 
grounds for disregarding a diagnosis of MSA.  However, this view has been 
challenged by neuropsychological studies documenting CI in MSA patients and 
by some case studies of pathologically confirmed MSA patients reported to have 
CI (Testa et al., 1993; Wakabayashi et al., 1998; Konagaya et al., 1999; Shibuya et 
al., 2000; Soliveri et al., 2000; Lange et al., 2003; Krishnan et al., 2006; Kawai et 
al., 2008; O’Sullivan et al., 2008; Brown et al., 2010).  The most common 
presentation of cognitive abnormality in MSA is fronto-subcortical executive 
dysfunction followed by memory and visuospatial impairment (Testa et al., 1993; 
Robbins et al., 1994; Meco et al., 1996; Kao et al., 2009; Colosimo et al., 2010). 
Functional imaging studies demonstrated fronto-striatal dysfunction (Kawai et 
al., 2008) and hypoperfusion in prefrontal, frontal, temporal and parietal regions, 
which are probably the consequence of subcortical deafferentation of the cortical 
regions (De Volder et al., 1989; Gilman et al., 1994; Otsuka et al., 1996; Lee et al., 
2008 b). In this study, the pathological profiles of MSA patients with 
documented cognitive impairment and those with normal cognition were 
evaluated to elucidate possible mechanisms leading to diminished cognitive 
function. Regional GCI burden and neuronal loss were analysed in addition to 
Alzheimer’s pathology and other additional pathological changes. 
Cortical and limbic regions play an important role in cognitive function, 
therefore, pathology in these structures may lead to CI. In this study, a 
statistically significant difference in the GCI burden in cortical or limbic regions 
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between the MSA-CI and MSA-CN groups was not established. Despite the 
presence of GCIs in these regions, neuronal loss was minimal. The microscopic 
findings of the cohort of this thesis are similar to three Japanese case reports of 
MSA patients with cognitive impairment showing widespread GCIs and minimal 
neuronal loss in cortical regions  (Wakabayashi et al., 1998; Konagaya et al., 1999; 
Shibuya et al., 2000). The macroscopical findings, however, were unremarkable in 
both the CI and CN groups of the cohort of this thesis, unlike the Japanese case 
reports where frontal or temporal lobe atrophy was reported.  The minimal 
difference in GCI and neuronal pathology between these two groups 
demonstrated in the current study may suggest that they do not play a primary 
role in the development of cognitive dysfunction in MSA.  
The concept of subcortical dementia refers to cognitive disturbances caused by 
primary pathology in the basal ganglia, brainstem and cerebellum  (Turner et al. 
2002). Therefore, greater subcortical pathology in the CI group may contribute 
to their altered cognitive profiles.  There was widespread GCI pathology and 
neuronal loss in the StrN and OPCA regions in this cohort, however, a 
statistically significant difference was not observed between CI and CN group. 
As such, CI in MSA may not be contributed to by GCI and neuronal subcortical 
pathology. 
MMSE scores were used to categorise MSA cases into the cognitively impaired 
and normal groups. MMSE is widely used to assess cognitive impairment both as 
a screening tool and for purposes of diagnosis, however, its reliability has been 
challenged in the literature (Lopez et al., 2005; Mitchell, 2009; Nieuwenhuis-
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Mark, 2010).   The MMSE detects global cognitive impairment and has been 
shown to not be very reliable in distinguishing MCI in normal aging population 
and those with early dementia (Mitchell, 2009). As a test of global cognitive 
impairment, the MMSE is not informative on the specific domain affected and 
does not detect impairment in executive function (Lopez et al., 2005). This calls 
into question the usefulness of the MMSE on patients with MSA whose leading 
cognitive impairment is fronto-subcortical executive dysfunction (Testa et al., 
1993; Robbins et al., 1994; Meco et al., 1996; Kao et al., 2009). Therefore, using 
neuropsychometry tests designed to detect executive dysfunction maybe better 
suited for classifying MSA patients with cognitive impairment. Despite its 
limitations, the wide use of the MMSE renders it the most common measure of 
cognition in medical records and that is why it was employed as one measure to 
assess the cognitive state of the cohort of this study by retrospective analysis of 
clinical notes. The neurologists’ and carers’ judgement of cognitive decline which 
was significant enough to affect the patient’s activities of daily living was also 
included in the inclusion criteria in this study to improve sensitivity. 
Concomitant involvement of Alzheimer’s pathology in the form of Aβ plaques 
and tau pathology could also contribute to the cognitive impairment observed in 
MSA. Aβ plaques and tau load were analysed in this cohort. A diffuse and 
mature plaques were quantified in the frontal, temporal, parietal, occipital and 
entorhinal cortices. Both diffuse and mature A plaques were more abundant in 
the CN group. In addition, no cases scored above a Braak and Braak stage II for 
Alzheimer’s disease tau staging and the proportion of cases with tau pathology in 
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the CI group is similar to that in the CN group. These findings are interesting as 
a synergistic relationship between αsyn and Alzheimer’s pathology has been 
demonstrated in PD, the most common α-synucleinopathy (Masliah et al., 2001; 
Lashley et al., 2008; Compta et al., 2013). Furthermore, a detailed study of PD 
cases with and without documented dementia showed that a combination of the 
degree of αsyn, tau and Aβ pathology best predicted the occurrence of dementia 
(Compta et al., 2011). This synergistic relationship was not observed in MSA 
patients of this cohort, suggesting αsyn pathology in MSA is not associated with 
an increase in tau or Aβ aggregation suggesting differences in the properties of 
αsyn in MSA and PD. Additional pathological changes were also assessed.  Lewy 
body pathology, TDP-43 pathology, CAA and SVD were uncommon in this 
cohort, and therefore, are unlikely to contribute to CI in MSA.  
Future studies to address the mechanism of cognitive impairment in MSA may 
investigate loss of synaptic connectivity and neurotransmitter abnormalities. 
There is evidence in the literature that synaptic pathology plays a role in 
psychiatric and neurological disorders (Blanpied and Ehlers, 2004; Gouras et al., 
2010; van Spronsen and Hoogenraad, 2010). Alterations in the synaptic 
connections and proteins due to αsyn accumulation has been demonstrated in 
DLB, PD and PD with dementia patients and in cell culture models  (Schulz-
Schaeffer, 2010; Scott et al., 2010).  These studies justify the examination of 
synaptic pathology in MSA as it may prove to be the determining factor for 
cognitive impairment.   
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Neurotransmitter (acetylcholine, serotonin, noradrenaline, and/or dopamine) 
depletion has been shown in AD, vascular dementia and PD and is suggested as 
a contributing factor, if not the major factor,  in the development of dementia  
(Perry et al., 1987; Court and Perry, 2003; Alisky, 2006; Hirano et al., 2012). Loss 
of cholinergic, catecholaminergic and serotonergic neurons have been 
demonstrated in MSA (Kato et al., 1995; Benarroch et al., 1998, 2001, 2002, 
2004; Tada et al., 2009). Therefore it is possible that the loss of these neurons 
results in reduced neurotransmitter levels, which in turn, affects the function of 
their target sites, which include cortical regions.  Radiological, biochemical and 
neuropathological testing of these neurotransmitters in addition to correlations 
with neuropsychological tests will shed light into the extent of involvement of 
neurotransmitter depletion to cognitive impairment in MSA.  
Conclusion and further directions 
 CI may be intrinsic to the MSA disease process as it is independent of 
Alzheimer’s pathology and other concomitant pathologies. Increased GCI load 
and neuronal loss in cortical, limbic and subcortical structures are not however 
related to CI in MSA. Further investigation of synaptic pathology, 
neurotransmitter abnormalities, subcortical deafferentation and correlating of 
neuropsychological, radiological and neuropathological findings are warranted to 
elucidate the pathogenic substrates leading to cognitive impairment in MSA. 
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3.2. LONG DURATION AND MINIMAL CHANGE MSA 
3.2.1. Introduction 
MSA is an adult onset disease usually presenting in the fifth decade of life and 
with a mean disease duration of 6-9 years (Wenning et al., 1994 b; Ben-Shlomo et 
al., 1997; Watanabe et al., 2002; Gilman et al., 2008; Schrag et al., 2008).  It is 
clinically diagnosed as MSA-P or MSA-C based on predominant parkinsonian or 
cerebellar presentations respectively,  in addition to definite, probable, and 
possible with regards to certainty of the diagnosis (Gilman et al., 2008). 
Neuropathological confirmation is needed for a definite diagnosis. MSA is 
pathologically subtyped as SND, OPCA or mixed type reflecting the degree of 
neuronal loss in StrN and OPC structures (Ozawa et al., 2004). As with other 
diseases, there are MSA patients who do not follow the ‘classical’ presentation of 
the disease as they display variations in neuropathological and/or clinical profiles. 
It is important to note these ‘non-classical’ MSA patient groups and explore any 
clinico-pathological correlations that may exist in them.  Long disease duration 
and the minimal change MSA are two examples of such groups.  
Long disease duration MSA refers to patients who experience a disease course 
that can last over 10 years (Wenning et al., 1994 b; Masui et al., 2011; Piao et al., 
2001; Wakabayashi et al., 1998; Konagaya et al., 1999). Due to the rarity of such 
patients, there are few published reports detailing the clinical and pathological 
presentation of long duration MSA (Wakabayashi et al., 1998; Konagaya et al., 
1999; Piao et al., 2001; Masui et al., 2011; Petrovic et al., 2012).  Factors 
contributing to speed of deterioration and survival in MSA are unclear, however, 
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autonomic failure and early respiratory irregularities have been shown to be poor 
prognostic factors (Watanabe et al., 2002; O’Sullivan et al., 2008; Tada et al., 
2009). The leading causes of mortality in MSA are sudden unexpected death 
(SUD) and infection (Munschauer et al., 1990; Sadaoka et al., 1996; Wakabayashi 
et al., 2005; Papapetropoulos et al., 2007; Shimohata et al., 2008; Tada et al., 
2009). 
Minimal change MSA is a pathological characterisation reflecting restricted 
neuronal loss to the substantia nigra and locus coeruleus, unlike the typical 
distribution in MSA where neuronal loss is evident in multiple structures of the 
StrN and OPC pathways (Wenning et al., 2002; Wakabayashi et al., 2005; 
Wenning et al., 1994 a; Huang et al., 2005). In the cases described by Wenning 
and colleagues (Wenning et al., 1994 a), the neuropathological examination of 
two patients who presented with parkinsonism and autonomic failure revealed 
neuronal loss that was confined to the substantia nigra and locus coeruleus while  
GCIs were  found in abundance throughout the brain. Neuronal loss limited to 
OPC regions in addition to widespread GCIs was reported by Wakabayashi and 
colleagues (Wakabayashi et al., 2005) in a patient who presented with cerebellar 
signs, dysarthria, and saccadic eye movement.  
This section focuses on assessing neuropathological changes in long duration and 
minimal change MSA and to compare these with MSA cases having a typical 
disease duration and spectrum of neuronal loss to uncover substrates that may 
contribute to the different clinico-pathological presentation of these sub-groups. 
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3.2.2. Hypothesis 
The distribution and severity of pathological changes in patients with long 
disease duration or minimal change MSA differs from typical MSA group. 
3.2.3. Aim  
The aim of this study is to determine the distribution and burden of   
pathological changes in long disease duration and minimal change MSA as 
compared to control (typical) MSA cases and to explore possible clinico-
pathological correlations.  
3.2.4. Case selection 
Four cases in the long duration (one of which was provided by Toronto Western 
Hospital), six in the minimal change and eight control MSA cases were selected 
from the archives of QSBB. Cases were included into the long duration group if 
they had a disease duration 15 years. The minimal change group is a 
pathological characterization where cases have neuronal loss restricted to the 
substantia nigra and/or locus coeruleus. Patients in the control MSA group are 
those that have a more ‘classical’ presentation i.e. a disease duration of 5-10 years 
and neuronal loss not restricted to either the substantia nigra or locus coeruleus. 
The cases in the long duration and minimal change MSA were age (≤ 5 years 
difference) and sex – matched with the controls. The demographics of this 
cohort are presented in Table ‎3.5.  
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3.2.5. Methods 
Formalin-fixed paraffin-embedded (FFPE) blocks from the following regions 
were used: anterior frontal, posterior frontal, parietal, temporal, occipital and 
cingulate cortices, hippocampus, amygdala, basal ganglia, substantia nigra, pons, 
medulla and cerebellum. Immunohistochemical and routine histological staining 
techniques were used to assess neuronal loss, GCIs, NCIs, gliosis, and 
concomitant pathologies (A, CAA, tau, TDP-43, Lewy bodies, and SVD) as 
described in ‎2 Materials and methods, sections ‎2.3.  
Neuronal loss was assessed in haematoxylin and eosin stained sections. Gliosis 
was determined using immunohistochemical staining for glial fibrillary acidic 
protein (GFAP) and both GCIs and NCIs were visualized using αsyn 
immunohistochemistry. The following regions were investigated: neocortex 
(anterior frontal, posterior frontal, temporal, parietal, occipital, cingulate), 
hippocampus, amygdala, caudate, putamen, globus pallidus, substantia nigra, 
pontine nuclei, inferior olivary nucleus and Purkinje cell layer. MSA subtype was 
determined by semi-quantitative assessment of neuronal loss in the caudate, 
putamen, globus pallidus, substantia nigra, pontine nuclei, inferior olivary nucleus 
and Purkinje cell layer based on a published method (Ozawa et al., 2004). GCIs, 
NCIs, neuronal loss and gliosis were graded on a 0 to +3 scale to reflect the 
severity of pathology as described (Ozawa et al., 2004). Concomitant pathologies: 
cortical A deposition (neuritic plaque frequency), cerebral amyloid angiopathy 
(CAA), tau deposition, TDP-43 immunoreactive inclusions, Lewy bodies, and 
small vessel disease (SVD) were assessed according to published criteria as 
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described previously (Mirra et al., 1991; Braak et al., 2003, 2006; Williams et al., 
2007; Lashley et al., 2008; Mackenzie et al., 2010, 2011). Neuropathological 
assessments were conducted by J.L.H and Y.T.A. Intra- and inter-rater reliability 
was assessed by re-analysing 10% of slides.  
Statistical analysis 
Statistical analysis was performed using SPSS PASW Statistics 18 software. Intra-
rater reliability was assessed by intraclass correlation coefficient (ICC) and inter-
rater reliability by using Cohen’s Kappa. Comparisons between groups were 
performed using the Mann-Whitney U test and the level of statistical significance 
was set at p < 0.05. Where Bonferroni’s correction for multiple testing was 
applied, the significance level was set at p<0.003. χ2 / Fisher’s exact test was 
used to compare gender groups (significance level set at p < 0.05).    
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3.2.6. Results 
 
Demographic and clinical data  
Details of age and gender of the 3 patient groups are provided in Table ‎3.4.  
There was no significant difference in the distribution of gender and age of 
disease onset between the groups. A statistically significant difference was found 
in the duration of disease between the groups with the long duration cases 
having a longer disease duration than control MSA (Mann-Whitney U, p=0.006) 
while the minimal change MSA group had a shorter disease duration than control 
MSA (Mann-Whitney U, p=0.037). The clinical details of the cases are presented 
in Table ‎3.5.  
Minimal change MSA  
Three out of six patients presented with parkinsonism while the remaining 
presented with autonomic features. Mean disease duration was 5 years and all 
patients fulfilled clinical criteria for MSA diagnosis after a mean interval from 
first symptom onset of 18.7 months. Cerebellar ataxia, pyramidal signs and 
cognitive impairment were not present in this group of patients. All cases 
developed significant respiratory symptoms most frequently inspiratory stridor 
and episodes of unprovoked or exertional dyspnea. The cause of death was SUD 
in three patients while others succumbed because of pulmonary embolism, 
suicide and multiple myeloma respectively. All cases reached at least one disease 
disability milestone after a mean of 3.2 years from disease onset and 1.8 years 
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before death. The subgroup of SUD cases reached the majority of disability 
milestones, specifically all cases reached wheelchair or gait tool use state. Those 
cases dying  due to concurrent disease reached only one disability milestone and 
all of them were ambulatory in the period near to death. More precisely, only one 
patient from this subgroup reached the frequent falls state 6 years after disease 
onset. In addition, recurrent postural faintness or syncope was present in all 
patients succumbing from SUD after a mean latency of 7.3 months.          
Long duration MSA 
All 4 patients presented with the cardinal signs of parkinsonism. The mean 
interval from first symptom onset to evolution to criteria-defined MSA was 11.3 
years. Recurrent postural faintness or syncope was present in two patients after a 
mean latency of 12.5 years. Initial levodopa response was considered good in 
one, moderate in two, and poor in one patient. All patients developed dyskinesia 
after a mean duration of levodopa treatment of 4.3 years.  Two patients (one of 
which corresponds to case 9 in CI cohort) had MMSE of less than 26 out of 30, 
12 and 15 years after first symptom onset; one of whom developed visual 
hallucinations and dementia 17 years after the first motor symptom in the final 
year of her life. Frequent falling was the first activities of daily living (ADL) 
milestone to occur in all patients with a mean latency of 12 years. Mean latencies 
to wheelchair dependence, unintelligible speech and urinary catheterisation were 
between 12 to 13 years. 
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Glial and neuronal cytoplasmic inclusions 
GCI burden was assessed using a semi-quantitative method in all groups and 
comparisons were made between the following pairs: long duration and control 
MSA group; minimal change and control MSA group; long duration and minimal 
change group (Figure ‎3.5). GCI score was greater in the striatum and substantia 
nigra in the long duration group as compared to control MSA, while it was 
similar in both groups in the pons, inferior olivary nucleus and cerebellum. A 
greater GCI burden in long duration cases was also seen in cortical and limbic 
regions with the exception of the occipital cortex and amygdala where they were 
similar. The cingulate cortex had a higher GCI burden in controls. However, 
statistical significance was only reached in the caudate which showed greater 
numbers of GCIs than control MSA cases (Mann-Whitney U, p=0.002).  
In the minimal change group the GCI burden in the striatum, substantia nigra, 
cerebellum and hippocampus was greater than in the control MSA cases. In 
contrast with the long duration group, the minimal change cases showed a lesser 
degree of GCI pathology in the cortical regions as compared to control MSA. 
However, statistical significance was not reached in any of these regions (Mann-
Whitney U, p>0.003). Microscopic findings of a representative case of minimal 
change MSA is shown in Figure ‎3.9.  
Comparisons between the long duration and minimal change groups indicated 
that the long duration group shows a higher burden of GCI pathology in all of 
the regions analysed with the exception of the putamen, globus pallidus and 
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cerebellum, but statistical significance was only reached in the anterior frontal 
and temporal cortices (Mann-Whitney U, p=0.001).  
NCIs were most abundant in the inferior olivary nucleus and least frequent in the 
occipital cortex in all groups (Figure ‎3.6). With the exception of the cingulate 
cortex, putamen and pons, NCI burden was greater in long duration cases than 
control MSA cases in StrN and OPC regions as well as in the frontal cortex, 
hippocampus and amygdala but statistical significance was only reached in the 
caudate (Mann-Whitney U, p=0.00).The StrN and OPC regions of the minimal 
change group had a greater NCI burden than controls, with a statistical 
significance reached in the caudate and substantia nigra where there was an 
increased NCI burden compared with control MSA cases (Mann-Whitney U, 
p=0.002 and p=0.00 respectively) but no statistical difference was found between 
minimal change and long duration cases in these regions.  
Neuronal loss 
In keeping with the selection criteria neuronal loss in the minimal change group 
was restricted to the substantia nigra with the exception of one case with +1 loss 
in posterior putamen (Figure ‎3.7). A statistically greater degree of neuronal loss 
in control MSA compared with the minimal change group was confirmed in the 
caudate, putamen, globus pallidus and pons (Mann-Whitney U, p<0.003) 
Neuronal loss in cortical and limbic regions of long duration and minimal change 
cases was not detected and was only mild in control MSA cases in the frontal and 
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parietal cortices (Figure ‎3.7). The long duration cases showed no statistical 
difference in neuronal loss compared with the control cases in any of the regions 
examined. 
Gliosis 
Gliosis assessed using GFAP immunohistochemistry was present in all of the 
regions assessed in all cases (Figure ‎3.8). There was no statistically significant 
difference in the degree of gliosis between the control MSA and the long 
duration MSA. When comparing the minimal change and control MSA groups 
gliosis was significantly increased in the control MSA group the putamen, 
caudate, pons and cerebellar white matter (Mann-Whitney U, p<0.003). 
Concomitant pathologies 
The cases were examined for Alzheimer tau pathology and Braak and Braak 
staging was determined. Tau pathology was observed in long duration and 
control MSA cases only reached a maximum of Braak and Braak stage II. 
Neuritic A plaques were also restricted to long duration and control groups. 
CAA and SVD were only observed in five cases in the control MSA group, with 
one case having severe CAA and SVD while the others were mildly affected. 
Lewy bodies were not identified in brain stem nuclei in any of the cases and none 
had TDP-43 pathology (Table ‎3.6).   
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Table ‎3.4. Patient demographics for MSA subgroups 
 
 
 
 Long duration MSA Control MSA P-value 
n 4 8  
Gender (%) 4 (100) female 6 (75) female 0.515 
Age of onset (years) 50.8 ± 8.1 58.8 ± 10.9 0.126 
Disease duration 
(years) 
17.3 ± 1.7 8 ± 2.9 0.006 
 Minimal change MSA Control MSA P-value 
n 6 8  
Gender (%) 1 (16.7) female 6 (75) female 0.103 
Age of onset (years) 47.8 ± 11.5 58.8 ± 10.9 0.137 
Disease duration 
(years) 
5 ± 1.8 8 ± 2.9 0.037 
Data expressed as ± SD except for gender as n (percentage) female. Mann-Whitney 
test was applied except for gender where the chi-square test was used. 
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 Age at 
onset 
Disease 
duration 
(years) 
Initial 
presentation 
Second system 
involvement 
(latency in 
months) 
Additional autonomic 
symptoms 
(latency in months) 
Cerebellar 
signs 
Pyramidal 
signs 
Respiratory 
symptoms 
Cause of 
death 
Concomitant 
diseases 
MSA 
pathological 
type 
LD-MSA 1 62 15 Parkinsonism Autonomic 
UI (132) 
No No No No Bronchopne
umonia 
ND SND 
LD-MSA 2 50 17 Parkinsonism Autonomic 
UI (108) 
Postural faintness and 
syncope (120) 
No Yes IS Bronchopne
umonia 
ND SND 
LD-MSA 3 48 19 Parkinsonism Autonomic 
UR (132) 
No No No No Bronchopne
umonia 
ND Mixed 
LD-MSA 4 43 18 Parkinsonism Autonomic 
OH (168) 
Postural faintness (168) Yes Yes IS  ND OPCA 
MC-MSA 1 57.5 7.5 Autonomic 
(OH) 
Parkinsonism 
(12) 
Nocturia (18) 
Erectile dysfunction (18) 
Urinary retention 
No Yes Acute unprovoked 
dyspnoea; IS 
Pulmonary 
embolism 
and infarct 
Prostatic 
hyperplasia 
SND 
MC-MSA 2 33.5 5.5 Parkinsonism Autonomic UR; 
UF (12) 
OH  (14) No Yes IS Sudden death ND SND 
MC-MSA 3 39.5 6.5 Autonomic 
UI; OH 
Parkinsonism 
(36) 
Constipation (40) No No Obstructive sleep 
apnoea; IS 
Sudden death Depression SND 
MC-MSA 4 53 4 Parkinsonism Autonomic 
UI (2) 
OH (4) No Yes Dyspnoea on 
exertion;  IS 
Suicide Depression SND 
MC-MSA 5 41 4 Parkinsonism Autonomic 
OH (26) 
No No Yes Dyspnoea on 
exertion 
Sudden death ND SND 
MC-MSA 6 62.5 2.5 Autonomic 
UF; OH 
Parkinsonism 
(24) 
Nocturia (18) No No Acute unprovoked 
dyspnoea,  
Obstructive sleep 
apnoea 
Possible 
multiple 
myeloma 
Possible 
multiple 
myeloma 
Mixed 
Table ‎3.5. Clinical details of long duration, minimal change, and control MSA cases 
ND: non documented; OH: orthostatic hypotension; IS: inspiratory stridor; UI: urinary incontinence; UR: urinary retention; UF: urinary frequency; SD: sexual dysfunction; SND: striatonigral degeneration;  
OPCA: olivopontocerebellar atrophy 
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 Age at 
onset 
Disease 
duration 
(years) 
Initial 
presentation 
Second system 
involvement 
(latency in 
months) 
Additional autonomic 
symptoms 
(latency in months) 
Cerebellar 
signs 
Pyramidal 
signs 
Respiratory 
symptoms 
Cause of 
death 
Concomitant 
diseases 
MSA 
pathological 
type 
C-MSA 1 67 8 Parkinsonism Autonomic 
bradycardia (72) 
Breathing problems (86) No No Breathing problems Pneumonia ND Mixed 
C-MSA 2 47 9 Autonomic 
UI 
Parkinsonism 
(36) 
Autonomic 
OH (84) 
 
Yes Yes Irregular breathing 
rate 
Pneumonia ND Mixed 
C-MSA 3 58 9 Parkinsonism Autonomic 
UI (48) 
Constipation No No ND Pneumonia ND SND 
C-MSA 4 51 12 Autonomic 
SD & urinary 
symptoms 
Parkinsonism 
(120) 
Autonomic 
OH (132) 
 
Yes Yes Sleep apnoea Respiratory 
failure 
ND Mixed 
C-MSA 5 80 2 Ataxia Autonomic 
OH (24) 
ND Yes No Aspiration 
pneumonia 
Pneumonia ND OPCA 
C-MSA 6 63 9 Autonomic 
UI 
Ataxia (48) Autonomic 
SD (24) 
Yes No Bronchopneumonia Pneumonia ND OPCA 
C-MSA 7 53 6 Autonomic 
UI 
Parkinsonism (6) ND No Yes ND Respiratory 
failure 
ND OPCA 
C-MSA 8 51 9 Ataxia Autonomic 
UF (67) 
ND Yes Yes ND Pneumonia ND Mixed 
Table 3.4. Clinical details of long duration, minimal change, and control MSA cases (cont.) 
ND: non documented; OH: orthostatic hypotension; IS: inspiratory stridor; UI: urinary incontinence; UR: urinary retention; UF: urinary frequency; SD: sexual dysfunction; SND: striatonigral degeneration;  
OPCA: olivopontocerebellar atrophy 
         ‎3.2  Long duration and minimal change MSA      127 
 
 
 
 
 
 LD 
(n=4) 
MC 
(n=6) 
Control 
(n=8) 
CERAD neuritic plaque 
score 
Negative 
Infrequent 
Moderate 
Frequent 
 
1 
3 
0 
0 
 
6 
0 
0 
0 
 
4 
3 
1 
0 
CAA 0 0 3 
(mild, case 1 & 4;  
severe, case 6) 
Tau-pathology 
(maximum Braak & 
Braak stage II) 
3  0 7  
Lewy body pathology 0 0 0 
TDP-43 pathology 0 0 0 
SVD 0 0 3  
(mild, case 5 & 8;  
severe, case 6) 
Table ‎3.6. Concomitant pathology in MSA sub-groups 
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Figure 3.5 A 
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Figure 3.5 B 
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Figure ‎3.5. GCI burden in long duration, minimal change and control MSA groups  
Semi-quantitative analysis of GCI burden in long duration (n=4) (A) and minimal change (n=6) (B) MSA as compared to the control MSA group (n=8) and 
long duration MSA compared to minimal change MSA (C). GCI burden was significantly higher in the caudate of the long duration cases as compared to 
control MSA cases. When comparing long duration and minimal change MSA cases, a statistical significance was only found in the anterior frontal and 
temporal cortices, where GCI burden was higher in the long duration cases. The plots show median values as the line within the box, the box reflects the 
interquartile range and the whiskers the range of the values.   
(Mann-Whitney U test with Bonferroni correction for multiple comparisons at significance level p <0.003). 

outliers; extreme outliers; ♦ p <0.003. Ctx: cortex. 
Figure 3.5 C 
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Figure 3.6 A 
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Figure 3.6 B 
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Figure ‎3.6. NCI burden in long duration, minimal change and control MSA groups 
Semi-quantitative analysis of NCI burden in long duration (n=4) (A) and minimal change (n=6) (B) MSA as compared to the control MSA group (n=8) and 
long duration MSA compared to minimal change MSA (C). NCI burden was significantly higher in the caudate of the long duration MSA group as compared to 
controls. The caudate and substantia nigra of the minimal change MSA group displayed significantly greater numbers of NCIs compared with the control MSA group. 
The plots show median values as the line within the box, the box reflects the interquartile range and the whiskers the range of the values (Mann-Whitney U test with 
Bonferroni correction for multiple comparisons at significance level p <0.003).  

outliers; extreme outliers; 

p <0.003. Ctx: cortex. 
Figure 3.6 C 
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Figure 3.7 A 
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Figure 3.7 B 
 
p = 0.075 p = 0.075 
p = 1.00 
p = 0.025 
p = 1.00 p = 1.00 p = 1.00 p = 1.00 
♦ 
p = 0.00 
♦ 
p = 0.00 
p = 0.045 
♦ 
p = 0.001 p = 0.003 p = 0.003 
♦ 
p = 0.00 
         ‎3.2  Long duration and minimal change MSA      136 
 
Figure ‎3.7. Neuronal loss in long duration, minimal change and control MSA groups 
Semi-quantitative analysis of neuronal loss in long duration (n=4) (A) and minimal change (n=6) (B) MSA as compared to the control MSA group (n=8) 
and long duration MSA compared to minimal change MSA (C). Neuronal loss was not evident in the cortical and limbic regions of the long duration and 
minimal change MSA cases. Neuronal loss in minimal change MSA was significantly less in the putamen, caudate, globus pallidus and pontine base as 
compared to ‘classical MSA’ cases (p<0.003) thus satisfying selection criteria of neuronal loss restricted to substantia nigra and locus coeruleus. A 
statistical difference between long duration and control MSA cases was not found. The plots show median values as the line within the box, the box 
reflects the interquartile range and the whiskers the range of the values.  (Mann-Whitney U test with Bonferroni correction for multiple comparisons at significance level p 
<0.003).  

outliers; extreme outliers; 

p <0.003. 
  
Figure 3.7 C 
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Figure 3.8 A 
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Figure 3.8 B 
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Figure ‎3.8. Gliosis in long duration, minimal change and control MSA groups 
Semi-quantitative analysis of gliosis in long duration (n=4) (A) and minimal change (n=6) (B) MSA as compared to the control MSA 
group (n=8) and long duration MSA compared to minimal change MSA (C). Gliosis was abundant in all cases. A statistically significant 
difference was found between minimal change MSA and the control MSA group in the putamen, caudate, pontine base and cerebellum, 
where the level was higher in the control group. The plots show median values as the line within the box, the box reflects the 
interquartile range and the whiskers the range of the values (Mann-Whitney U test with Bonferroni correction for multiple comparisons 
at significance level p <0.003). 

outliers; extreme outliers; 

p <0.003. Ctx: cortex. 
Figure 3.8 C ♦ 
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Figure ‎3.9. Minimal change MSA profile 
A representative case of minimal change MSA, where neurons are well preserved in the putamen (A) and 
inferior olivary nucleus (B). The substantia nigra (C) and locus coeruleus (D) are severely affected by neuronal 
loss with few remaining pigmented neurons (arrows). Despite absence of neuronal loss in the putamen, this 
region has a heavy burden of GCIs (E) and astrogliosis (F).  A-D: haematoxylin and eosin; E: alpha-synuclein 
immunohistochemistry; F: GFAP immunohistochemistry. Scale bar: 50 m in all panels. 
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Table ‎3.7. Summary of significant findings 
 LD-MSA vs. Control MSA MC-MSA vs. Control MSA LD-MSA vs. MC MSA 
GCI Caudate:  
LD-MSA> Control MSA,  p=0.002 
No significant differences Anterior frontal cortex:  
LD-MSA> MC-MSA,  p=0.001  
 
Temporal cortex:  
LD-MSA> MC-MSA,  p=0.001 
NCI Caudate:  
LD-MSA> Control MSA,  p<0.001 
Caudate:  
MC-MSA > Control MSA, p=0.002 
 
Substantia nigra:  
MC-MSA > Control MSA, p<0.001 
No significant differences 
Neuronal 
loss 
No significant differences Caudate, putamen, globus pallidus and pons: 
Control MSA > MC-MSA, p≤0.001 
Caudate and globus pallidus:  
LD-MSA > MC-MSA, p<0.001 
Gliosis No significant differences Posterior frontal cortex, hippocampus, 
putamen, caudate, pons and cerebellar white 
matter: Control MSA > MC-MSA, p≤0.002 
Putamen and caudate:  
LD-MSA > MC-MSA, p≤0.001 
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Figure ‎3.10. Clinical profile in long duration, minimal change and control MSA 
groups 
Clinical disease milestones and disease course in long duration, minimal change and control 
MSA group. Gray rectangles represent mean duration of disease course starting from mean 
age of onset until mean age of death. Rapid disease progression ensued after onset of 
autonomic symptoms.  
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3.2.7. Discussion 
The clinical and pathological profiles of the long duration and minimal change 
MSA subgroups were reviewed and compared to a control MSA group with 
classical clinical presentation and pathological findings.  A common pathological 
observation of all groups was absent or minimal neuronal loss in the cortical and 
limbic regions despite the presence of widespread GCIs and NCIs. All groups 
showed widespread gliosis in cortical, limbic, StrN and OPC regions. Significant 
findings are summarised in Table ‎3.7. 
Long duration MSA  
GCI and NCI pathology was greater in the long duration MSA group when 
compared with control MSA but statistical significance was only reached in the 
caudate.  This increased severity of pathology in the caudate, a structure that is 
usually mildly affected, may be an indication of anatomical disease progression 
with time. Despite widespread αsyn pathology in the regions evaluated, neuronal 
loss was undetectable in the cortical and limbic regions and was limited to the 
StrN and OPC regions, where it showed no difference in severity compared with 
control MSA. These findings are in keeping with the published literature on long 
duration MSA cases, with the exception of one case, which exhibited severe 
neuronal loss in cortical and limbic regions (Wakabayashi et al., 1998; Konagaya 
et al., 1999; Piao et al., 2001; Masui et al., 2011).  Similarity in the distribution and 
severity of pathological changes in long duration MSA and the control MSA 
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group may imply that the pathology progresses at a slower rate over a longer 
duration in this clinical subgroup, making it a relatively ‘benign’ variant with a 
disease duration lasting for almost twice as long as classical MSA. Slowly 
progressive MSA has been suggested to be associated with minimal change 
pathology (Yoshida, 2007). However, this was not the observation in the long 
duration cases studied in this thesis as none of them had neuronal loss restricted 
to the substantia nigra or locus coeruleus. The long disease duration is more 
likely to be due to the late onset of autonomic symptoms as discussed below.  
Minimal change MSA  
Minimal change MSA has previously been defined as showing restricted neuronal 
loss in the substantia nigra and/or the locus coeruleus (Wenning et al., 1994 a; 
Huang et al., 2005; Wakabayashi et al., 2005). Careful evaluation of neuronal loss 
the minimal change cases in this thesis (of which cases MC-MSA 2 & 3 were 
previously described by Wenning and colleagues, 1994) using published 
assessment criteria (Ozawa et al., 2004) and a review of the published literature 
suggests that the definition of minimal change MSA may be revised as follows: 
Macroscopically, pallor of the substantia nigra and locus coeruleus. 
Microscopically, neuronal loss (+1 to +3) in the substantia nigra and locus 
coeruleus with not more than +1 in the cerebellar Purkinje cells and a maximum 
of +1 in one other structure.  
Despite the restricted neuronal loss, GCI burden in these minimal change cases 
did not differ significantly from the control group and was abundant in all 
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regions. The presence of αsyn pathology in areas where neuronal loss was not 
observed adds strength to the argument that oligodendroglial pathology plays a 
significant, and most likely primary, role in the pathogenic mechanism of MSA 
(Inoue et al., 1997; Wenning et al., 2008; Jellinger and Lantos, 2010). NCI burden 
was greater in the substantia nigra and caudate of the minimal change group than 
controls. Previous studies have suggested that NCIs represent early pathology in 
MSA and that NCI pathology decreases in quantity as the disease progresses as a 
result of neuronal cell loss (Yokoyama et al., 2001; Nishie et al., 2004; Yoshida, 
2007). The greater load of NCIs observed in patients with minimal change MSA 
may reflect that they have died at an earlier stage in the evolution of disease. 
Out of 135 MSA cases analysed from the QSBB collection, only six were 
identified as ‘minimal change’ cases.  All these cases fulfilled clinical criteria for 
MSA   during life.   Three of the six   died from causes other than MSA and it is 
reasonable to assume that they would have fulfilled criteria for ‘typical’ MSA had 
the disease not been interrupted. The other three minimal change MSA cases 
died of SUD and in this subgroup the disease progression was notably more 
rapid than control MSA, the patients’ disability reached all clinical milestones 
within three years of initial presentation (O’Sullivan et al., 2008) and that they  
seem to have had a short duration of disease (mean 5 years; SD 1.8 years).  A 
mean survival of 2.5 years was previously reported in 6 minimal change cases 
(Yoshida, 2007). Interestingly, all minimal change cases were diagnosed clinically 
as MSA-P and cerebellar features were not reported but this may just reflect the 
predominance of MSA-P in Western populations.  
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The leading causes of death in MSA are SUD, as a result of central brain stem 
autonomic failure and death due to infection (urinary tract infection or aspiration 
pneumonia) (Papapetropoulos et al., 2007). Proposed mechanisms leading to 
SUD include dysphagia, stridor, acute airway obstruction, and vocal cord 
abductor paralysis (Isozaki et al., 1996; Sadaoka et al., 1996; Silber and Levine, 
2000; Papapetropoulos et al., 2007; Shimohata et al., 2008). All six minimal 
change MSA cases had inspiratory stridor. Other prominent respiratory 
symptoms including dyspnea on exertion, episodes of acute unprovoked dyspnea 
and sleep apnea have also been noted. This shows that these respiratory 
symptoms may arise early in MSA even in cases with limited neuronal loss. In 
addition to early respiratory symptoms the three minimal change MSA cases with 
SUD had prominent symptomatic orthostatic hypotension and reached the 
majority of disease disability milestones (O’Sullivan et al., 2008), especially 
frequent falls and wheelchair dependant state within the first three years of 
clinical presentation (Figure ‎3.10). 
The importance of autonomic system involvement and the prognostic value of 
autonomic symptoms implies that the pathological involvement of brain stem 
nuclei plays an important role in disease progression in MSA (Watanabe et al., 
2002; Benarroch et al., 2004; O’Sullivan et al., 2008; Tada et al., 2009). This is 
reflected in the cohort of this thesis as a favourable outcome and prolonged 
disease duration associated with late onset of autonomic symptoms was seen in 
the long duration cases, while the minimal change cases, especially in those with 
SUD, had early onset of autonomic symptoms and shorter survival. The three 
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SUD minimal change cases also had an unusually early age of onset in their 30’s 
and early 40’s. It might be possible that these three cases represent an ‘aggressive’ 
variant of MSA with early onset and early sudden death due to early pathological 
involvement of vital cardiovascular and respiratory functions. 
Conclusion and further directions 
GCIs and NCIs were greater in the caudate of long duration MSA, while in the 
minimal change cases NCIs were more abundant in the caudate and substantia 
nigra. Other than those changes, there was no significant difference in the 
pathologies of these groups as compared to the group of control MSA patients in 
cortical, limbic, StrN and OPC region examined in this study. In contrast to 
previous findings (Ozawa et al., 2004), the results of this study suggest that the 
GCI burden in these disease subgroups does not correlate with the clinical 
outcome in either  long duration and minimal change groups nor does it correlate 
with the neuronal loss which is restricted in the minimal change group. 
Widespread GCIs in all subgroups of MSA and in areas of no, or minimal, 
neuronal loss adds strength to the argument that MSA is a primary 
oligodendrogliopathy.  Furthermore, the significance of onset of autonomic 
symptoms to disease progression warrants exploration of nuclei or connections 
associated with the autonomic system, including the intermediolateral column 
spinal cord, dorsal motor nucleus of vagus, medullary serotonergic and 
catecholaminergic neurons, as pathology in those regions may help identify 
significant pathological differences between the groups and better correlation 
between neuronal loss and GCI burden. 
         ‎3.2  Long duration and minimal change MSA      148 
 
 
 
Declaration: 
Clinical data for this chapter was compiled by Dr. Helen Ling and Dr. Igor 
Petrovic. 
 
This chapter contributed to the following papers: 
Asi, Y.T.*, Ling H*, Ahmed, Z, Lees, A.J., Revesz, T, Holton, J.L. Pathological 
changes in multiple system atrophy with cognitive impairment.  Submitted. 
Asi, Y.T, Ling, H. *, Petrovic, I.N. *, Ahmed, Z., Prashanth, L.K.., Hazrati, L.-N., 
Nishizawa, M,  Ozawa, T, Lang, A.E., Lees, A.J., Revesz, T. and Holton, J.L. 
Long duration and minimal change MSA: benign and aggressive variants?  Submitted. 
Petrovic, I.N., Ling, H., Asi, Y., Ahmed, Z., Prashanth, L.K.., Hazrati, L.-N., 
Lang, A.E., Revesz, T., Holton, J.L. and Lees, A.J., 2012. Multiple system atrophy-
parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov. Disord. 
27, 1186–1190. 
      149 
 
      
 
4     
  GCIS IN THE OLIGODENDROGLIAL LINEAGE 
 
4.1. INTRODUCTION 
Oligodendrocytes are the cell type most vulnerable to inclusion formation in 
MSA. Oligodendrocytes are one class of central nervous system (CNS) glial cells. 
Important functions of oligodendrocytes include forming myelin sheaths around 
axons thus facilitating propagation of action potentials through saltatory 
conduction and production of neurotrophic factors (Baumann and Pham-Dinh, 
2001). Neural stem cells undergo a number of proliferative and differentiation 
stages in the production of oligodendrocytes resulting in fully differentiated, 
mature myelin producing oligodendrocytes at the final stage. At different 
maturation stages cells in the oligodendrocyte lineage exhibit a number of 
different markers. Cues from neurons and astrocytes may play an important role 
in the process of maturation (Baumann and Pham-Dinh, 2001). As such, these 
cells have different morphological and antigenic characteristics as they mature 
(Figure ‎4.1) (Baumann and Pham-Dinh, 2001; Zhang, 2001; Buchet and Baron-
Van Evercooren, 2009; Espinosa-Jeffrey et al., 2009; Nishiyama et al., 2009).  
Olig2, a basic helix-loop-helix transcription factor, is important for the 
development of oligodendrocytes (Rowitch et al., 2002). Olig2 expression occurs 
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in pre-oligodendrocytes and persists throughout the lineage and is therefore used 
as a marker for oligodendrocytes. Identifying oligodendrocytes at different 
maturational stages is a challenging task as certain markers may be present in 
more than one stage, requiring the use of multiple markers for characterisation of 
a maturational state. Oligodendrocyte precursor cells may be identified by the 
markers NG2, PDGFRα, and  A2B5; premyelinating oligodendrocytes by 
galactocerebroside (GC) and 2’,3’-Cyclic nucleotide-3’-phosphohydrolase 
(CNPase); mature oligodendrocytes by GC, CNPase and myelin basic protein 
(MBP) with the addition of myelin oligodendrocyte glycoprotein (MOG) for 
myelinating oligodendrocytes (Baumann and Pham-Dinh, 2001; Zhang, 2001; 
Buchet and Baron-Van Evercooren, 2009; Espinosa-Jeffrey et al., 2009; 
Nishiyama et al., 2009).  
NG2+ cells are an abundant population of cells in the adult CNS (Levine et al., 
1993; Dawson et al., 2003). Though there is consensus that NG2+ cells are 
oligodendrocyte precursor cells, debate in the literature suggests that they are not 
limited to this function (Berry et al., 2002; Butt et al., 2002; Nishiyama et al., 
2009). In fact, the high density and distinct electrophysiological profile of some 
NG2+ cells resulted in calls for classifying NG2+ cells as a fourth glial type (Butt 
et al., 2002; Mallon et al., 2002; Nishiyama et al., 2009). NG2+ cells have been 
hypothesized to play a part in remyelination and monitoring of CNS integrity as 
studies have shown them to respond to demyelinating insults (Franklin, 2002; 
Franklin and ffrench-Constant, 2008). 
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The presence of GCIs in oligodendrocytes is essential for a definite diagnosis of 
MSA. Cells containing GCIs were characterized as mature oligodendrocytes 
according to morphological features and for their negative staining of neuronal 
(neurofilament), astrocytic (GFAP) and microglial (Mac 387) markers (Papp et 
al., 1989). Accumulation of GCIs in different oligodendrocyte maturational 
stages, however, has not been studied and is the focus of this chapter. 
Establishing the oligodendrocyte maturational stage at which GCIs begin to form 
will provide greater insight into the pathogenic mechanism of MSA. 
 
4.2. HYPOTHESIS 
αSyn accumulation as GCIs in oligodendrocytes occurs at different stages of 
oligodendrocyte maturation. 
4.3. AIM 
To investigate the involvement of NG2+ cells, immature oligodendrocytes and 
mature oligodendrocytes by αsyn pathology in MSA.   
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Figure ‎4.1. Oligodendrocyte maturational stages 
Oligodendrocytes undergo proliferation and differentiation from the stem cell stage to the mature myelinating stage, where the appearance and 
disappearance of certain markers dictates the fate of the cells.  Above are some markers expressed during each developmental stage of the 
oligodendrocyte lineage.  
PDGFRα: platelet-derived growth factor receptorα; GalC: galactocerebroside; CNPase: 2',3'-cyclic nucleotide 3'-phosphodiesterase; MAG: myelin-associated glycoprotein; 
MBP: myelin basic protein; PLP:  proteolipid protein. 
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4.4. METHOD 
Double and triple immunofluorescence was carried out as described in Chapter ‎2                                                                                               
Materials and methods section ‎2.6. Briefly, 8µm thick frozen sections were cut 
from the posterior frontal cortex and cerebellum of 3 MSA cases. Sections were 
incubated in two or three successive rounds of primary antibody followed by 
secondary antibody incubation. The primary antibodies include NG2 (1:200; 
R&D Systems, Minneapolis, MN), CNPase (1:100; Abcam, Cambridge, UK), 
MBP (1:500; Convance, Cambridge, UK) and αsyn (1:800; Abcam, Cambridge, 
UK). Alexa Fluor® secondary antibodies (1:1000; Invitrogen, Paisley, UK) were 
used for detection of CNPase, MBP and αsyn while the TSA Plus Fluorescence 
Systems kit (PerkinElmer, Massachusetts, USA) was used for NG2 detection. 
Qualitative analysis was conducted by systematically scanning the entire section 
for evidence of co-localisation using widefield and confocal fluorescence 
microscopy (Leica DM550 and Leica SPE, Leica Microsystems, Milton Keynes, 
UK).   
αSyn, NG2 and MBP immunohistochemistry were incubated in the primary 
antibody as above. The Vector stain Elite ABC Kit (Vector Laboratories, 
Burlingame, CA) was used as the detection system for αSyn and MBP, while the 
Dako REAL™ EnVision™ Detection System (Dako, Cambridgeshire, UK) was 
used for NG2. Therefore after washes in PBS, the tissues were incubated with 
biotinylated goat anti-rabbit IgG  or biotinylated goat anti-mouse IgG (Vector 
Laboratories, Burlingame, CA) at a dilution of 1:200 for 30 min at RT. After 
washing off the secondary antibody, the sections were incubated in the avidin-
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biotin complex solution for 30 min at RT. For the NG2 antibody however, the 
Dako REAL™ EnVision™ Detection System (Dako, Cambridgeshire, UK) was 
used. The tissues were incubated in the Dako REAL™ EnVision™/HRP, 
Rabbit/Mouse reagent for 30 min at RT. After washes in PBS, they were treated 
in the diaminobenzidine (DAB) solution for 3 min. The DAB solution was 
washed off and the tissues were counterstained in Mayer’s haematoxylin for 3 
min. The tissue sections were then dehydrated in graded alcohol (70%, 90%, and 
absolute alcohol), cleared in three changes of xylene, and then mounted with 
DPX mounting medium.     
4.5. RESULTS 
Double and triple immunofluorescence microscopy was carried out to identify 
co-localisation of αsyn positive GCIs with positive (+) or negative (―) 
immunoreactivity of a cell marker(s) of interest for each maturational stage. 
Oligodendrocyte precursor cells were identified with NG2+ immunoreactivity, 
immature oligodendrocytes as CNPase+/MBP― and mature oligodendrocytes as 
CNPase+/MBP+.  
NG2+ cells (Figure ‎4.2) commonly exhibit stellate, multi-branching morphology, 
although some cells may appear bipolar and more polarized. The long delicate 
processes of NG2+ cells may also display a “beads and swellings” morphology. 
NG2+ cells and GCIs were widespread in the frontal cortex (Figure ‎4.3) and 
cerebellum (Figure ‎4.4). They were found in close proximity to each other in 
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some areas, however, did not co-localise. These results indicate that GCI do not 
accumulate in NG2+ cells.   
 
Immature oligodendrocytes, indicated by CNPase+/MBP― staining, were 
undetectable in tissue sections, while mature oligodendrocytes (CNPase+/MBP+) 
were present in great abundance.  αSyn co-localised with CNPase+/MBP+ cells 
confirming that GCIs are present in mature oligodendrocytes (Figure ‎4.5).  
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Figure ‎4.2. Cell and inclusions in MSA 
Immunohistochemistry of αsyn-positive GCIs (A), NG2+ cells (B) and MBP 
positive staining in the frontal cortex (C) and cerebellar white matter (D) of 
MSA. CNPase-positive staining in white matter tracts and the granule cell layer of 
the cerebellum an adult mouse brain as illustrated by the manufacturer (E).  
αsyn: α-synuclein; GCIs: glial cytoplasmic inclusions; MBP: myelin basic protein; Scale bar: 20µm 
E E 
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Figure ‎4.3. GCIs and NG2+ cells in frontal white matter 
Double immunofluorescence microscopy of frozen human MSA cortical sections 
(8µm) for αSyn (red), and NG2 (green) with nuclear DAPI stain (blue). GCIs (red, 
arrowheads) identified by αSyn immunoreactivity around glial nuclei (DAPI, blue) 
and NG2+ cells (green, arrows) are both present in frontal cortex white matter. 
Some GCIs and NG2+ cells are located in close proximity, however, they do not 
co-localize indicating that GCIs are not found in NG2+ cells. Lipofuscin (lipid-
containing granules) are fluorescent at any excitation wavelength and are seen in 
the merged image as yellow-orange deposits.  
GCIs: glial cytoplasmic inclusions; DAPI: 4',6-Diamidino-2-Phenylindole.  
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Figure ‎4.4. GCIs and NG2+ cells in cerebellar white matter 
GCIs (red, arrowheads) and NG2+ cells (green, arrows) in human MSA cerebellar 
white matter sections (8µm). Thus GCIs were not identified in NG2+ oligodendrocyte 
precursor cells. Lipofuscin (lipid-containing granules) fluoresce at any excitation 
wavelength and are seen in the merged image as yellow-orange deposits.  
GCIs: glial cytoplasmic inclusions; DAPI: 4',6-Diamidino-2-Phenylindole.  
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 Figure ‎4.5. GCIs and mature oligodendrocytes in cerebellar white matter 
MBP (light blue)  and CNPase  (green) are both present in mature myelinating 
oligodendrocytes in MSA cerebellar white matter sections (8µm). The merged image 
shows that GCIs (red, arrow head) co-localize with MBP and CNPase (white, arrow) 
indicating that GCIs accumulate in mature myelinating oligodendrocytes. Nucleus is 
represented by dark blue DAPI staining.  
αSyn: α-synuclein; CNPase: 2',3'-cyclic nucleotide 3'-phosphodiesterase; MBP: myelin basic protein; 
DAPI: 4',6-Diamidino-2-Phenylindole. 
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4.6. DISCUSSION  
GCIs are the hallmark of MSA and their morphologic characteristics coupled 
with antigenic characterisation of cell type indicate that they accumulate in 
oligodendrocytes (Papp et al., 1989). Despite the discovery of GCIs in 1989, the  
mechanisms leading to their formation remain unclear (Papp et al., 1989; Ubhi et 
al., 2011). Understanding at which oligodendrocyte maturational stage GCIs 
accumulate is one line of research that can bring us closer to understanding the 
mechanism of GCI formation and is the focus of this chapter. 
Oligodendrocyte progenitor cells which are NG2+ do not co-localize with αsyn 
which suggests that GCIs do not accumulate in these cells. Confirming previous 
studies (Papp et al., 1989), the inclusions were found in mature oligodendrocytes 
as indicated by αsyn co-localisation with CNPase+/MBP+ cells.  The presence of 
GCIs in CNPase+/MBP+ cells but not in NG2+ cells indicates that only mature 
oligodendrocytes are susceptible to GCI formation. These findings parallel those 
found in an multiple sclerosis (MS) rat model where αsyn protein was not found 
in NG2+  cells but was present in CNPase+ oligodendrocytes in the spinal cord 
of myelin oligodendrocyte glycoprotein (MOG)-induced experimental 
autoimmune encephalomyelitis (EAE) rats (Papadopoulos et al., 2006). What are 
the reasons behind NG2+ cells’ resistance and mature oligodendrocytes’ 
vulnerability to GCI formation? One speculation is a role for myelin in this 
process as NG2+ cells lack myelin proteins and an extensive microtubule 
network (Richter-Landsberg, 2000). Myelin formation is a dynamic process 
involving interaction and transport of lipids and proteins with the aid of the 
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microtubule network (Pfeiffer et al., 1993). In addition to acting as a highway for 
lipid and protein transport, the oligodendrocyte microtubule network plays a role 
in myelin compaction and stabilization (Richter-Landsberg, 2000). Disruption of 
the oligodendrocyte microtubule network inhibits the translocation of essential 
proteins and mRNA to the myelin compartment which eventually leads to myelin 
damage (Carson et al., 1997).  αSyn has been shown to interact with membranes, 
vesicular transport and microtubule associated proteins (MAP) in neurons (Iwai 
et al., 1995; Kahle et al., 2000; Riedel et al., 2009; Reynolds et al., 2011) but its 
role in oligodendrocytes is unknown especially while a consensus is yet to be 
reached on whether oligodendrocytes are capable of producing αsyn (Mori et al., 
2002, 2003; Miller et al., 2005). However, similar roles for αsyn may be inferred 
in mature oligodendrocytes in light of the fact that mature oligodendrocytes 
contain microtubules and MAP also found in neurons such as tau and MAP2 
(LoPresti et al., 1995; Müller et al., 1997; Richter-Landsberg, 2000) in addition to 
the synergistic relationship found between αsyn and tau (Muntane et al., 2008; 
Riedel et al., 2009; Clinton et al., 2010; Badiola et al., 2011).  Aberrant changes in 
αsyn, through oligomerisation and fibrillization, may lead to inclusion formation 
and alter the interaction of αsyn with microtubules and MAP recruiting them into 
the inclusion and disrupting the microtubule network. Cell culture evidence 
suggests that αsyn functions as a MAP and that loss of αsyn microtubule-
assembly activity induces tubulin aggregation (Alim et al., 2004). Tubulin 
oligomers, in turn, seed αsyn fibrillogenesis creating a cycle where αsyn and 
tubulin both induce and exacerbate aggregate formation (Alim et al., 2002, 2004). 
GCIs have been shown to contain αsyn, tau, α- and β-tubulin in addition to other 
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proteins (Papp et al., 1989; Gai et al., 1999; Nakamura et al., 2000; Kawamoto et 
al., 2002, 2007; Pountney et al., 2011; Chiba et al., 2012). Therefore, it may be 
hypothesized that the interaction of αsyn with myelin and microtubules renders 
mature oligodendrocytes more susceptible to GCI formation than NG2+ cells.  
Determining presence of GCIs in immature pre-myelinating oligodendrocytes, an 
intermediate phase between NG2+ cells and mature oligodendrocytes, proved to 
be a more challenging task. Immature oligodendrocytes, identified as 
CNPase+/MBP― cells, are non-myelinating oligodendrocytes and were 
undetectable in the frontal cortex and cerebellum of this cohort. The lack of 
immature oligodendrocytes may be explained by the age of the cases studied and 
the transient nature of this oligodendrocyte maturational stage. The number of 
immature oligodendrocytes peaks around 28 – 41 gestational weeks and 
myelination begins at around 30 gestational weeks and progress over several 
decades (Hasegawa et al., 1992; Back et al., 2001; Jakovcevski et al., 2009). In 
addition, there is a caudal to rostral pattern where myelination begins in the 
spinal cord, followed by  the brainstem and subcortical structures then finally 
cortical structures after birth (Hasegawa et al., 1992; Back et al., 2001; 
Jakovcevski et al., 2009).  Transition of immature oligodendrocytes to mature 
myelinating oligodendrocytes is a regulated process with a narrow window of 
differentiation and myelination - transitioning from immature oligodendrocytes 
to myelinating oligodendrocytes within 2 days and myelinating axons within 12-
18 hours (Pfeiffer et al., 1993; Bradl and Lassmann, 2010). It is therefore not 
surprising that immature oligodendrocytes are sparse or not found by the fifth 
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decade of life, the mean age of onset of MSA, and when myelination is complete 
and oligodendrocytes fully differentiated.   
A further possible source of immature oligodendrocytes would be those that 
arise due to activation of oligodendrocyte precursor cells (NG2+ cells) as part of 
the disease process.  Myelin loss is a pathological event in MSA and NG2+ cells 
have been shown to respond to demyelinating events by exiting their quiescent 
state and populating demyelinated lesions as demonstrated in MS studies 
(Franklin, 2002; Franklin and ffrench-Constant, 2008).  Though some degree of 
remyelination does occur in MS, it is a suboptimal process resulting in thinner, 
disproportionate myelin to axon diameter (Franklin and ffrench-Constant, 2008). 
One hypothesis for the failure of remyelination in MS is inadequate 
differentiation of oligodendrocyte precursor cells (Franklin, 2002). Therefore 
even if it were proposed that similar remyelination events occur in MSA, the 
inadequate differentiation of oligodendrocyte precursor cells and transient 
presence of immature oligodendrocytes suggest that this maturational stage does 
not play a vital role in the pathogenesis of MSA.  
Conclusion  
GCIs occur within mature myelinating oligodendrocytes while oligodendrocyte 
precursor cells or immature oligodendrocytes are unaffected by αsyn pathology. 
Understanding the reasons for this preferential accumulation of GCIs could be 
vital in understanding disease propagation in MSA. It may be hypothesized that a 
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possible interaction of αsyn with myelin and microtubules renders mature 
oligodendrocytes more susceptible to GCI formation than NG2+ cells. 
 
 
This chapter contributed to the following paper: 
Ahmed, Z., Asi, Y.T., Lees, A.J., Revesz, T. and Holton, J.L., 2013. Identification 
and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive 
supranuclear palsy and Parkinson’s disease. Brain pathology, 23(3), pp.263–273. 
(Contribution to paper: execution of experiments, data collection and analysis 
and drafting and review of manuscript). 
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5      
  REGIONAL AND CELLULAR EXPRESSION OF SNCA IN 
MSA 
 
5.1. INTRODUCTION 
Much information on transcriptional regulation and mutations of the αsyn gene 
(SNCA) has been contributed from PD studies, due to the longer history of 
research and resources available to the PD field. PD and MSA are α-
synucleinopathies and so lessons learned from PD studies may be used as leads 
or guides for research in MSA. PD exists in inherited and sporadic forms while 
MSA is largely regarded as a sporadic disease as genetic clues to prove otherwise 
remain to be discovered and validated. To date, there are three reports suggesting 
inheritance of MSA in German  and Japanese families (Wullner et al., 2004; Soma 
et al., 2006; Hara et al., 2007). A dosage effect of SNCA has been identified 
where duplication and triplication of the gene leads to different parkinsonian 
phenotypes (Fuchs et al., 2007; Ross et al., 2008). SNCA mutations known to 
have cause PD were used as a guide for candidate examination in MSA cases, 
however, there is conflicting evidence for the effect of SNCA mutations and 
multiplication in MSA. While some groups failed to detect  mutations or 
multiplications of SNCA in pathologically confirmed MSA cases, other studies 
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identified single nucleotide polymorphism (SNP) in SNCA; rs11931074, 
rs3822086 and rs3775444, to be associated with increased risk for developing 
MSA (Ozawa et al., 1999; Lincoln et al., 2007; Al-Chalabi et al., 2009; Scholz et 
al., 2009; Ross et al., 2010). Mutations in SNCA may also lead to a pathological 
spectrum encompassing that seen in PD and MSA as seen in the case of G51D 
mutation which includes neuronal and oligodendroglial αsyn-positive inclusions 
(Kiely et al., 2013). 
In addition to examining mutations and multiplications of SNCA, there has been 
some attempt to examine SNCA mRNA expression in MSA. Variations in 
SNCA mRNA expression using in situ hybridization (ISH) were found in 
different regions of the normal human brain (Solano et al., 2000). Strong 
expression was detected in the substantia nigra, entorhinal cortex, granule cell 
layer of the dentate gyrus, intralaminar nuclei, locus coeruleus, basis pontis, 
granule cell layer of cerebellum, and inferior olive. In the same study, SNCA 
mRNA expression was not detected in the globus pallidus, dorsal medial nucleus, 
subthalamic nucleus, superior colliculus, red nucleus, crus cerebri, periaqueductal 
gray, pontine tegmentum, and molecular layer of cerebellum. Ozawa and 
colleagues (2001) found that SNCA mRNA levels in cortical regions (frontal, 
temporal or occipital) of MSA brains did not differ from those in controls using 
quantitative PCR (qPCR). Cortical areas are less severely affected than 
subcortical regions in MSA and that may be a possible explanation for the similar 
SNCA levels between MSA and controls.  It may be plausible that expression 
differences are more likely to arise in areas more severely affected in MSA such 
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as the pons and cerebellum. However, as with the evidence for SNCA mutations, 
there are conflicting results with regards to SNCA expression in the pons. Jin 
and colleagues (2008) observed no difference in SNCA copy number and mRNA 
expression in the pons of  MSA and control cases, while down-regulation in 
MSA cases was reported by Langerveld and colleagues (2007). Alternative 
splicing of SNCA mRNA results in the production of different isoforms of the 
protein, and changes in the mRNA expression level of these isoforms were 
evident in PD, DLB, and MSA (Beyer et al., 2008 a). The mRNA expression level 
of isoform SNCA 98 was found to be up regulated in the frontal cortices of 
MSA, PD, and DLB patients. Unlike PD and DLB however, there was no 
significant difference in the level of SNCA 126 mRNA in MSA (Beyer et al., 
2008 a).  
The previous studies focused on understanding SNCA mRNA expression in 
MSA at the regional level. However, since the pathological hallmark of MSA is 
αsyn accumulation in oligodendrocytes, a more pertinent question is what is the 
expression profile of SNCA at the cellular level? To date, there is one published 
study addressing this question (Miller et al., 2005) in which double-labelling ISH 
for αsyn and proteolipid protein (PLP), an oligodendrocyte marker was 
performed. The findings of this revealed that SNCA is not expressed in 
oligodendrocytes of MSA or control brains. αSyn is regarded as a pre-synaptic 
neuronal protein and so understanding its origins in oligodendrocytes in MSA is 
important to unravelling the pathogenic mechanisms of this disease.   
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5.2. HYPOTHESIS 
a. SNCA mRNA expression in MSA is altered and is greater in brain regions 
with greater αsyn pathology.  
b. Accumulation of αsyn in oligodendrocytes in MSA is due to 
overexpression of SNCA mRNA in oligodendrocytes. 
 
5.3. AIM 
To determine the regional and cellular expression profile of SNCA 
mRNA in MSA. 
 
5.4. CASE SELECTION  
MSA cases were pathologically typed according to published criteria (Ozawa et 
al., 2004) and grouped into mixed, SND and OPCA types as described in 
Chapter 2: Materials and methods section 2.4. Frozen tissue from 5 MSA-SND, 5 
MSA-OPCA, 5 MSA-mixed types were selected and sex and age –matched to 5 
PD and 4 normal control cases to study regional SNCA mRNA expression 
(Table ‎5.1). The regions studied were the posterior frontal cortex (grey matter 
and white matter), occipital cortex (grey matter and white matter), dorsal 
putamen, pontine base and cerebellar white matter. For the cellular expression 
study, the pons of 5 MSA-mixed type and 6 normal controls was used to isolate 
neurons and oligodendrocytes. Cases that did not have frozen tissue available 
were excluded.  The demographics of this cohort are presented in Table ‎5.2.
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Table ‎5.1. Regional expression cohort demographics 
MSA: multiple system atrophy; PD: Parkinson’s disease; SND: striatonigral degeneration; 
OPCA: Olivopontocerebellar atrophy; NA: not applicable; ND: not documented.  
 
 
Case Age Sex Diagnosis MSA Pathological 
Type 
PMI 
(hrs) 
1 56 F MSA Mixed 28 
2 62 M MSA Mixed 20 
3 64 F MSA Mixed 52 
4 66 M MSA Mixed 105 
5 70 F MSA Mixed 65 
6 50 F MSA SND 4 
7 54 F MSA SND 47 
8 58 F MSA SND 11 
9 63 M MSA SND 27 
10 72 M MSA SND 50 
11 56 M MSA OPCA 37 
12 60 F MSA OPCA 62 
13 61 M MSA OPCA ND 
14 64 M MSA OPCA 35 
15 66 F MSA OPCA 74 
16 61 F PD  NA 26 
17 63 M PD NA 37 
18 65 M PD NA 43 
19 67 F PD NA 108 
20 70 M PD NA 75 
21 57 M Control NA 79 
22 69 M Control NA ND 
23 71 M Control NA 39 
24 73 F Control NA 24 
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Table ‎5.2. Cellular expression cohort demographics 
 
 
MSA: multiple system atrophy; NA: not applicable; ND: not documented.  
Case Age Sex Diagnosis MSA 
Pathological 
Type 
PMI 
(hrs) 
RIN 
before 
LCM 
RIN 
after 
LCM 
1 50 M MSA Mixed 30 4.8 2.6 
2 70 F MSA Mixed 65 5.8 ND 
3 56 M MSA Mixed 75 4.7 ND 
4 64 F MSA Mixed 99 4.4 2.8 
5 64 M MSA Mixed 100 5.1 3.1 
6 69 M Control NA ND 4.4 ND 
7 82 F Control NA ND 4.8 3.6 
8 73 F Control NA 24 5.3 2.0 
9 85 M Control NA 78 4.2 2.2 
10 80 F Control NA 49 3.9 2.5 
11 83 M Control NA 63 4.2 2.3 
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5.5. METHOD 
5.5.1. Reference genes 
The candidate reference genes tested were TBP, UBC, GAPDH, RPLP0, 
YWHAZ, B2M and SDHA and were chosen based on published literature 
(Vandesompele et al., 2002; Coulson et al., 2008; Trabzuni et al., 2011). The 
number and choice of reference genes was determined using the Stratagene 
(Agilent Technologies, California) and qBase (Biogazelle, Belgium) softwares as 
described in Chapter 2: Materials and methods, section 2.13.3. 
5.5.2. Regional expression study 
Frozen tissue samples for regional expression study were collected as described 
in, section ‎2.6. Tissue was homogenized, RNA extracted and reverse 
transcription were carried out using TissueRuptor (Qiagen), RNeasy Mini Kit 
(Qiagen) and SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, UK) 
according to manufacturer’s instructions and as described in Chapter 2: Materials 
and methods, sections ‎2.10 and ‎2.12. qPCR was performed on Stratagene 
MX3000p (Agilent technologies, CA) using Power SYBR Green Master Mix 
(Applied Biosystems) and detailed in Chapter 2: Materials and methods, 
section ‎2.14.2.  
5.5.3. Cellular expression study 
Neurons from the pontine base (1000 cells) and oligodendrocytes from 
cerebellar white matter (1000 cells) of MSA and control cases were isolated 
using PixCell II laser capture microdissection system (Arcturus Engineering, 
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Mountain View, CA, USA) and Arcturus CapSure Macro caps (Applied 
Biosystems, UK, LCM0211) as described in Chapter 2: Materials and methods, 
section ‎2.9 and based on a published protocol (Waller et al., 2012). Neurons were 
identified using Toluidine blue nuclear stain (Chapter 2: Materials and methods, 
section ‎2.8.2) and oligodendrocytes using Anti-OSP in a rapid IHC protocol 
(Chapter 2: Materials and methods, section ‎2.8.1). RNA extraction was carried 
out using Arcturus PicoPure RNA isolation kit (Applied Biosystems, UK, 
KIT0204) and reverse transcription using SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen, UK) according to manufacturer’s instructions and as 
described in Chapter 2: Materials and methods, sections ‎2.11 and ‎2.12. qPCR was 
performed on Stratagene MX3000p (Agilent technologies, CA) using Power 
SYBR Green Master Mix (Applied Biosystems) and detailed in Chapter 2: 
Materials and methods, section ‎2.14.2.  
5.5.4. Allen Brain Atlases 
The Allen Brain Atlas (ABA) is a resource that provides gene expression data 
from human, mouse and rhesus macaque brains using ISH and/or microarray 
techniques. The atlases utilized for the purposes this thesis are the Human Brain 
Atlas (HBA) and Developing Human Brain Atlas (DevHBA) (Hawrylycz et al., 
2012). These atlases are found at the following website http://www.brain-
map.org.
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5.6. RESULTS 
5.6.1. Reference gene analysis 
Seven genes – TATA box binding protein (TBP), ubiquitin C (UBC), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), ribosomal protein large P0 (RPLP0), 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide (YWHAZ), β2 microglobulin (B2M) and succinate dehydrogenase 
complex, subunit A, flavoprotein (SDHA) - were chosen based on published 
literature (Vandesompele et al., 2002; Coulson et al., 2008; Trabzuni et al., 2011) 
and analysed to determine which are the most suitable as reference genes for this 
study. Initial quality control check of the reference genes primers was assessed by 
melt curve analysis (Figure ‎5.1) and agarose gel electrophoresis. Multiple peaks 
on a melting curve plot and bands on an agarose gel indicate the production of 
non-specific  products such as primer-dimers in addition to the desired product 
rendering the primer set unsuitable for qPCR experiments (Ririe et al., 1997). 
One set of primers for each gene was assessed except for UBC and TBP, where 
two sets of primers were assessed. More than one peak was detected for primers 
UBC-2, SDHA and RPLP0 and therefore they were excluded as candidate 
reference genes. Only primers that produced a single peak on the melt curve 
graph and a band at the predicted size on the agarose gel were included for 
gNorm analysis using qBase plus (qBase+) software (Vandesompele et al., 2002).  
This analysis allows the determination of the most suitable reference genes 
(according to the stability of their expression in disease and normal conditions) 
and the number of reference genes recommended to carry out the desired qPCR 
assay.  
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A qPCR experiment on MSA and controls using the primers TBP-1, TBP-2, 
UBC-1, GAPDH, YWHAZ and B2M was conducted for gNorm analysis. The 
output of gNorm analysis provides gNorm M and gNorm V values (Figure ‎5.2). 
The gNorm M value is indicative of the average expression stability of the gene 
and a value of 0.5 or less is an indication of greater stability. The most stable 
genes were TBP-1 (gNorm M = 0.329), TBP-2 (gNorm M = 0.422), UBC-1 
(gNorm M = 0.397) and GAPDH (gNorm M = 0.498). The gNormV value 
(<0.15) reflects the optimal number of reference genes that need to be used for 
the experiment and in this experiment the recommended number of reference 
genes was set at three. As such, TBP-1, UBC-1 and GAPDH were selected as 
appropriate reference genes (Table ‎5.3). Standard curve analysis of these 
reference genes indicates that they have comparable efficiencies and parallel 
slopes and are therefore suitable for experimental use (Figure ‎5.3). 
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Figure ‎5.1. Melt curve analysis of reference 
genes. 
Melting curve analysis of UBC-1 (A), UBC-2 
(B), TBP-1 (C), TBP-2 (D), GAPDH (E), 
SDHA (F), B2M (G), YWHAZ (H), and 
RPLP0 (I) with fluorescence intensity plotted 
on the y-axis and temperature on the x-axis. 
Multiple peaks on the plot indicate that there 
are specific and non-specific products 
produced by the primer set. Therefore, only 
those primer sets with single peaks (UBC-1, 
TBP-1, TBP-2, GAPDH, B2M and YWHAZ) 
were included for further analysis.  
A B 
C D 
E F 
G H 
I 
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Figure ‎5.2. gNorm reference gene analysis. 
 
gNormM (A) and gNormV (B) results of gNorm analysis. gNorm M values ≤ 0.5 
indicate stability of expression. TBP-1 (0.329), TBP-2 (0.422), UBC-1 (0.397) and 
GAPDH (0.498) were more stably expressed than B2M (0.624) and YWHAZ 
(0.737). A gNorm V value of <0.15 was reached at 3 genes indicating that the 
optimal number of reference genes needed for analysis is three. 
B 
A 
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Figure ‎5.3. Standard curve of reference genes. 
Standard curve of the reference genes UBC (yellow), TBP (blue), and GAPDH 
(orange). These reference genes have parallel slopes and therefore are suitable 
for use in qPCR experiments. The efficiencies of these genes are 92.2% for 
UBC, 88.1% for TBP and 84.7% for GAPDH. 
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Table ‎5.3. Primer information 
Gene SNCA TBP UBC GAPDH 
Gene name synuclein, alpha (non A4 component of 
amyloid precursor) 
TATA box binding protein Ubiquitin C 
Glyceraldehyde-3-phosphate 
dehydrogenase 
RefSeq no. NM_001146055.1 NM_003194 NM_021009 NM_002046 
Primer 
sequence F: CAACAGTGGCTGAGAAGACCA 
R: GCTCCTTCTTCATTCTTGCCCA   
F: 
TGCACAGGAGCCAAGAGTGAA 
R:  
CACATCACAGCTCCCCACCA 
F:  
ATTTGGGTCGCGGTTCTTG 
R: 
TGCCTTGACATTCTCGATGGT 
F: 
GAAATCCCATCACCATCTTCCAGG 
R:  
GAGCCCCAGCCTTCTCCATG 
Alignment F: base 228 to 249 
R: base 369 to 390 
F: base 892 to 913 
R: base 1004 to 1024 
F: base 399 to 418 
R: base 511 to 532 
F: base 313 to 337 
R: base 413 to 433 
Amplicon 
length (bp) 
163 132 133 120 
Organism Homo sapiens Homo sapiens Homo sapiens Homo sapiens 
Source 
In house design 
RTPrimerDB 
(ID: 2630) 
RTPrimerDB 
(ID: 8) 
RTPrimerDB 
(ID: 1108) 
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5.6.2. Regional expression 
SNCA mRNA expression level was examined in the posterior frontal region, 
occipital region, dorsal putamen, pontine base and cerebellar white matter of 
MSA, PD and control cases. MSA cases were further divided into the three 
pathological subgroups: Mixed, SND and OPCA. TBP, UBC-1 and GAPDH 
were the reference genes used to obtain normalized expression values. A 
multilevel statistical model was applied in analysing the data whereby the data 
was first adjusted for regional effect and then adjusted to control for group effect 
(Figure ‎5.4).  
The mean level of SNCA mRNA expression was highest in PD and lowest in 
MSA-SND, however, there was no overall statistically significant difference in 
expression between the groups (p=0.14; Figure ‎5.4 A). After adjusting for group 
effect, the highest expression was found in the occipital cortex while the lowest 
was in the putamen. The differences between regions was found to be statistically 
significant (p<0.0001; Figure ‎5.4 B). This regional difference in SNCA mRNA 
expression has also been demonstrated in other databases where higher 
expression was also found in cortical regions compared to subcortical and 
cerebellar regions (Figure ‎5.5).  
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Figure ‎5.4. SNCA mRNA regional expression 
 
Expression of SNCA in different groups after adjusting for regional effect indicate that 
the lowest level of expression is in  the MSA-SND group while the highest was in the 
PD group (A), however, these findings did not reach statistical significance (p=0.14). 
Comparing expression in different regions while adjusting for group effect (B), shows 
that there is a statistically significant difference in SNCA expression between regions 
(p<0.0001). The lowest expression was found in the dorsal putamen and the highest in 
the occipital cortex. Multilevel model test with significance level set at p=0.05. The boxplot show 
median values as the line within the box, the box reflects the interquartile range and the whiskers the 
range of the values.   
PFR: posterior frontal region; OR: occipital region; Put-D: dorsal putamen; CBM: cerebellum; Ctx: 
cortex; WM: white matter;  MSA: multiple system atrophy; SND: striatonigral degeneration; OPC: 
olivopontocerebellar; PD: idiopathic Parkinson’s disease.  
 
B 
A 
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Figure ‎5.5. SNCA mRNA expression from UKBEC dataset 
Microarray analysis of SNCA mRNA expression in different regions of 
normal control brains from UKBEC dataset showing greater expression 
in cortical regions than subcortical and cerebellar.  
CRBL: cerebellum; FCTX: frontal cortex; OCTX: occipital cortex; PUTM: 
putamen; WHMT: white matter; TCTX: temporal cortex; SNCA: α-synuclein  
  
A 
B 
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5.6.3. Cellular expression  
5.6.3.1. LCM DATA 
Neurons and OSP-positive oligodendrocytes were isolated from both MSA-
mixed and control brain tissue sections by LCM (Figure ‎5.6).  SNCA mRNA 
expression was detected in neurons and oligodendrocytes of both MSA and 
control cases, with the highest level of expression found in MSA 
oligodendrocytes (Figure ‎5.7 A).  
The fold changes in SNCA mRNA expression between the different cell types 
and groups were also calculated (Figure ‎5.7 B). There was a slight increase in 
expression in MSA oligodendrocytes as compared to control oligodendrocytes 
(fold change = 0.7, Mann Whitney U test, p=0.18). Expression in MSA neurons, 
on the other hand, was slightly decreased as compared to control neurons (fold 
change = -0.4, Mann Whitney U test, p=0.46). Comparing the different cell types 
within the same groups reveals that control oligodendrocytes express 0.3 times 
(Mann Whitney U test, p=0.92) more SNCA than control neurons. The greatest 
difference was seen between MSA oligodendrocytes and neurons as expression in 
MSA oligodendrocytes is 3.1 times higher than MSA neurons (Mann Whitney U 
test, p=0.16).  
RNA quality was assessed using the Agilent Bioanalyser 2100. Maintenance of 
RNA quality was adequate as assessed by the RIN of samples before and after 
LCM was carried out and this is in keeping with previous findings (Waller et al., 
2012). Prior to LCM, samples had a mean RIN of 4.7 (range 4.2-5.8) declining to 
2.6 (range 2.0-3.1) after LCM.  
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Figure ‎5.6. LCM of neurons and oligodendrocytes 
Schematic of LCM (A-C) and LCM of neurons identified by Toluidine nuclear stain (D-F) 
and oligodendrocytes identified by OSP-immunohistochemistry (G-I) from frozen post-
mortem human brain tissue. Once cells of interest were identified in the tissue section 
(A,D,G), the laser was fired on those cells causing the thermoplastic film on the cap to 
melt and the cells to adhere to the film (B,E,H). The cap was then lifted carrying with it 
the targeted cells and leaving behind unwanted cells (C,F,I).    
OSP: oligodendrocyte specific protein 
A 
D 
G 
E F 
H I 
B C 
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Figure ‎5.7. SNCA mRNA cellular expression  
 
SNCA is expressed in neurons and oligodendrocytes of both MSA and control cases. 
Expression in neurons is greater in controls as compared to MSA (p=0.47), in 
contrast to oligodendrocytes where expression is greater in MSA (p=0.18), however, 
these results did not reach statistical significance (A). The bar graph represents fold 
change of expression values between the different cases and cell types (B). Although 
none of the differences reached statistical significance, the bar graph shows increased 
expression in MSA oligodendrocytes when compared to control oligodendrocytes 
(p=0.18), MSA neurons (p=0.16) and control neurons (p=0.18).   
In contrast, there was a slight decrease in αSyn expression in MSA neurons as 
compared to control neurons (p=0.46). Mann-Whitney U test with significance level set at 
p=0.05. The boxplot shows median values as the line within the box, the box reflects the 
interquartile range and the whiskers the range of the values.   
Oligo: oligodendrocytes; MSA: multiple system atrophy. 
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5.6.3.2. HUMAN BRAIN ATLAS (HBA) AND DEVELOPING HUMAN 
BRAIN ATLAS (DEVHBA) 
There is a clear demarcation between grey and white matter in cortical areas, as 
such, data from cortical areas were chosen to assess SNCA mRNA expression 
from the HBA and DevHBA. Neuronal SNCA mRNA expression was assessed 
in grey matter as this area is enriched in neurons. White matter, on the other 
hand, is an oligodendrocyte enriched region and is therefore taken as a proxy for 
oligodendrocyte SNCA mRNA expression. The cortical regions available in the 
HBA include the temporal and visual cortices, while, the prefrontal and visual 
cortices were part of the DevHBA dataset. The data reviewed is SNCA ISH 
from normal, adult brain.  
Neurons in the grey matter of prefrontal, temporal and visual cortices show 
strong expression of SNCA mRNA (Figure ‎5.8). SNCA mRNA expression is 
not evident in the white matter of the same cortical regions which may indicate 
that it is not expressed by oligodendrocytes or present in axons (Figure ‎5.9).  
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Figure ‎5.8. SNCA ISH in cortex of human brain 
 
The cortex is a neuron-rich area of the brain. It is evident here that there 
is strong SNCA mRNA expression in neurons of the prefrontal, 
temporal and occipital cortices. The left column represents the ISH 
sections and the right column is the corresponding Nissl stain sections to 
help visualize cells. 
ISH data from the Allen Brain Atlas (Hawrylycz et al., 2012) http://www.brain-
map.org. 
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Figure ‎5.9. SNCA ISH in subcortical white matter of human brain 
 
White matter is an oligodendrocyte-rich area of the brain. SNCA mRNA 
expression in oligodendrocytes is not evident in these sections of white 
matter from the prefrontal, temporal and visual cortices. The left column 
represents the ISH sections and the right column is the corresponding 
Nissl stain sections to help visualize cells. 
 
ISH data from the Allen Brain Atlas (Hawrylycz et al., 2012) http://www.brain-
map.org. 
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5.7. DISCUSSION 
αSyn has been localized in the brain to neuronal presynaptic terminals and is 
thought to play a role in neuronal plasticity, vesicular transport and membrane 
interaction (Iwai et al., 1995; Kahle et al., 2000; Reynolds et al., 2011).  There has 
been great interest in αsyn in MSA since its identification as one of the main 
constituents of GCIs. Understanding the expression pattern of SNCA mRNA in 
MSA at both the regional and cellular levels is essential to determine if changes in 
expression play a role in MSA pathogenesis and whether this influences regional 
vulnerability to disease. The regional expression analysis demonstrates that 
SNCA expression level varies across different brain regions in control, MSA and 
PD groups.  The greatest expression is found in the occipital cortex and the 
lowest level in the putamen. However, SNCA mRNA expression is not 
significantly different between the MSA subgroups, PD and control cases in all 
regions. The expression trend found in MSA and control cases of this cohort is 
similar to that found in other expression databases such as UKBEC (Trabzuni et 
al., 2011) and Allen Brain Atlas (Hawrylycz et al., 2012) which analyze gene 
expression in control human brains (Figure ‎5.5).  The similarity in trend, where 
SNCA is generally expressed more in cortical regions than subcortical and 
cerebellar regions, has two main implications. The first is that the vulnerability of 
StrN and OPC regions is not associated with a higher baseline expression level of 
SNCA. It could be hypothesized that the abundance of GCIs in specific regions 
is due to higher expression levels of SNCA in the normal condition in those 
regions that is exacerbated by disease. The findings of this study, however, do 
not support this hypothesis as SNCA mRNA levels are higher in cortical than 
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subcortical regions in both normal and disease cases, while GCI pathology is 
greater in StrN and OPC regions in MSA. This also indicates that the disease has 
not caused an alteration in expression levels in areas of greater vulnerability.  The 
undetectable difference in SNCA expression level between the different MSA 
groups, PD and controls may imply that factors contributing to pathogenic 
mechanisms of MSA may be further downstream and not at the transcriptional 
level and may suggest that impaired αsyn degradation may contribute to the 
disease.  
Another possibility is that any differences at the transcriptional level are masked 
by the cellular heterogeneity of the samples. The major cell type of white matter 
is oligodendrocytes, but this region also contains axons, astrocytes and microglia. 
Therefore, it may be inferred that the SNCA expression found in white matter 
samples is contributed to by axons, oligodendrocytes and other glial cells. 
Although it has long been suggested that mature oligodendrocytes lack SNCA 
(Solano et al., 2000; Miller et al., 2005; Jin et al., 2008), cell-culture evidence 
indicates that rat and mouse oligodendrocytes express SNCA, and in some cases 
this expression is transient, appearing in precursor cells and declining as they 
mature (Richter-Landsberg et al., 2000; Culvenor et al., 2002; Nielsen et al., 
2006). The contribution of axons to expression values of white matter samples is 
a valid argument especially that axons have been shown to have a local repository 
of mRNA and that SNCA has been shown to be transported down axons in 
hippocampal cultures (Withers et al., 1997). There have been attempts to identify 
and characterize the axonal transcriptome and the source of this local repository 
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has been shown to be from neuronal as well as glial nuclei  (Cutillo et al., 1983; 
Giuditta et al., 2008).  
To overcome this problem of cellular heterogeneity, LCM was used to obtain 
samples highly enriched in neurons and oligodendrocytes as LCM isolation of 
OSP-positive oligodendrocytes has been shown to provide an oligodendrocyte-
enriched sample (Waller et al., 2012). Using this approach this study has 
unmasked interesting findings in SNCA expression profile in neurons and 
oligodendrocytes of MSA and control cases. Firstly, SNCA expression was 
detected in oligodendrocytes of both control and MSA cases confirming the 
findings in white matter samples in the regional analysis of this and other 
cohorts. Secondly, the highest SNCA expression was found in MSA 
oligodendrocytes as compared to control oligodendrocytes, MSA neurons and 
control neurons. Therefore, not only has SNCA been found to be expressed by 
oligodendrocytes, but in the disease condition, this expression seems to be 
increased. This overexpression in MSA parallels findings in MS studies which 
show an  increase in SNCA mRNA and protein expression in the presence of 
inflammatory and cell stress signals (Tanji et al., 2001; Papadopoulos et al., 2006; 
Lu et al., 2009). 
The overexpression of SNCA mRNA in MSA oligodendrocytes may be a 
mechanism contributing to the accumulation of the αsyn protein in MSA 
oligodendrocytes as GCIs. In addition to overexpression by oligodendrocytes, 
the fold change difference between neurons and oligodendrocytes may also be a 
contributing factor. There is a subtle fold change difference between neurons 
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and oligodendrocytes of controls, where it is slightly higher in oligodendrocytes. 
In MSA, however, this fold difference is ten times higher. This may suggest that 
there is an expression equilibrium between neurons and oligodendrocytes and a 
disruption in this equilibrium could be a disease modifying factor. Though 
speculative, MSA oligodendrocytes may be overexpressing to compensate for a 
possible shortage caused by the slight down regulation by MSA neurons and 
aiding in replenishing αsyn pool in neurons. The cellular expression of SNCA in 
MSA may also explain the pathological profile of the disease.  GCIs are found in 
greater abundance than NCIs in MSA, and this greater susceptibility of 
oligodendrocytes to inclusion formation may be a reflection of overexpression of 
SNCA by oligodendrocytes in MSA. 
SNCA mRNA expression in oligodendrocyte-rich white matter areas and LCM-
oligodendrocytes samples, of both normal and disease groups adds further 
evidence to the on-going debate in the literature on whether SNCA mRNA 
and/or protein is present in oligodendrocytes of normal and disease cases. 
Microarray data of databases such as UKBEC and Allen Human Brain Atlas have 
shown similar findings in their cohorts as found in the cohort of this thesis 
indicating the reproducibility of SNCA mRNA expression detection by qPCR 
and microarray techniques. Unlike qPCR and microarray, there is undetectable 
SNCA expression in white matter areas in ISH experiments. The undetectable 
signal using ISH may not necessarily indicate an absence of expression but rather 
the resolution limitation of the technique (Miller et al., 2005; Deglincerti and 
Jaffrey, 2012). This is a more plausible explanation as SNCA was clearly detected 
‎5.7  Discussion           192 
 
by qPCR and microarray. The higher sensitivity power of qPCR and microarray 
techniques comes at the expense of losing anatomical localization of expression 
in different cells and regions in intact tissue, as is feasible by ISH. However, 
using LCM to isolate specific cell types is one way of overcoming this 
impediment. LCM is a powerful tool so long as one is aware of its limitations, 
especially when using human post mortem tissue. LCM allows single cell 
isolation, however, there will always be some minor degree of contamination 
from the area surrounding the cell that falls within the laser spot. Another caveat 
is that with every additional processing step the likelihood of further RNA 
degradation is increased and in LCM those extra steps are the staining of the cells 
followed by laser capture. Furthermore, this is a time consuming process where 
hours may be spent on one sample to collect an adequate number of cell that 
would result in a substantial RNA yield.  
 Another technique for isolating single-cell populations is fluorescence-activated 
cell sorting (FACS). FACS may be employed to separate specific cell types from 
brain homogenates which may then be used for molecular analysis (Schwartz et 
al., 2003; Nielsen et al., 2006; Olah et al., 2012; Dammer et al., 2013). It would be 
beneficial to compare the results and quality of LCM- and FACS- isolated cells of 
post-mortem tissue as sampling from human cases rather than animal and cell 
models is the most accurate representation of disease-related changes. 
Expression of genes in LCM- or FACS- isolated samples may then be conducted 
using qPCR and microarray or using new technologies such as Nanostring – a 
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multiplex digital gene expression platform analysing up to 800 genes (Morrow 
and Donaldson, 2011; Cajigas et al., 2012; Northcott et al., 2012).  
The promising findings of the LCM experiment of this thesis open the door to 
further exploration into the molecular pathogenesis of MSA. The first step would 
be to repeat and expand the experiment on a different, larger cohort to ensure 
reproducibility of the findings. Inclusion of unaffected brain regions may help to 
elucidate the selective vulnerability of StrN and OPC regions.  In addition to 
affected and unaffected brain regions, examination of expression in MSA cases 
with short disease duration and long disease duration may provide further insight 
into the role of SNCA mRNA expression on clinical outcome.  A further step 
would be to characterize SNCA mRNA expression at different stages of 
oligodendrocyte maturation. The oligodendrocyte lineage comprises precursor, 
immature, mature non-myelinating and mature myelinating cells and αsyn protein 
in GCIs has been found in mature but not precursor oligodendrocytes in MSA 
(Papp et al., 1989; Ahmed et al., 2012).  Therefore, determining SNCA mRNA 
expression in the different maturation stages may provide further insight into any 
underlying vulnerability of cells of oligodendrocytes lineage. Furthermore, 
expression analysis on FACS-isolated cells using the same markers as those of 
the LCM experiment is warranted to determine the feasibility of this technique. If 
adequate RNA quality and quantity are obtained using FACS, then it may prove 
as a useful alternative or complimentary tool to LCM analysis. Studying the 
transcriptome and proteome of single cell populations from control and disease 
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human post-mortem tissue will provide greater insight into the molecular 
mechanisms leading to disease 
Conclusion and future directions 
SNCA mRNA overexpression in mature oligodendrocytes in MSA is a possible 
mechanism by which GCIs form. Further exploration of SNCA mRNA 
expression in affected and unaffected brain regions and in MSA patients with 
different clinico-pathological profiles will provide further insight into the 
contribution of cellular SNCA mRNA expression to regional vulnerability and 
clinical outcome in MSA.  
 
This chapter contributed to the following paper: 
 
Asi, Y.T, Simpson, J.E., Heath, P.R., Wharton, S.B., Lees, A.J., Revesz, T, 
Houlden, H, Holton, J.L. Alpha-synuclein mRNA expression in oligodendrocytes in 
MSA.  Accepted GLIA. 
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6       
  THE ROLE OF EXTRACELLULAR ALPHA-SYNUCLEIN IN 
GCI FORMATION 
 
6.1. INTRODUCTION 
MSA is proposed to be a primary oligodendrogliopathy with secondary 
neurodegeneration due to myelin dysfunction, accumulation of αsyn, and axonal 
damage (Wenning et al., 2008; Jellinger and Lantos, 2010). Abnormal 
accumulation of αsyn in oligodendrocytes as GCIs is the pathological hallmark of 
MSA, however, the mechanism of this accumulation is yet to be established. 
Candidate hypotheses to the mechanisms of inclusion body formation in 
oligodendrocytes cells are overexpression of the protein by oligodendrocytes, 
oligodendrocytes internalization of the protein from the external environment, 
and compromised efficacy of the protein degradation system. 
In vitro models utilizing oligodendroglial cells rather than other glial cells are 
better suited as MSA models as inclusions in other glial cells have not been 
detected in MSA, however, there are few studies addressing the mechanism for 
αsyn accumulation in oligodendroglial cells. Stefanova and colleagues used 
astrocytoma cells and found that overexpression of αsyn has detrimental effects 
on the cells that are exacerbated by the presence of oxidative stress (Stefanova et 
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al., 2001, 2005 b). Overexpression of αsyn in the oligodendroglial cell line OLN-
93 results in disorganization of the microtubule network but does not cause cell 
death as it does in the astrocytoma cells (Scholz et al., 2007). These studies 
overexpressed αsyn in glial cell cultures as a means of recapitulating inclusion 
body formation and the pathological consequences that follow. Although these 
studies provide insight into the sequelae of abnormal protein accumulation, they 
do not address the question of how the inclusion bodies initially form. In 
addition to overexpression of SNCA in oligodendroglial cell lines, these cell lines 
were used to examine the mechanism of αsyn internalization (Kisos et al., 2012; 
Konno et al., 2012). Oli-neu, OLN-93, KG1C, MO3.13 oligodendroglial cell 
lines were used to demonstrate that oligodendroglia are capable of internalizing 
exogenous αsyn present in the media and that the uptake proceeded in a time- , 
concentration- and endocytotic- dependant manner (Kisos et al., 2012; Konno et 
al., 2012). In addition to oligodendrocytes, endocytotic internalization of 
extracellular αsyn by astrocytes and microglia has also been demonstrated (Lee et 
al., 2008 a, 2010).  
In vivo models provide evidence for the capacity of neuron-to-neuron αsyn 
transmission (Desplats et al., 2009; Hansen et al., 2011). GFP-labelled mouse 
neuronal stem cells grafted into the hippocampus of transgenic mice expressing 
human αsyn were immunopositive for human αsyn as early as one week after 
post transplantation (Desplats et al., 2009). Similarly, mouse embryonic 
mesencephalic neurons transplanted into the striatum of transgenic mice 
expressing human αsyn developed human αsyn-positive puncta (Hansen et al., 
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2011). Transmission of αsyn from host to grafted neurons in PD patients with 
the development of LB in the grafted neurons provides further evidence of the 
pathological spread of αsyn (Kordower et al., 2008; Li et al., 2008; Angot and 
Brundin, 2009).  
Moving to  a different approach, the effect of intracerebral inoculation of αsyn 
into mutant and wild-type mice was investigated (Luk et al., 2012 a; b; Masuda-
Suzukake et al., 2013). The inoculated αsyn initiated LB/LN-like inclusions, cell-
to-cell transmission of inclusions, neuronal loss and motor deficits. These studies 
indicate that similar neuropathological changes may be induced in both mutant 
and wild-type mice.  
Although in vitro studies suggest that oligodendrocytes are capable of 
internalizing αsyn, this has not been shown in vivo. In vivo evidence of αsyn 
transmission have provided confirmation for neuron-to-neuron transfer but has 
not established uptake of αsyn by glia. The focus of this chapter is to investigate 
whether uptake of extracellular αsyn by oligodendrocytes represents a possible 
mechanism for inclusion formation.  
6.2. HYPOTHESIS 
a. αSyn accumulation in oligodendrocytes in MSA as GCIs is due to 
internalization of αsyn derived from neurons or the surrounding 
environment by oligodendrocytes.  
b. Accumulation of αsyn in oligodendrocytes affects myelin sheath integrity, 
axonal integrity, and neuronal survival in a time dependant manner. 
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6.3. AIM 
To determine if αsyn is taken up by oligodendrocytes as a possible 
mechanism for the formation of GCIs in MSA using an in vivo model.  
 
6.4. METHOD 
C57BL/6JOlaHsd mice (Harlan, Bicester, UK) between 2-4 months of age were 
anesthetized using isoflurane. The mice were placed on the stereotaxic frame and 
injected in one hemisphere with either MSA, PD, or control human brain lysates 
(5µg total protein). Lysate preparation was as described in Chapter 2: Materials 
and methods, section 2.14.1. Using a single needle insertion at +0.2mm relative 
to Bregma and +2.0mm from midline, 2.0µL of the inoculum was introduced 
into the dorsolateral striatum (2.6mm beneath the dura) and somatosensory 
cortex (0.8mm beneath the dura) at a rate of 0.15µL/min. The mice were 
monitored carefully during surgery and after recovery and were then sacrificed at 
the pre-determined time points of 4 and 30 days post inoculation (dpi) with a 
dose of Lethobarb 20% w/v Solution (Ayrton Saunders Limited, UK). After 
transcardial perfusion with PBS, the brains were removed, fixed in formalin for 
at least 24 hours, then processed and embedded in paraffin.   A total of six mice 
were injected for each lysate and time point.  This protocol was initially carried 
out using fluorescent microbeads (FluoSpheres, Invitrogen) to verify correct 
injection site. 
Eight-micrometre-thick serial section were cut, deparaffinised and placed in 
methanol/H2O2 (100:1) solution for 10 min to eliminate endogenous peroxidase 
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activity. Following washes in PBS, pre-treatment was carried out by pressure 
cooking in citrate buffer at pH 6.0.  Sections were then placed in 10% non-fat 
milk for 30 min at room temperature (RT) to reduce non-specific binding, 
followed by incubation in the primary antibody for 1 hour at RT. After washes in 
PBS, the sections are incubated with primary antibody at a dilution of 1:200 for 
30 min at RT. The secondary antibody was washed off then the sections were 
incubated in the avidin-biotin complex solution for 30 min at RT. After washes 
in PBS, they were treated in the 3,3’-diaminobenzidine (DAB) solution for 3 min. 
The DAB solution was washed off and the tissues were counterstained in 
Mayer’s haematoxylin for 10 sec. The tissue sections were then dehydrated in 
graded alcohol (70%, 90%, and absolute alcohol), cleared in three changes of 
xylene, and then mounted with DPX mounting medium. 
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Table ‎6.1. Antibodies used in in vivo study 
 Host Reactivity Dilution Source (cat. no.) 
Primary antibody     
αSyn Mouse Human, mouse 1:50 Vector Laboratories, Burlingame, CA (VP A106) 
αSyn Mouse Human, mouse 1:1000 BD Transduction (610787) 
LB509 Mouse Human, mouse 1:500 Abcam (ab27766) 
αSyn Rabbit Human, mouse 1:800 Abcam (ab15530) 
αSyn Sheep Human, mouse 1:800 Chemicon (AB5334P) 
αSyn Mouse Mouse 1:200 Cell signalling (4179) 
Secondary antibody     
Biotinylated rabbit anti-mouse IgG Rabbit Mouse 1:200 DakoCytomation , Denmark (E0354) 
Biotinylated swine anti-rabbit IgG Swine Rabbit 1:200 DakoCytomation , Denmark (E0353) 
Biotinylated rabbit anti-sheep IgG Rabbit Sheep 1:200 Vector Laboratories, Burlingame, CA (BA-600) 
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6.5. RESULTS 
6.5.1. Intracerebral inoculation of fluorescent microbeads 
Fluorescent microbeads (FluoSpheres, Invitrogen) were initially inoculated into 
the mice at the desired coordinates to ensure inoculation into the cortex and 
striatum as indicated in Figure ‎6.1. 
6.5.2. αSyn pathology 
The entire mouse brain was sectioned (120 sections) and a battery of αsyn 
antibodies (Table ‎6.1) was tested on tissue sections at 40µm intervals. αSyn 
positive staining was undetectable in neurons or glial cells in all sections and 
levels of the mouse brain inoculated with MSA, PD or control lysate.  
 
  
                   ‎6.5  Results      202 
 
Figure ‎6.1. Fluorescent beads inoculation 
Fluorescent beads were intracerebrally inoculated at the specified coordinates to 
ensure that the cortex and striatum are successfully targeted (A). A schematic 
representation of fluorescent beads location. Coronal brain image obtained from 
Allen Brain Atlas (B).  
A 
B 
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6.6. DISCUSSION  
GCIs found in oligodendrocytes in MSA is the pathological hallmark of the 
disease. αSyn is the main constituent of GCIs, however, the mechanisms by 
which it accumulates are poorly understood. The hypothesis tested in this 
chapter is that internalization of extracellular αsyn is one mechanism by which 
GCIs form.  Luk and colleagues demonstrated that unilateral  intracerebral 
inoculation of pathological αsyn into transgenic mice overexpressing human 
A53T and C57BL6/C3H  wild-type mice resulted in uptake of αsyn by neurons 
to form LB-like pathology and that the pathology spread to the contralateral side 
(Luk et al., 2012 a; b). Masuda-Suzukake and colleagues performed a similar 
experiment, however, using lysates from human DLB brain as the inoculum. The 
C57BL/6J wild-type mice recapitulated pathology seen in DLB as LB-like 
inclusions formed in neurons and spread to multiple regions of the brain 
(Masuda-Suzukake et al., 2013).   
Informed by the methods and findings of these studies, lysates from MSA, PD 
and control human brains were inoculated intracerebrally into C57BL/6JOlaHsd 
wild-type mice to test the hypothesis that oligodendrocytes internalize 
extracellular αsyn. MSA, PD and control human brains were used to investigate 
whether the uptake of αsyn, if successful, is selective to the source of αsyn 
species and it is postulated that different strains of αsyn may exist (Bousset et al.; 
Guo et al., 2013). C57BL/6JOlaHsd are a subline of the C57BL/6 mice that lack 
the SNCA gene (Specht and Schoepfer, 2001) and were chosen so that uptake of 
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αsyn from the human brain lysates may be examined without any interference 
from endogenous mouse αsyn.   
αSyn immunoreactivity was not observed in neurons or glia of mice inoculated 
with MSA, PD or control human brain lysates at both the 4 and 30 dpi time-
points. The lack of αsyn immunoreactivity has several implications. Firstly, that 
neurons and glia are incapable of internalizing αsyn from MSA, PD or control 
human brain lysates. This is highly unlikely as previous studies with human DLB 
or AD brain lysate in to mice were successful in recapitulating the pathology 
(Kane et al., 2000; Borlikova et al., 2013; Masuda-Suzukake et al., 2013). A 
second implication is that the cells did take up the protein, however, the amount 
taken up may have been below the detection limit of the assay. Thirdly, the lack 
of pathology may also have been due to the relatively short incubation time 
warranting further assessments of time-points longer than 30 dpi. Furthermore, 
that the lack of endogenous αsyn may have affected the successful uptake of the 
injected αsyn. Therefore, this study needs to be taken further by inoculating 
C57BL/6 mice that express αsyn and transgenic mice (e.g. mice overexpressing 
A53T mutant human αsyn) with MSA, PD or control human brain lysates and to 
examine any pathology that may ensue. Only then will it be possible to state with 
greater confidence that oligodendrocytes do not internalize extracellular αsyn in 
an in vivo model. The evidence in the literature demonstrates that 
oligodendrocytes are capable internalising αsyn by endocytosis in vitro, however, 
in vivo confirmation of these findings has yet to be established.  
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Conclusion and future directions 
Internalization of extracellular αsyn by oligodendrocytes is a possible mechanism 
by which GCIs form in MSA. Evidence from in vitro studies indicates that this 
mechanism takes place, however, in vivo confirmation of these findings has yet to 
be established. An in vivo model would be to inoculate wild-type and transgenic 
mice with human MSA brain homogenate and look for evidence of αsyn uptake 
by oligodendrocytes and the resultant load of αsyn pathology at the different 
time-points. Taking the study further, other pathological changes such as myelin 
loss, axonal damage, neuronal loss and gliosis may also be examined to determine 
if any correlations exist with αsyn pathology load and progression with time.  
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7        
CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1. CLINICO-PATHOLOGICAL STUDIES SUMMARY AND FUTURE 
DIRECTIONS 
MSA is an adult onset neurodegenerative disease where patients clinically present 
with varying degrees of parkinsonism, cerebellar ataxia and autonomic 
dysfunction. The pathological manifestations of this disease are most severely 
seen in the StrN and OPC structures and include GCIs, NCIs, myelin damage, 
neuronal loss and gliosis. GCIs are the pathological hallmark of MSA and are 
required for a definite diagnosis. MSA patients are clinically subtyped into MSA-
P and MSA-C reflecting a predominance for parkinsonian and cerebellar features 
respectively. Pathological subtyping into SND, OPC or mixed is made post-
mortem indicating predominant neuronal loss in StrN and OPC structures of the 
brain. These clinical and pathological groups of MSA are the most noted, 
however, other subtypes of MSA do exist such as MSA with CI, long duration 
MSA and minimal change MSA. Exploring the relationships between the clinical 
and pathological profiles of these subtypes allows better understanding of the 
evolution of the disease and opportunities for therapeutic interventions. 
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Cognitive impairment is regarded as an exclusion criterion for a diagnosis of 
MSA, however, this view has been challenged by neuropsychological studies 
documenting CI in MSA patients and by some case studies of pathologically 
confirmed MSA patients reported to have CI (Testa et al., 1993; Wakabayashi et 
al., 1998; Konagaya et al., 1999; Shibuya et al., 2000; Soliveri et al., 2000; Lange et 
al., 2003; Krishnan et al., 2006; Kawai et al., 2008; O’Sullivan et al., 2008; Brown 
et al., 2010).  CI seems to be inherent to the disease as concomitant pathologies 
associated with CI were uncommon in MSA in the cohort studied in this thesis 
and factors other than GCI load and neuronal loss may influence the cognitive 
decline. The synergistic relationship between αsyn, tau and Aβ pathology seen in 
PD (Masliah et al., 2001; Lashley et al., 2008; Compta et al., 2011, 2013) was not 
recapitulated in MSA suggesting αsyn pathology in MSA is not associated with an 
increase in tau or Aβ aggregation and this may be due to possible differences in 
the properties of αsyn in MSA and PD. Therefore, future directions for this 
study would be to characterize the biochemical properties of αsyn in cognitively 
impaired MSA and PD cases. Also, exploring other substrates associated with CI 
such as synaptic pathology, neurotransmitter abnormalities and subcortical 
deafferentation is warranted to understand their contribution to cognitive 
impairment in MSA. 
Long duration and minimal change MSA are two rare subtypes where the former 
have an unusually long survival period of more than 10 years and the later have 
restricted neuronal loss to the substantia nigra and/or locus coeruleus. The 
clinico-pathological profiles of these subtypes provide further insight into the 
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evolution of the disease. Widespread GCI pathology in areas that exhibit no, or 
minimal, neuronal loss adds further credence to the hypothesis that MSA is a 
primary oligodendrogliopathy. Furthermore, these cases highlight the significance 
of the involvement of the autonomic system as cases rapidly declined upon onset 
of autonomic symptoms. Therefore, carrying this study forward warrants 
exploration of nuclei and connections associated with the autonomic system, 
including the intermediolateral column spinal cord, dorsal motor nucleus of 
vagus, medullary serotonergic and catecholaminergic neurons, to uncover the 
contribution of pathology in these structures to the clinico-pathological profiles 
of long duration, minimal change and typical MSA.  
Clinico-pathological studies are important to understanding the evolution of 
disease. The limitations of the clinico-pathological studies of this thesis are 
inherent to retrospective review of medical records when reconstructing the 
clinical profiles of the cases. The studies are also limited by the small number of 
cases and so interpretations must be made with caution. The strength of the 
studies includes the use of detailed neuropathological assessment according to 
published criteria.  
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7.2. ALPHA-SYNUCLEIN ORIGIN IN OLIGODENDROCYTES 
SUMMARY AND FUTURE DIRECTIONS 
GCIs in oligodendrocytes are found in greater abundance than other types of 
inclusions (GNIs, NCIs, NNIs and inclusions in other glia) in MSA. The 
abundant presence of these αsyn-positive oligodendroglial inclusions in 
numerous brain structures in MSA indicates the important role they play in the 
pathogenesis of the disease. αSyn is mainly found in neurons in the CNS, while 
its presence in oligodendrocytes remains a matter of debate. As the main 
constituent of GCIs, it is important to understand the origin of αsyn in 
oligodendrocytes in order to establish the step-by-step mechanisms by which 
GCIs form. To address this, the expression profile of SNCA mRNA and αsyn 
protein in the different cells of the MSA brain were explored in this thesis. αSyn-
positive GCIs are found to occur within mature myelinating oligodendrocytes 
but not within oligodendrocyte precursor cells or immature oligodendrocytes. 
This indicates that oligodendrocytes are vulnerable to GCI formation at the 
mature myelinating stage. Furthermore, SNCA mRNA was detected by qPCR in 
LCM-isolated mature oligodendrocytes of both MSA and normal control cases 
and expression was greater in MSA. The implication here is that overexpression 
of SNCA mRNA leads to increased de novo production of αsyn protein in 
oligodendrocyte which contributes to the formation of GCIs. This is a significant 
finding and prompts re-evaluation of the position that there is an absence of 
SNCA mRNA in oligodendrocytes of normal and MSA cases (Miller et al., 
2005). The study by Miller and colleagues is only study in the literature to date 
that addresses the question of SNCA mRNA expression in oligodendrocytes in 
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MSA using human post-mortem tissue, however, the detection limit of in situ 
hybridization technique may explain their negative findings (Miller et al., 2005).  
The findings of the cellular expression study of this thesis need to be replicated 
and validate in a different cohort, but preliminarily highlight the importance of 
the contribution of SNCA mRNA overexpression in oligodendrocytes to 
inclusion formation in MSA. SNCA mRNA expression in oligodendrocyte 
precursor cells could be a point for future consideration, however, it would be a 
very challenging task due to the difficulty of immunohistochemical detection of 
these cells. However, future success in isolating and analysing SNCA mRNA 
expression in these oligodendrocyte precursor cells may provide further insight 
into the pattern of SNCA transcription and translation in the oligodendrocyte 
lineage in MSA and explain why αsyn is found in mature oligodendrocytes but 
not in the precursor cells.  
In addition to de novo production, an alternative hypothesis to the origin of αsyn 
in oligodendrocytes is internalization of extracellular αsyn by oligodendrocytes. 
There is cell culture evidence that this may occur, however, in vivo confirmation is 
lacking and was sought in this thesis. The findings of this study were inconclusive 
and warrant further investigations using multiple strains of wild-type and 
transgenic mice to determine the capability of oligodendrocytes in internalizing 
αsyn and to elucidate the contribution of endogenous αsyn to the uptake process. 
In addition, the use of MSA, PD and control human brain homogenates will 
further clarify if the uptake of αsyn is dependent on its source. Different protein 
strains resulting in different phenotypic traits in the host have been demonstrated 
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in prion diseases (Aguzzi et al., 2007) and recent studies propose that different 
αsyn strains may exist with different propensities to form aggregates, recruit 
other proteins and penetrate into cells (Bousset et al.; Guo et al., 2013). 
Therefore, the hypothesis of different αsyn strains may be further supported if 
the mice exhibit varying pathologies, where mice inoculated with PD 
homogenates exhibit greater neuronal pathology while those inoculated with 
MSA homogenates exhibit greater oligodendroglial pathology.  
The main limitation of using post-mortem human tissue for expression analysis is 
preservation of RNA quality. Additional processing steps required for isolating 
cells by LCM further compromises RNA quality.  LCM allows single cell 
isolation, however, there will always be some minor degree of contamination 
from the area surrounding the cell that falls within the laser spot. Furthermore, 
this is a time consuming process where hours may be spent on one sample to 
collect an adequate number of cell that would result in a substantial RNA yield.  
The main limitation of the in vivo study was time constraint. The methodology 
has been previously published and shown to produce results, however, the results 
of this thesis are inconclusive as additional strains of wild-type and transgenic 
mice need to be added to the study.   
A hypothetical model of the molecular pathogenesis of MSA based on the 
findings of this thesis and that of published literature is summarised in 
Figure ‎7.1.  
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Figure ‎7.1. Hypothesised molecular pathogenesis of MSA 
 
1) αSyn is found in mature myelinating oligodendrocytes but not in precursor cells (NG2+ cells). The origin of αsyn in mature 
oligodendrocytes may be due to a combination of de novo production and internalization through cell-to-cell transfer. A possible role for 
αsyn in oligodendrocytes is interaction with myelin and the microtubule network. 2) Overexpression of SNCA mRNA, uptake of 
extracellular αsyn, aberrant interaction with myelin, microtubules and MAPs and inefficient degradation of the protein may lead to 
formation of GCIs. 3) As a consequence, there is disruption of the oligodendroglial-myelin-axon-neuron axis leading to myelin loss, 
axonal damage, synaptic dysfunction and neuronal death which are exacerbated by inflammatory cues. 
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7.3. CONCLUSIONS AND FUTURE DIRECTIONS 
Establishing the step-by-step mechanisms by which GCIs form in 
oligodendrocytes in MSA is important to understanding the molecular 
pathogenesis of the disease. Future directions may focus on the role of cellular 
SNCA overexpression and its impact on inclusion formation and cell survival. 
Analysing SNCA expression in LCM-isolated neurons and oligodendrocytes in 
affected and unaffected brain regions in long duration, minimal change and 
typical MSA may help to elucidate the selective vulnerability of StrN and OPC 
regions and provide further insight into the role of SNCA mRNA expression on 
clinical outcome. Furthermore, comparing cellular SNCA expression   among 
different α-synucleinopathies may elucidate the preferential accumulation of αsyn 
in oligodendrocytes in MSA and neurons in PD and DLB.  
Despite a common protein culprit, the different pathological and clinical 
outcomes of members of the α-synucleinopathy group of diseases suggest that 
there are differences in the properties of αsyn at the transcriptional or 
posttranscriptional level. Different conformational and structural properties of 
αsyn have been demonstrated (Bousset et al.; Guo et al., 2013), therefore, 
investigating the properties of αsyn in these MSA, PD and DLB may provide 
further insight into reasons behind their different clinico-pathological profiles. 
In addition, research into the role of αsyn in oligodendrocytes is warranted. It is 
important to better understand the ultrastructural localisation of αsyn in 
oligodendrocytes and its interaction with components of myelin and the 
microtubule network. Microtubule-polymerizing activity of αsyn has been 
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demonstrated in COS-1 cultured cells in addition to loss of polymerizing 
potential by the αsyn mutants A30P and A53T  (Alim et al., 2004). Loss of αsyn 
microtubule assembly activity induces tubulin aggregation and tubulin oligomers 
act as seeds for αsyn fibrillogenesis creating a cycle for inclusion formation that 
may be triggered or exacerbated by αsyn or tubulin (Alim et al., 2002, 2004). The 
role of αsyn as a microtubule-associated protein and the consequences of loss of 
this activity need to be further investigated in oligodendrocytes. Co-culture 
systems using microfluidic chambers which separate neuronal cell body in one 
compartment and axons and oligodendrocytes in another may provide a platform 
to study the effect of blocking αsyn microtubule-polymerization on the integrity 
of myelin, axon and cell body (Taylor et al., 2005; Park et al., 2009). Therefore, it 
may be hypothesized that disruption in αsyn microtubule-polymerization activity 
in oligodendrocytes may lead to destabilization and oligomerisation of 
microtubules which seed αsyn aggregation leading to inclusion formation and 
myelin damage.  A clearer view of the role of αsyn in oligodendrocyte is essential 
to building the step-by-step mechanisms by which GCIs form and cause myelin 
disruption, therefore, coming closer to  unravelling “the nature of the beast” 
(Quinn, 1989). 
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